CN114746422B - 具有1,2,3,4-四氢萘部分的衍生物或其药学上可接受的盐以及包含它们的药物组合物 - Google Patents
具有1,2,3,4-四氢萘部分的衍生物或其药学上可接受的盐以及包含它们的药物组合物 Download PDFInfo
- Publication number
- CN114746422B CN114746422B CN202080075121.6A CN202080075121A CN114746422B CN 114746422 B CN114746422 B CN 114746422B CN 202080075121 A CN202080075121 A CN 202080075121A CN 114746422 B CN114746422 B CN 114746422B
- Authority
- CN
- China
- Prior art keywords
- carbamate
- quinuclidin
- tetrahydronaphthalen
- dimethyl
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 150000003839 salts Chemical class 0.000 title claims abstract description 76
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 12
- 125000005329 tetralinyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 title abstract description 17
- 150000001875 compounds Chemical class 0.000 claims abstract description 121
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 26
- 201000010099 disease Diseases 0.000 claims abstract description 20
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 19
- 102000044956 Ceramide glucosyltransferases Human genes 0.000 claims abstract description 15
- 108091000114 ceramide glucosyltransferase Proteins 0.000 claims abstract description 15
- 238000004519 manufacturing process Methods 0.000 claims abstract description 13
- 208000024720 Fabry Disease Diseases 0.000 claims abstract description 10
- 208000015872 Gaucher disease Diseases 0.000 claims abstract description 10
- 208000018737 Parkinson disease Diseases 0.000 claims abstract description 8
- 230000002265 prevention Effects 0.000 claims abstract description 5
- -1 2, 3-dihydrobenzodioxinyl Chemical group 0.000 claims description 756
- 125000000217 alkyl group Chemical group 0.000 claims description 35
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims description 34
- 125000003545 alkoxy group Chemical group 0.000 claims description 31
- 229910052739 hydrogen Inorganic materials 0.000 claims description 24
- 239000001257 hydrogen Substances 0.000 claims description 24
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 23
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 19
- 229910052736 halogen Inorganic materials 0.000 claims description 16
- 125000005843 halogen group Chemical group 0.000 claims description 16
- 150000002367 halogens Chemical group 0.000 claims description 16
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 15
- 125000004432 carbon atom Chemical group C* 0.000 claims description 11
- 125000003277 amino group Chemical group 0.000 claims description 10
- 125000000623 heterocyclic group Chemical group 0.000 claims description 9
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 8
- 229910052799 carbon Inorganic materials 0.000 claims description 8
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 8
- 229910052757 nitrogen Inorganic materials 0.000 claims description 8
- 229910052760 oxygen Inorganic materials 0.000 claims description 8
- 239000001301 oxygen Substances 0.000 claims description 8
- 125000003282 alkyl amino group Chemical group 0.000 claims description 7
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 7
- 239000004480 active ingredient Substances 0.000 claims description 6
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 125000002757 morpholinyl group Chemical group 0.000 claims description 6
- 125000004434 sulfur atom Chemical group 0.000 claims description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
- 125000005605 benzo group Chemical group 0.000 claims description 3
- 125000002047 benzodioxolyl group Chemical group O1OC(C2=C1C=CC=C2)* 0.000 claims description 3
- 125000004076 pyridyl group Chemical group 0.000 claims description 3
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 3
- 125000001544 thienyl group Chemical group 0.000 claims description 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 254
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 39
- 238000000034 method Methods 0.000 description 32
- 238000002360 preparation method Methods 0.000 description 32
- 210000004027 cell Anatomy 0.000 description 25
- 238000006243 chemical reaction Methods 0.000 description 22
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 21
- 239000011541 reaction mixture Substances 0.000 description 20
- 239000000243 solution Substances 0.000 description 17
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 15
- 239000000203 mixture Substances 0.000 description 15
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 14
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 13
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 12
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 12
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- 102000004190 Enzymes Human genes 0.000 description 9
- 108090000790 Enzymes Proteins 0.000 description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 239000007787 solid Substances 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 229930186217 Glycolipid Natural products 0.000 description 8
- YFHRCLAKZBDRHN-MRXNPFEDSA-N [(3s)-1-azabicyclo[2.2.2]octan-3-yl] n-[2-[2-(4-fluorophenyl)-1,3-thiazol-4-yl]propan-2-yl]carbamate Chemical compound O([C@H]1C2CCN(CC2)C1)C(=O)NC(C)(C)C(N=1)=CSC=1C1=CC=C(F)C=C1 YFHRCLAKZBDRHN-MRXNPFEDSA-N 0.000 description 8
- 238000006911 enzymatic reaction Methods 0.000 description 8
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical class O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 7
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 7
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 7
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 7
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 7
- 238000006069 Suzuki reaction reaction Methods 0.000 description 7
- 239000002253 acid Substances 0.000 description 7
- 150000001642 boronic acid derivatives Chemical class 0.000 description 7
- 229940106189 ceramide Drugs 0.000 description 7
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 7
- 150000002305 glucosylceramides Chemical class 0.000 description 7
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 7
- 239000012044 organic layer Substances 0.000 description 7
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 6
- 238000004440 column chromatography Methods 0.000 description 6
- 208000035475 disorder Diseases 0.000 description 6
- 239000003112 inhibitor Substances 0.000 description 6
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 6
- 239000007858 starting material Substances 0.000 description 6
- 239000000758 substrate Substances 0.000 description 6
- 238000005406 washing Methods 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 5
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-diisopropylethylamine Substances CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 5
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 5
- 238000009825 accumulation Methods 0.000 description 5
- 229940121375 antifungal agent Drugs 0.000 description 5
- 125000003118 aryl group Chemical group 0.000 description 5
- 125000002619 bicyclic group Chemical group 0.000 description 5
- 238000005119 centrifugation Methods 0.000 description 5
- 239000012091 fetal bovine serum Substances 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 238000003860 storage Methods 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 208000002678 Mucopolysaccharidoses Diseases 0.000 description 4
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 4
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 4
- 239000003429 antifungal agent Substances 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000012267 brine Substances 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 125000001072 heteroaryl group Chemical group 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 206010028093 mucopolysaccharidosis Diseases 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 239000012312 sodium hydride Substances 0.000 description 4
- 229910000104 sodium hydride Inorganic materials 0.000 description 4
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 4
- 230000004137 sphingolipid metabolism Effects 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 230000000699 topical effect Effects 0.000 description 4
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 102100024308 Ceramide synthase Human genes 0.000 description 3
- 229920002261 Corn starch Polymers 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 208000015439 Lysosomal storage disease Diseases 0.000 description 3
- 208000008955 Mucolipidoses Diseases 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 108091005804 Peptidases Proteins 0.000 description 3
- 229940122907 Phosphatase inhibitor Drugs 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- 239000004365 Protease Substances 0.000 description 3
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 3
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- 239000012980 RPMI-1640 medium Substances 0.000 description 3
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- HSCJRCZFDFQWRP-JZMIEXBBSA-N UDP-alpha-D-glucose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OP(O)(=O)OP(O)(=O)OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](N2C(NC(=O)C=C2)=O)O1 HSCJRCZFDFQWRP-JZMIEXBBSA-N 0.000 description 3
- HSCJRCZFDFQWRP-UHFFFAOYSA-N Uridindiphosphoglukose Natural products OC1C(O)C(O)C(CO)OC1OP(O)(=O)OP(O)(=O)OCC1C(O)C(O)C(N2C(NC(=O)C=C2)=O)O1 HSCJRCZFDFQWRP-UHFFFAOYSA-N 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 229910021529 ammonia Inorganic materials 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 125000004429 atom Chemical group 0.000 description 3
- ACBQROXDOHKANW-UHFFFAOYSA-N bis(4-nitrophenyl) carbonate Chemical compound C1=CC([N+](=O)[O-])=CC=C1OC(=O)OC1=CC=C([N+]([O-])=O)C=C1 ACBQROXDOHKANW-UHFFFAOYSA-N 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000008120 corn starch Substances 0.000 description 3
- 238000007405 data analysis Methods 0.000 description 3
- 108010061814 dihydroceramide desaturase Proteins 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 235000013355 food flavoring agent Nutrition 0.000 description 3
- 235000003599 food sweetener Nutrition 0.000 description 3
- 229960002743 glutamine Drugs 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
- 239000000375 suspending agent Substances 0.000 description 3
- 239000003765 sweetening agent Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- NXLNNXIXOYSCMB-UHFFFAOYSA-N (4-nitrophenyl) carbonochloridate Chemical compound [O-][N+](=O)C1=CC=C(OC(Cl)=O)C=C1 NXLNNXIXOYSCMB-UHFFFAOYSA-N 0.000 description 2
- IMFIXLKZDLUQBQ-UHFFFAOYSA-N 1,2,3,3a,4,5-hexahydropyrrolo[3,2-b]pyrrole Chemical class N1CC=C2NCCC21 IMFIXLKZDLUQBQ-UHFFFAOYSA-N 0.000 description 2
- OGYGFUAIIOPWQD-UHFFFAOYSA-N 1,3-thiazolidine Chemical compound C1CSCN1 OGYGFUAIIOPWQD-UHFFFAOYSA-N 0.000 description 2
- WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- JOCCCKOFQRTOIM-UHFFFAOYSA-M 2-chloroethyl(dimethyl)sulfanium;iodide Chemical compound [I-].C[S+](C)CCCl JOCCCKOFQRTOIM-UHFFFAOYSA-M 0.000 description 2
- IVLICPVPXWEGCA-UHFFFAOYSA-N 3-quinuclidinol Chemical compound C1C[C@@H]2C(O)C[N@]1CC2 IVLICPVPXWEGCA-UHFFFAOYSA-N 0.000 description 2
- 102100022548 Beta-hexosaminidase subunit alpha Human genes 0.000 description 2
- NXPKUTXSCKUFPY-UHFFFAOYSA-N CC1(CCC2=C(C1N)C=C(C=C2)Br)C.Cl Chemical compound CC1(CCC2=C(C1N)C=C(C=C2)Br)C.Cl NXPKUTXSCKUFPY-UHFFFAOYSA-N 0.000 description 2
- 102000009016 Cholera Toxin Human genes 0.000 description 2
- 108010049048 Cholera Toxin Proteins 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 208000010055 Globoid Cell Leukodystrophy Diseases 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 208000028226 Krabbe disease Diseases 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- 229930182816 L-glutamine Natural products 0.000 description 2
- 201000011442 Metachromatic leukodystrophy Diseases 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 206010072930 Mucolipidosis type IV Diseases 0.000 description 2
- 102100026502 Mucolipin-1 Human genes 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 208000014060 Niemann-Pick disease Diseases 0.000 description 2
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 2
- WYNCHZVNFNFDNH-UHFFFAOYSA-N Oxazolidine Chemical compound C1COCN1 WYNCHZVNFNFDNH-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- 206010038468 Renal hypertrophy Diseases 0.000 description 2
- 208000021811 Sandhoff disease Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 208000022292 Tay-Sachs disease Diseases 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- 229960005261 aspartic acid Drugs 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- 239000004327 boric acid Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000013592 cell lysate Substances 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000002641 enzyme replacement therapy Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 125000003914 fluoranthenyl group Chemical group C1(=CC=C2C=CC=C3C4=CC=CC=C4C1=C23)* 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 229940125921 glucosylceramide synthase inhibitor Drugs 0.000 description 2
- 150000002339 glycosphingolipids Chemical class 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
- 239000007951 isotonicity adjuster Substances 0.000 description 2
- 201000008627 kidney hypertrophy Diseases 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- OKKJLVBELUTLKV-VMNATFBRSA-N methanol-d1 Chemical compound [2H]OC OKKJLVBELUTLKV-VMNATFBRSA-N 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 description 2
- AHHWIHXENZJRFG-UHFFFAOYSA-N oxetane Chemical compound C1COC1 AHHWIHXENZJRFG-UHFFFAOYSA-N 0.000 description 2
- 239000006201 parenteral dosage form Substances 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 2
- 239000003495 polar organic solvent Substances 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 229910000160 potassium phosphate Inorganic materials 0.000 description 2
- 235000011009 potassium phosphates Nutrition 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- USPWKWBDZOARPV-UHFFFAOYSA-N pyrazolidine Chemical compound C1CNNC1 USPWKWBDZOARPV-UHFFFAOYSA-N 0.000 description 2
- 229960000948 quinine Drugs 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 208000037921 secondary disease Diseases 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 150000003408 sphingolipids Chemical class 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 150000003536 tetrazoles Chemical class 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 238000003260 vortexing Methods 0.000 description 2
- VCGRFBXVSFAGGA-UHFFFAOYSA-N (1,1-dioxo-1,4-thiazinan-4-yl)-[6-[[3-(4-fluorophenyl)-5-methyl-1,2-oxazol-4-yl]methoxy]pyridin-3-yl]methanone Chemical compound CC=1ON=C(C=2C=CC(F)=CC=2)C=1COC(N=C1)=CC=C1C(=O)N1CCS(=O)(=O)CC1 VCGRFBXVSFAGGA-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- MAYZWDRUFKUGGP-VIFPVBQESA-N (3s)-1-[5-tert-butyl-3-[(1-methyltetrazol-5-yl)methyl]triazolo[4,5-d]pyrimidin-7-yl]pyrrolidin-3-ol Chemical compound CN1N=NN=C1CN1C2=NC(C(C)(C)C)=NC(N3C[C@@H](O)CC3)=C2N=N1 MAYZWDRUFKUGGP-VIFPVBQESA-N 0.000 description 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- UKGJZDSUJSPAJL-YPUOHESYSA-N (e)-n-[(1r)-1-[3,5-difluoro-4-(methanesulfonamido)phenyl]ethyl]-3-[2-propyl-6-(trifluoromethyl)pyridin-3-yl]prop-2-enamide Chemical compound CCCC1=NC(C(F)(F)F)=CC=C1\C=C\C(=O)N[C@H](C)C1=CC(F)=C(NS(C)(=O)=O)C(F)=C1 UKGJZDSUJSPAJL-YPUOHESYSA-N 0.000 description 1
- ZGYIXVSQHOKQRZ-COIATFDQSA-N (e)-n-[4-[3-chloro-4-(pyridin-2-ylmethoxy)anilino]-3-cyano-7-[(3s)-oxolan-3-yl]oxyquinolin-6-yl]-4-(dimethylamino)but-2-enamide Chemical compound N#CC1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 ZGYIXVSQHOKQRZ-COIATFDQSA-N 0.000 description 1
- MOWXJLUYGFNTAL-DEOSSOPVSA-N (s)-[2-chloro-4-fluoro-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(6-methoxypyridazin-3-yl)methanol Chemical compound N1=NC(OC)=CC=C1[C@@H](O)C1=CC(C=2C3=CC=C(C=C3N=CN=2)N2CCOCC2)=C(F)C=C1Cl MOWXJLUYGFNTAL-DEOSSOPVSA-N 0.000 description 1
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 1
- FNQJDLTXOVEEFB-UHFFFAOYSA-N 1,2,3-benzothiadiazole Chemical class C1=CC=C2SN=NC2=C1 FNQJDLTXOVEEFB-UHFFFAOYSA-N 0.000 description 1
- CIISBYKBBMFLEZ-UHFFFAOYSA-N 1,2-oxazolidine Chemical compound C1CNOC1 CIISBYKBBMFLEZ-UHFFFAOYSA-N 0.000 description 1
- YJTKZCDBKVTVBY-UHFFFAOYSA-N 1,3-Diphenylbenzene Chemical group C1=CC=CC=C1C1=CC=CC(C=2C=CC=CC=2)=C1 YJTKZCDBKVTVBY-UHFFFAOYSA-N 0.000 description 1
- 150000000183 1,3-benzoxazoles Chemical class 0.000 description 1
- WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical compound C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 description 1
- IMLSAISZLJGWPP-UHFFFAOYSA-N 1,3-dithiolane Chemical compound C1CSCS1 IMLSAISZLJGWPP-UHFFFAOYSA-N 0.000 description 1
- APWRZPQBPCAXFP-UHFFFAOYSA-N 1-(1-oxo-2H-isoquinolin-5-yl)-5-(trifluoromethyl)-N-[2-(trifluoromethyl)pyridin-4-yl]pyrazole-4-carboxamide Chemical compound O=C1NC=CC2=C(C=CC=C12)N1N=CC(=C1C(F)(F)F)C(=O)NC1=CC(=NC=C1)C(F)(F)F APWRZPQBPCAXFP-UHFFFAOYSA-N 0.000 description 1
- ABDDQTDRAHXHOC-QMMMGPOBSA-N 1-[(7s)-5,7-dihydro-4h-thieno[2,3-c]pyran-7-yl]-n-methylmethanamine Chemical compound CNC[C@@H]1OCCC2=C1SC=C2 ABDDQTDRAHXHOC-QMMMGPOBSA-N 0.000 description 1
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical class C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 1
- MYFKLQFBFSHBPA-UHFFFAOYSA-N 1-chloro-2-methylsulfanylethane Chemical compound CSCCCl MYFKLQFBFSHBPA-UHFFFAOYSA-N 0.000 description 1
- LLSRLLPHUVVLQJ-UHFFFAOYSA-N 1-cycloheptyldiazepane Chemical class C1CCCCCC1N1NCCCCC1 LLSRLLPHUVVLQJ-UHFFFAOYSA-N 0.000 description 1
- QUIJMHDIAFOPRK-UHFFFAOYSA-N 1-cyclooctylazocane Chemical class C1CCCCCCC1N1CCCCCCC1 QUIJMHDIAFOPRK-UHFFFAOYSA-N 0.000 description 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- ODMMNALOCMNQJZ-UHFFFAOYSA-N 1H-pyrrolizine Chemical compound C1=CC=C2CC=CN21 ODMMNALOCMNQJZ-UHFFFAOYSA-N 0.000 description 1
- JAAIPIWKKXCNOC-UHFFFAOYSA-N 1h-tetrazol-1-ium-5-thiolate Chemical compound SC1=NN=NN1 JAAIPIWKKXCNOC-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- MGADZUXDNSDTHW-UHFFFAOYSA-N 2H-pyran Chemical compound C1OC=CC=C1 MGADZUXDNSDTHW-UHFFFAOYSA-N 0.000 description 1
- HCDMJFOHIXMBOV-UHFFFAOYSA-N 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-4,7-dihydropyrrolo[4,5]pyrido[1,2-d]pyrimidin-2-one Chemical compound C=1C2=C3N(CC)C(=O)N(C=4C(=C(OC)C=C(OC)C=4F)F)CC3=CN=C2NC=1CN1CCOCC1 HCDMJFOHIXMBOV-UHFFFAOYSA-N 0.000 description 1
- BYHQTRFJOGIQAO-GOSISDBHSA-N 3-(4-bromophenyl)-8-[(2R)-2-hydroxypropyl]-1-[(3-methoxyphenyl)methyl]-1,3,8-triazaspiro[4.5]decan-2-one Chemical compound C[C@H](CN1CCC2(CC1)CN(C(=O)N2CC3=CC(=CC=C3)OC)C4=CC=C(C=C4)Br)O BYHQTRFJOGIQAO-GOSISDBHSA-N 0.000 description 1
- YGYGASJNJTYNOL-CQSZACIVSA-N 3-[(4r)-2,2-dimethyl-1,1-dioxothian-4-yl]-5-(4-fluorophenyl)-1h-indole-7-carboxamide Chemical compound C1CS(=O)(=O)C(C)(C)C[C@@H]1C1=CNC2=C(C(N)=O)C=C(C=3C=CC(F)=CC=3)C=C12 YGYGASJNJTYNOL-CQSZACIVSA-N 0.000 description 1
- WNEODWDFDXWOLU-QHCPKHFHSA-N 3-[3-(hydroxymethyl)-4-[1-methyl-5-[[5-[(2s)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]pyridin-2-yl]amino]-6-oxopyridin-3-yl]pyridin-2-yl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one Chemical compound C([C@@H](N(CC1)C=2C=NC(NC=3C(N(C)C=C(C=3)C=3C(=C(N4C(C5=CC=6CC(C)(C)CC=6N5CC4)=O)N=CC=3)CO)=O)=CC=2)C)N1C1COC1 WNEODWDFDXWOLU-QHCPKHFHSA-N 0.000 description 1
- SRVXSISGYBMIHR-UHFFFAOYSA-N 3-[3-[3-(2-amino-2-oxoethyl)phenyl]-5-chlorophenyl]-3-(5-methyl-1,3-thiazol-2-yl)propanoic acid Chemical compound S1C(C)=CN=C1C(CC(O)=O)C1=CC(Cl)=CC(C=2C=C(CC(N)=O)C=CC=2)=C1 SRVXSISGYBMIHR-UHFFFAOYSA-N 0.000 description 1
- UOQHWNPVNXSDDO-UHFFFAOYSA-N 3-bromoimidazo[1,2-a]pyridine-6-carbonitrile Chemical compound C1=CC(C#N)=CN2C(Br)=CN=C21 UOQHWNPVNXSDDO-UHFFFAOYSA-N 0.000 description 1
- UNTNRNUQVKDIPV-UHFFFAOYSA-N 3h-dithiazole Chemical compound N1SSC=C1 UNTNRNUQVKDIPV-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- VJPPLCNBDLZIFG-ZDUSSCGKSA-N 4-[(3S)-3-(but-2-ynoylamino)piperidin-1-yl]-5-fluoro-2,3-dimethyl-1H-indole-7-carboxamide Chemical compound C(C#CC)(=O)N[C@@H]1CN(CCC1)C1=C2C(=C(NC2=C(C=C1F)C(=O)N)C)C VJPPLCNBDLZIFG-ZDUSSCGKSA-N 0.000 description 1
- YFCIFWOJYYFDQP-PTWZRHHISA-N 4-[3-amino-6-[(1S,3S,4S)-3-fluoro-4-hydroxycyclohexyl]pyrazin-2-yl]-N-[(1S)-1-(3-bromo-5-fluorophenyl)-2-(methylamino)ethyl]-2-fluorobenzamide Chemical compound CNC[C@@H](NC(=O)c1ccc(cc1F)-c1nc(cnc1N)[C@H]1CC[C@H](O)[C@@H](F)C1)c1cc(F)cc(Br)c1 YFCIFWOJYYFDQP-PTWZRHHISA-N 0.000 description 1
- XYWIPYBIIRTJMM-IBGZPJMESA-N 4-[[(2S)-2-[4-[5-chloro-2-[4-(trifluoromethyl)triazol-1-yl]phenyl]-5-methoxy-2-oxopyridin-1-yl]butanoyl]amino]-2-fluorobenzamide Chemical compound CC[C@H](N1C=C(OC)C(=CC1=O)C1=C(C=CC(Cl)=C1)N1C=C(N=N1)C(F)(F)F)C(=O)NC1=CC(F)=C(C=C1)C(N)=O XYWIPYBIIRTJMM-IBGZPJMESA-N 0.000 description 1
- KVCQTKNUUQOELD-UHFFFAOYSA-N 4-amino-n-[1-(3-chloro-2-fluoroanilino)-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N=1C=CC2=C(NC(=O)C=3C4=NC=NC(N)=C4SC=3)C(C)=CC=C2C=1NC1=CC=CC(Cl)=C1F KVCQTKNUUQOELD-UHFFFAOYSA-N 0.000 description 1
- LBUNNMJLXWQQBY-UHFFFAOYSA-N 4-fluorophenylboronic acid Chemical compound OB(O)C1=CC=C(F)C=C1 LBUNNMJLXWQQBY-UHFFFAOYSA-N 0.000 description 1
- IRPVABHDSJVBNZ-RTHVDDQRSA-N 5-[1-(cyclopropylmethyl)-5-[(1R,5S)-3-(oxetan-3-yl)-3-azabicyclo[3.1.0]hexan-6-yl]pyrazol-3-yl]-3-(trifluoromethyl)pyridin-2-amine Chemical compound C1=C(C(F)(F)F)C(N)=NC=C1C1=NN(CC2CC2)C(C2[C@@H]3CN(C[C@@H]32)C2COC2)=C1 IRPVABHDSJVBNZ-RTHVDDQRSA-N 0.000 description 1
- KCBWAFJCKVKYHO-UHFFFAOYSA-N 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-[[4-[1-propan-2-yl-4-(trifluoromethyl)imidazol-2-yl]phenyl]methyl]pyrazolo[3,4-d]pyrimidine Chemical compound C1(CC1)C1=NC=NC(=C1C1=NC=C2C(=N1)N(N=C2)CC1=CC=C(C=C1)C=1N(C=C(N=1)C(F)(F)F)C(C)C)OC KCBWAFJCKVKYHO-UHFFFAOYSA-N 0.000 description 1
- JBGXAYOORBASGV-UHFFFAOYSA-N 6-bromo-1,2,3,4-tetrahydronaphthalen-1-amine Chemical compound BrC1=CC=C2C(N)CCCC2=C1 JBGXAYOORBASGV-UHFFFAOYSA-N 0.000 description 1
- OSDHOOBPMBLALZ-UHFFFAOYSA-N 6-bromo-3,4-dihydro-2h-naphthalen-1-one Chemical compound O=C1CCCC2=CC(Br)=CC=C21 OSDHOOBPMBLALZ-UHFFFAOYSA-N 0.000 description 1
- PHUSWQSCHYYQQF-UHFFFAOYSA-N 7-bromo-1,2,3,4-tetrahydronaphthalen-1-amine Chemical compound C1=C(Br)C=C2C(N)CCCC2=C1 PHUSWQSCHYYQQF-UHFFFAOYSA-N 0.000 description 1
- YGVDCGFUUUJCDF-UHFFFAOYSA-N 7-bromo-3,4-dihydro-2h-naphthalen-1-one Chemical compound C1CCC(=O)C2=CC(Br)=CC=C21 YGVDCGFUUUJCDF-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- CYJRNFFLTBEQSQ-UHFFFAOYSA-N 8-(3-methyl-1-benzothiophen-5-yl)-N-(4-methylsulfonylpyridin-3-yl)quinoxalin-6-amine Chemical compound CS(=O)(=O)C1=C(C=NC=C1)NC=1C=C2N=CC=NC2=C(C=1)C=1C=CC2=C(C(=CS2)C)C=1 CYJRNFFLTBEQSQ-UHFFFAOYSA-N 0.000 description 1
- ZRPZPNYZFSJUPA-UHFFFAOYSA-N ARS-1620 Chemical compound Oc1cccc(F)c1-c1c(Cl)cc2c(ncnc2c1F)N1CCN(CC1)C(=O)C=C ZRPZPNYZFSJUPA-UHFFFAOYSA-N 0.000 description 1
- 108010006533 ATP-Binding Cassette Transporters Proteins 0.000 description 1
- 102000005416 ATP-Binding Cassette Transporters Human genes 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 235000003130 Arctium lappa Nutrition 0.000 description 1
- 244000294263 Arctium minus Species 0.000 description 1
- 235000008078 Arctium minus Nutrition 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 238000009020 BCA Protein Assay Kit Methods 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 102100027386 Beta-1,4-galactosyltransferase 6 Human genes 0.000 description 1
- SXNBFBJWIKPQAR-UHFFFAOYSA-N BrC=1C=C2CCC3(C(C2=CC=1)=O)CC3 Chemical compound BrC=1C=C2CCC3(C(C2=CC=1)=O)CC3 SXNBFBJWIKPQAR-UHFFFAOYSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- DSIXYORBRQBNQE-UHFFFAOYSA-N C1CC2(CC2)C(C3=C1C=C(C=C3)Br)N.Cl Chemical compound C1CC2(CC2)C(C3=C1C=C(C=C3)Br)N.Cl DSIXYORBRQBNQE-UHFFFAOYSA-N 0.000 description 1
- YXXVNZLRRXOWMQ-UHFFFAOYSA-N CC1(CCC2=C(C1N)C=CC(=C2)Br)C.Cl Chemical compound CC1(CCC2=C(C1N)C=CC(=C2)Br)C.Cl YXXVNZLRRXOWMQ-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- GISRWBROCYNDME-PELMWDNLSA-N F[C@H]1[C@H]([C@H](NC1=O)COC1=NC=CC2=CC(=C(C=C12)OC)C(=O)N)C Chemical compound F[C@H]1[C@H]([C@H](NC1=O)COC1=NC=CC2=CC(=C(C=C12)OC)C(=O)N)C GISRWBROCYNDME-PELMWDNLSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 201000008892 GM1 Gangliosidosis Diseases 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000051366 Glycosyltransferases Human genes 0.000 description 1
- 108700023372 Glycosyltransferases Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 description 1
- WRYCSMQKUKOKBP-UHFFFAOYSA-N Imidazolidine Chemical compound C1CNCN1 WRYCSMQKUKOKBP-UHFFFAOYSA-N 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 208000027933 Mannosidase Deficiency disease Diseases 0.000 description 1
- AYCPARAPKDAOEN-LJQANCHMSA-N N-[(1S)-2-(dimethylamino)-1-phenylethyl]-6,6-dimethyl-3-[(2-methyl-4-thieno[3,2-d]pyrimidinyl)amino]-1,4-dihydropyrrolo[3,4-c]pyrazole-5-carboxamide Chemical compound C1([C@H](NC(=O)N2C(C=3NN=C(NC=4C=5SC=CC=5N=C(C)N=4)C=3C2)(C)C)CN(C)C)=CC=CC=C1 AYCPARAPKDAOEN-LJQANCHMSA-N 0.000 description 1
- YDNKGFDKKRUKPY-TURZORIXSA-N N-hexadecanoylsphingosine Chemical compound CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)\C=C\CCCCCCCCCCCCC YDNKGFDKKRUKPY-TURZORIXSA-N 0.000 description 1
- SYVQDYVGPKOMFY-UHUGOGIASA-N NC(O[C@@](CCCC1=C2)(C3C(CC4)CCN4C3)C1=CC=C2Br)=O Chemical compound NC(O[C@@](CCCC1=C2)(C3C(CC4)CCN4C3)C1=CC=C2Br)=O SYVQDYVGPKOMFY-UHUGOGIASA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- IDRGFNPZDVBSSE-UHFFFAOYSA-N OCCN1CCN(CC1)c1ccc(Nc2ncc3cccc(-c4cccc(NC(=O)C=C)c4)c3n2)c(F)c1F Chemical compound OCCN1CCN(CC1)c1ccc(Nc2ncc3cccc(-c4cccc(NC(=O)C=C)c4)c3n2)c(F)c1F IDRGFNPZDVBSSE-UHFFFAOYSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 241000508269 Psidium Species 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 208000029033 Spinal Cord disease Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- 108010058742 UDPgalactose-glucosylceramide galactosyltransferase Proteins 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- LXRZVMYMQHNYJB-UNXOBOICSA-N [(1R,2S,4R)-4-[[5-[4-[(1R)-7-chloro-1,2,3,4-tetrahydroisoquinolin-1-yl]-5-methylthiophene-2-carbonyl]pyrimidin-4-yl]amino]-2-hydroxycyclopentyl]methyl sulfamate Chemical compound CC1=C(C=C(S1)C(=O)C1=C(N[C@H]2C[C@H](O)[C@@H](COS(N)(=O)=O)C2)N=CN=C1)[C@@H]1NCCC2=C1C=C(Cl)C=C2 LXRZVMYMQHNYJB-UNXOBOICSA-N 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- 229960003767 alanine Drugs 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 102000005840 alpha-Galactosidase Human genes 0.000 description 1
- 108010030291 alpha-Galactosidase Proteins 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 229940111121 antirheumatic drug quinolines Drugs 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229960003121 arginine Drugs 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 150000001556 benzimidazoles Chemical class 0.000 description 1
- 150000008316 benzisoxazoles Chemical class 0.000 description 1
- 150000005528 benzodioxoles Chemical class 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical class C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 1
- 150000001565 benzotriazoles Chemical class 0.000 description 1
- 102000006995 beta-Glucosidase Human genes 0.000 description 1
- 108010047754 beta-Glucosidase Proteins 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 125000002676 chrysenyl group Chemical group C1(=CC=CC=2C3=CC=C4C=CC=CC4=C3C=CC12)* 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 150000001907 coumarones Chemical class 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 229960002433 cysteine Drugs 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 210000001787 dendrite Anatomy 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 208000033679 diabetic kidney disease Diseases 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 150000002012 dioxanes Chemical class 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 229960002598 fumaric acid Drugs 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 150000002270 gangliosides Chemical class 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229960005219 gentisic acid Drugs 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000003451 hyperinsulinaemic effect Effects 0.000 description 1
- 201000008980 hyperinsulinism Diseases 0.000 description 1
- 150000005233 imidazopyridazines Chemical class 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 150000002475 indoles Chemical class 0.000 description 1
- 150000002476 indolines Chemical class 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 235000014705 isoleucine Nutrition 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 125000005921 isopentoxy group Chemical group 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000002537 isoquinolines Chemical class 0.000 description 1
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229940099563 lactobionic acid Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229960003646 lysine Drugs 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 230000002132 lysosomal effect Effects 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 150000002780 morpholines Chemical class 0.000 description 1
- 201000007769 mucolipidosis Diseases 0.000 description 1
- HZIRBXILQRLFIK-IEECYHMASA-N n-[(e,2s,3s)-1,3-dihydroxyoctadec-4-en-2-yl]-6-[(4-nitro-2,1,3-benzoxadiazol-7-yl)amino]hexanamide Chemical compound CCCCCCCCCCCCC\C=C\[C@H](O)[C@H](CO)NC(=O)CCCCCNC1=CC=C([N+]([O-])=O)C2=NON=C12 HZIRBXILQRLFIK-IEECYHMASA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 125000000962 organic group Chemical group 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- IVYVEXWXPMKAAP-UHFFFAOYSA-N oxatetrazole Chemical compound N=1N=NON=1 IVYVEXWXPMKAAP-UHFFFAOYSA-N 0.000 description 1
- 150000004893 oxazines Chemical class 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- LXNAVEXFUKBNMK-UHFFFAOYSA-N palladium(II) acetate Substances [Pd].CC(O)=O.CC(O)=O LXNAVEXFUKBNMK-UHFFFAOYSA-N 0.000 description 1
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 125000002080 perylenyl group Chemical group C1(=CC=C2C=CC=C3C4=CC=CC5=CC=CC(C1=C23)=C45)* 0.000 description 1
- 125000005561 phenanthryl group Chemical group 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 208000030761 polycystic kidney disease Diseases 0.000 description 1
- LZMJNVRJMFMYQS-UHFFFAOYSA-N poseltinib Chemical compound C1CN(C)CCN1C(C=C1)=CC=C1NC1=NC(OC=2C=C(NC(=O)C=C)C=CC=2)=C(OC=C2)C2=N1 LZMJNVRJMFMYQS-UHFFFAOYSA-N 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 229960002429 proline Drugs 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000002331 protein detection Methods 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 210000002763 pyramidal cell Anatomy 0.000 description 1
- 125000001725 pyrenyl group Chemical group 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- RQGPLDBZHMVWCH-UHFFFAOYSA-N pyrrolo[3,2-b]pyrrole Chemical class C1=NC2=CC=NC2=C1 RQGPLDBZHMVWCH-UHFFFAOYSA-N 0.000 description 1
- 150000005255 pyrrolopyridines Chemical class 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 150000003248 quinolines Chemical class 0.000 description 1
- 150000008584 quinuclidines Chemical class 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- XIIOFHFUYBLOLW-UHFFFAOYSA-N selpercatinib Chemical compound OC(COC=1C=C(C=2N(C=1)N=CC=2C#N)C=1C=NC(=CC=1)N1CC2N(C(C1)C2)CC=1C=NC(=CC=1)OC)(C)C XIIOFHFUYBLOLW-UHFFFAOYSA-N 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 229960001153 serine Drugs 0.000 description 1
- 235000004400 serine Nutrition 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- XGVXKJKTISMIOW-ZDUSSCGKSA-N simurosertib Chemical compound N1N=CC(C=2SC=3C(=O)NC(=NC=3C=2)[C@H]2N3CCC(CC3)C2)=C1C XGVXKJKTISMIOW-ZDUSSCGKSA-N 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- 235000009518 sodium iodide Nutrition 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 150000003460 sulfonic acids Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000001935 tetracenyl group Chemical group C1(=CC=CC2=CC3=CC4=CC=CC=C4C=C3C=C12)* 0.000 description 1
- RAOIDOHSFRTOEL-UHFFFAOYSA-N tetrahydrothiophene Chemical compound C1CCSC1 RAOIDOHSFRTOEL-UHFFFAOYSA-N 0.000 description 1
- CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetraline Natural products C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 description 1
- VLLMWSRANPNYQX-UHFFFAOYSA-N thiadiazole Chemical compound C1=CSN=N1.C1=CSN=N1 VLLMWSRANPNYQX-UHFFFAOYSA-N 0.000 description 1
- PMKIYXFOEJFWIC-UHFFFAOYSA-N thiatetrazole Chemical compound N=1N=NSN=1 PMKIYXFOEJFWIC-UHFFFAOYSA-N 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 125000003960 triphenylenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3C3=CC=CC=C3C12)* 0.000 description 1
- 229960004441 tyrosine Drugs 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N urethane group Chemical group NC(=O)OCC JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 229960004295 valine Drugs 0.000 description 1
- 235000014393 valine Nutrition 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
本发明提供了一种具有1,2,3,4‑四氢萘部分的新化合物或其药学上可接受的盐、该新化合物或其药学上可接受的盐的制备方法、包含该新化合物或其药学上可接受的盐的药物组合物及它们的用途。具有1,2,3,4‑四氢萘部分的化合物或其药学上可接受的盐具有针对葡萄糖神经酰胺合酶(GCS)的抑制活性,因此可有效地用于预防或治疗与GCS有关的各种疾病,例如戈谢病、法布里病、泰‑萨克斯病、帕金森病等。
Description
技术领域
本发明涉及对葡萄糖神经酰胺合酶(GCS)具有抑制活性的化合物,即具有1,2,3,4-四氢萘部分的衍生物或其药学上可接受的盐,它们的制备方法,包含它们的药物组合物及它们的用途。
背景技术
溶酶体贮积症(Lysosomal storage disorders,LSDs)是由溶酶体中某些酶的遗传性缺乏或缺陷引起的代谢紊乱。随着不代谢(non-metabolized)或不降解(non-degraded)底物(substrate)的积累,LSDs在全身表现出各种病理性症状。目前,已知的LSDs约有50种类型,根据所积累的物质,这些LSDs主要分为例如粘多糖贮积症(mucopolysaccaridose)、寡糖贮积症(oligosaccharidosis)和神经鞘脂贮积症(sphingolipidoses)等疾病。
在这些疾病中,神经鞘脂贮积症为与鞘脂代谢相关的一类糖脂贮积障碍,表现出由于各种膜鞘糖脂(membrane glycosphingolipids,GSLs)如葡萄糖神经酰胺(glucosylceramide)、三己环神经酰胺(trihexocylceramide)等的积累而引起的病症。例如,当与鞘脂代谢相关的酶,如β-葡萄糖苷酶、α-半乳糖苷酶等,不具有正常的活性时,其底物(如葡萄糖神经酰胺、三己环神经酰胺等)积累,从而表现出各种病症,例如戈谢病(Gaucher disease)、法布里病(Fabry disease)等。
已知有两种类型的用于LSDs的疗法。第一种方法是替代或补充不足或有缺陷的(deficient)代谢酶。虽然这种酶替代疗法(enzyme replacement therapy,ERT)是安全有效的,但需要定期静脉内给药相关酶,并根据酶反应调节剂量,成本较高。特别是,由于难以将酶分配到神经系统,因此ERT在治疗与神经系统相关的症状方面没有显示令人满意的功效。此外,还存在经常产生针对所施用的酶(administered enzyme)的自身抗体的问题。
第二种方法是底物减少疗法(substrate reduction therapy,SRT),用于抑制累积的底物的合成。葡萄糖神经酰胺合酶(GCS)(也称为“UDP-葡萄糖:神经酰胺糖基转移酶”、“UDP-葡萄糖:N-酰基鞘氨醇D-葡糖基转移酶”或“EC 2.4.1.80”)是一种涉及鞘脂代谢的酶,参与神经酰胺与葡萄糖反应生成葡萄糖神经酰胺。所得到的葡萄糖神经酰胺被转化为各种GSL。葡萄糖神经酰胺合酶(GCS)抑制剂抑制GCS的活性,从而减少体内葡萄糖神经酰胺的产生,并防止糖脂例如三己环神经酰胺、GM1和GM2在细胞或器官内的异常积累。
因此,GCS抑制剂抑制GCS的活性以防止糖脂的积累,因此可用于治疗溶酶体贮积症,尤其是糖脂贮积障碍,例如GM1神经节苷脂贮积症(gangliosidosis)、泰-萨克斯病(Tay-Sachs disease)、桑德霍夫病(Sandhoff disease)、戈谢病、法布里病、尼曼-皮克病(Niemann-Pick disease)(A型和B型)、异染性脑白质营养不良(metachromaticleukodystrophy)、克拉伯病(Krabbe disease)等。GCS抑制剂也可用于治疗与糖脂贮积相关的继发性疾病(secondary diseases),例如尼曼-皮克病(C型)、粘多糖贮积症(mucopolysaccharidosis)和粘脂贮积症IV型(mucolipidosis type IV)(参见Chen CS,etal.,Abnormal transport along the lysosomal pathway in mucolipidosis,type IVdisease Proc Natl Acad Sci U S A.1998May26;95(11):6373-8;和Goodman LA,et al.,Ectopic dendrites occur only on cortical pyramidal cells containing elevatedGM2 ganglioside inα-mannosidosis,Proc Natl Acad Sci U S A.1991Dec 15;88(24):11330-4)。此外,据报道,GCS抑制剂可用于治疗与糖脂积累相关的疾病,例如肾肥大(例如糖尿病肾病);高血糖症或高胰岛素血症;糖脂合成异常的癌症;由使用细胞表面糖脂作为受体的生物体(organism)引起的传染病;葡萄糖神经酰胺的合成是必需的或重要的传染病;出现糖脂合成过多的疾病(例如,动脉粥样硬化、多囊肾病和肾肥大);与巨噬细胞的补充和活性相关的神经障碍和/或神经损伤(例如,阿尔茨海默病(Alzheimer’s disease)、癫痫、中风、脊髓疾病、帕金森病(Parkinson’s disease)等);炎症性疾病或障碍(例如,类风湿性关节炎、克罗恩病(Crohn’s disease)、哮喘、败血症);以及糖尿病和肥胖症(参见WO2006/053043)。并且,GCS的过表达干扰神经酰胺诱导的细胞凋亡(参见Liu YY,et al.,Uncoupling ceramide glycosylation by transfection of glucosylceramidesynthase antisense reverses adriamycin resistance,J Biol Chem.2000Mar 10;275(10):7138-43)。因此,GCS抑制剂可用于通过诱导患病细胞凋亡来治疗增殖性疾病,例如癌症。
已经进行了各种研究以开发GCS抑制剂。例如,在WO 2005/068426、WO 2006/053043、WO 2008/150486、WO 2009/117150、WO 2010/014554、WO 2014/043068等中公开了对GCS具有抑制活性的各种化合物。
发明内容
技术问题
本发明人发现具有6,6-稠合双环部分(6,6-fused bicyclic moiety),即1,2,3,4-四氢萘部分的衍生物或其药学上可接受的盐具有优异的对葡萄糖神经酰胺合酶(GCS)的抑制活性。因此,具有1,2,3,4-四氢萘部分的衍生物或其药学上可接受的盐可以有效地用于预防或治疗与GCS相关的各种疾病,例如戈谢病、法布里病、泰-萨克斯病、帕金森病等。
因此,本发明提供了上述具有1,2,3,4-四氢萘部分的衍生物或其药学上可接受的盐、它们的制备方法、包含它们的药物组合物及它们的用途。
技术方案
根据本发明的一个方面,提供了一种具有1,2,3,4-四氢萘部分的衍生物或其药学上可接受的盐。
根据本发明的另一方面,提供了一种用于制备具有1,2,3,4-四氢萘部分的所述衍生物或其药学上可接受的盐的方法。
根据本发明的又另一方面,提供了一种药物组合物,其包含所述具有1,2,3,4-四氢萘部分的衍生物或其药学上可接受的盐作为活性成分。
根据本发明的又另一方面,提供了一种治疗方法,其包括施用所述具有1,2,3,4-四氢萘部分的衍生物或其药学上可接受的盐。
根据本发明的又另一方面,提供了所述具有1,2,3,4-四氢萘部分的衍生物或其药学上可接受的盐在制备用于抑制葡萄糖神经酰胺合酶的药物中的用途。
发明的有益效果
本发明发现,具有6,6-稠合双环部分,即1,2,3,4-四氢萘部分的衍生物或其药学上可接受的盐对葡萄糖神经酰胺合酶(GCS)具有优异的抑制活性。因此,根据本发明的化合物或其药学上可接受的盐可有效地用于预防或治疗与GCS相关的各种疾病,例如戈谢病、法布里病、泰-萨克斯病、帕金森病等。
具体实施方式
如本文所用,术语“烷基”是指直链或支链脂肪族烃基。例如,C1~C6烷基意指具有1至6个碳原子的直链或支链脂肪族烃,例如甲基、乙基、丙基、正丁基、正戊基、正己基、异丙基、异丁基、仲丁基、叔丁基、新戊基和异戊基。
术语“羟基”是指“-OH”基团。术语“烷氧基”是指通过用烷基取代羟基中的氢原子而形成的基团。例如,C1~C6烷氧基包括甲氧基、乙氧基、丙氧基、正丁氧基、正戊氧基、异丙氧基、仲丁氧基、叔丁氧基、新戊氧基和异戊氧基。
术语“卤素”是指氟、溴、氯或碘基团。
除非另有定义,否则术语“环烷基”是指饱和脂肪族3-元环至10-元环,优选3-元环至7-元环。典型的环烷基包括环丙基、环丁基、环戊基、环己基等,但不限于此。
术语“芳基”是指通过从芳烃中除去一个氢原子而衍生的有机基团,该芳烃包括单稠环体系或多稠环体系(mono or poly-fused ring system),例如5-元至14-元取代或未取代的环,并且其中多个芳基通过单键连接的形式(form)。“芳基”包括例如苯基、萘基、联苯基、三联苯基、蒽基、茚基(indenyl)、芴基(fluorenyl)、菲基(phenanthryl)、三亚苯基、芘基(pyrenyl)、苝基(perylenyl)、基(chrysenyl)、并四苯基(naphthacenyl)、荧蒽基(fluoranthenyl)等,但不限于此。
术语“杂芳基(heteroaryl)”是指具有1至3个选自氮(N)原子、氧(O)原子和硫(S)原子的杂原子的5-元至12-元芳族基团,包括5-元或6-元单环杂芳基和通过5-元或6-元单环杂芳基与苯或吡啶环稠合形成的双环杂芳基。并且,术语“杂环(heterocycle)”是指具有一个或多个,优选1个至4个选自氧(O)原子、氮(N)原子和硫(S)原子的相同或不同杂原子的3-元至12-元单环或多环,但不含芳环。杂芳基或杂环的非限制性实例包括氧杂环丁烷(oxetane)、吡咯烷、吡咯、四氢呋喃、呋喃、四氢噻吩、噻吩、咪唑烷(imidazolidine)、咪唑、吡唑烷(pyrazolidine)、吡唑、吡咯嗪(pyrrolizine)、噁唑烷(oxazolidine)、噁唑、异噁唑烷、异噁唑、噻唑烷(thiazolidine)、噻唑、异噻唑烷、异噻唑、二氧戊环(dioxolane)、二硫戊环(dithiolane)、噁二唑、噻二唑、二噻唑、四唑(tetrazole)、噁四唑(oxatetrazole)、噻四唑(thiatetrazole)、哌啶、吡啶、嘧啶、四氢吡喃、吡喃、噻烷(thiane)、噻喃、哌嗪(piperazine)、二嗪(diazine)、吗啉、噁嗪、二氧六环(dioxane)、吲哚、二氢吲哚、苯并二氧杂环戊烯、苯并噻吩、苯并呋喃、苯并咪唑、苯并噁唑(bezoxazole)、苯并异噁唑、苯并噻唑、苯并噻二唑、苯并三唑、喹啉、异喹啉、嘌呤、呋喃并吡啶(furopyridine)、单或双氮杂双环类(例如奎宁环、二氮杂双环庚烷、单氮杂双环辛烷、二氮杂螺十一烷(diazaspiroundecane)等)、六氢吡咯并吡咯(hexahydropyrrolopyrrole)、吡咯并吡咯、吡咯并吡啶、咪唑并哒嗪(imidazopyridazine)、二氢苯并二噁英、二氢苯并呋喃等,但不限于此。
术语“氨基(amino)”是指“-NH2”基团。术语“烷基氨基(alkylamino)”是指被单烷基或二烷基取代的氨基。例如,C1~C6烷基氨基包括被单-或双-C1~C6烷基取代的氨基。
术语“烷硫基(alkylthio)”是指“-SR”基团,其中R是烷基。术语“氰基(cyano)”是指“-CN”。
本发明提供了具有6,6-稠合双环部分,即1,2,3,4-四氢萘部分的衍生物或其药学上可接受的盐,即式1的化合物或其药学上可接受的盐:
<式1>
其中,
L为-O-、-CO-、-CR1R2-或-NR3-,
R1和R2彼此独立地是氢;卤素;C1~C6烷基;具有氮原子、氧原子或硫原子的C1~C6烷基;C3~C10环烷基;3-元至12-元杂环;或C1~C6烷氧基,
R3是氢;C1~C6烷基;具有氮原子、氧原子或硫原子的C1~C6烷基;C3~C10环烷基;3-元至12-元杂环;或C1~C6烷氧基,
X是氢;卤素;C1~C6烷基;被1至3个卤素原子取代的C1~C6烷基;具有氮原子、氧原子或硫原子的C1~C6烷基;C1~C6烷氧基;或被1至3个卤素原子取代的C1~C6烷氧基,
Y、Q和Z彼此独立地是-CR4R5-,
R4和R5彼此独立地是氢;卤素;C1~C6烷基;具有氮原子、氧原子或硫原子的C1~C6烷基;C3~C10环烷基;3-元至12-元杂环;或C1~C6烷氧基;或R4和R5与它们所连接的Y、Q或Z的碳原子一起形成C3~C10环烷基,
W是一个键、-CH2-、-O-、-NH-、-CH2CH2-、-CH=CH-或-C≡C-,
A环是6-元至12-元芳基;5-元至12-元杂芳基;C3~C10环烷基;或3-元至12-元杂环,并且
X1、X2、X3和X4彼此独立地是氢;氰基;卤素;C1~C6烷基;被1至3个卤素原子取代的C1~C6烷基;C3~C10环烷基;3-元至12-元杂环;C1~C6烷氧基;C1~C6烷氧基-C1~C6烷氧基;被1至3个卤素原子取代的C1~C6烷氧基;C1~C6烷硫基;吗啉基;氨基;单-或双-C1~C6烷基氨基;C1~C6烷基羰基;羟基;或硝基。
在根据本发明的式1的化合物或其药学上可接受的盐中,L可以是-O-。
在根据本发明的式1的化合物或其药学上可接受的盐中,X可以是氢;卤素;或C1~C6烷氧基。
在根据本发明的式1的化合物或其药学上可接受的盐中,R4和R5可以彼此独立地是氢或C1~C6烷基;或者可以与它们所连接的Y、Q或Z的碳原子一起形成C3~C10环烷基。在一个实施方案中,Y可以是-CH2-。在另一个实施方案中,Q可以是-CH2-。在另一个实施方案中,Y可以是-CH2-;Q可以是-CH2-;并且Z可以是-CR4R5-;并且R4和R5可以彼此独立地是氢或C1~C6烷基,或者可以与Z的碳原子一起形成C3~C10环烷基。
在根据本发明的式1的化合物或其药学上可接受的盐中,W可以是一个键(即,A环直接键合到1,2,3,4-四氢萘部分)。
在根据本发明的式1的化合物或其药学上可接受的盐中,A环可以是苯基、苯并二氧杂环戊烯基、2,3-二氢苯并二噁英基、2,3-二氢苯并呋喃基、吡啶基、吡咯并[2.3-b]吡啶基、嘧啶基或噻吩基。
在根据本发明的式1的化合物或其药学上可接受的盐中,X1、X2、X3和X4可以彼此独立地是氢;氰基;卤素;C1~C6烷基;被1至3个卤素原子取代的C1~C6烷基;C3~C10环烷基;C1~C6烷氧基;C1~C6烷氧基-C1~C6烷氧基;被1至3个卤素原子取代的C1~C6烷氧基;吗啉基;单-或双-C1~C6烷基氨基;或C1~C6烷基羰基。
在本发明的一个优选的实施方案中,
L是-O-,
X是氢;卤素;或C1~C6烷氧基,
R4和R5彼此独立地是氢或C1~C6烷基;或者R4和R5与它们所连接的Y、Q或Z的碳原子一起形成C3~C10环烷基,
W是一个键,
A环是苯基、苯并二氧杂环戊烯基、2,3-二氢苯并二噁英基、2,3-二氢苯并呋喃基、吡啶基、吡咯并[2.3-b]吡啶基、嘧啶基或噻吩基,并且
X1、X2、X3和X4彼此独立地是氢;氰基;卤素;C1~C6烷基;被1至3个卤素原子取代的C1~C6烷基;C3~C10环烷基;C1~C6烷氧基;C1~C6烷氧基-C1~C6烷氧基;被1至3个卤素原子取代的C1~C6烷氧基;吗啉基;单-或双-C1~C6烷基氨基;或C1~C6烷基羰基。
在所述实施方案中,Y可以是-CH2-。
在所述实施方案中,Q可以是-CH2-。
在所述实施方案中,Y可以是-CH2-;Q可以是-CH2-;并且Z可以是-CR4R5-;并且R4和R5可以彼此独立地是氢或C1~C6烷基,或可以与Z的碳原子一起形成C3~C10环烷基。
在式1的化合物或其药学上可接受的盐中,优选的化合物包括选自以下的化合物,包括其药学上可接受的盐:
(S)-奎宁环-3-基(6-(4-氟苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(4-氯苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(4-(三氟甲基)苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(4-(三氟甲氧基)苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(3-氟苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(3-氯苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(3-(三氟甲基)苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(3-(三氟甲氧基)苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(2-氟苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(2-氯苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(2-(三氟甲基)苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(2-(三氟甲氧基)苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(4-(二氟甲氧基)苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(对甲苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(3,4-二氟苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(2,5-二氟苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(3,5-二氟苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(2,4-二氟苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(2,3-二氟苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(2,3,4-三氟苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(2,4,5-三氟苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(3,4-二氯苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(2,5-二氯苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(3,5-二氯苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(4-(2-甲氧基乙氧基)苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(4-(甲氧基甲氧基)苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(3-(2-甲氧基乙氧基)苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(3-(甲氧基甲氧基)苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(2-(2-甲氧基乙氧基)苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(2-(甲氧基甲氧基)苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(4-乙基苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(4-丙基苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(4-丁基苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(4-异丙基苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(4-异丁基苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(4-(叔丁基)苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(4-环丙基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(3-乙基苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(3-(叔丁基)苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(3-异丙基苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(2-乙基苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(2,2-二氟苯并[d][1,3]二氧杂环戊烯-5-基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(2,3-二氢苯并[b][1,4]二噁英-6-基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(2,3-二氢苯并呋喃-6-基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(4-吗啉代苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(4-甲氧基苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(3-甲氧基苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(2-甲氧基苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(3-氟吡啶-4-基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(2-甲基吡啶-4-基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(2-甲氧基吡啶-4-基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(1H-吡咯并[2,3-b]吡啶-5-基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(嘧啶-5-基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(1H-吡咯并[2,3-b]吡啶-4-基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(7-(4-氟苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(7-(4-氯苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(7-(对甲苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(7-(3-(氟苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(7-(3-(氯苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(7-(3-(三氟甲基)苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(7-(2-(氟苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(7-(2-氯苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(7-(2-(三氟甲基)苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(7-(3,4-二氟苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(7-(2,4-二氟苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(7-(2,4,5-三氟苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(7-(2,5-二氟苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(7-(3,5-二氟苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(7-(2,3,4-三氟苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(7-(3,4-二氯苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(7-(2,5-二氯苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(7-(吡啶-4-基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(7-(吡啶-3-基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(7-(邻甲苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(7-(2-甲氧基苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(7-(2-乙氧基苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(7-(3-甲氧基苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(7-(2-异丙氧基苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(7-(4-(2-甲氧基乙氧基)苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(7-(4-甲氧基苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(7-(4-乙氧基苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(7-(4-丙氧基苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(7-(4-异丙氧基苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(7-(苯并[d]二氧杂环戊烯-5-基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(7-(间甲苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(4-氟苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(4-氯苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(2,2-二甲基-6-(4-(三氟甲基)苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(2,2-二甲基-6-(4-(三氟甲氧基)苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(3-氟苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(3-氯苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(2,2-二甲基-6-(3-(三氟甲基)苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(2,2-二甲基-6-(3-(三氟甲氧基)苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(2-氟苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(2-氯苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(2,2-二甲基-6-(2-(三氟甲基)苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(2,2-二甲基-6-(2-(三氟甲氧基)苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(2,2-二甲基-6-(对甲苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(4-(二氟甲氧基)苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(3,4-二氟苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(2,4-二氟苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(2,3-二氟苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(2,5-二氟苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(3,5-二氟苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(2,5-二氯苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(3,4-二氯苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(3,5-二氯苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(2,2-二甲基-6-(2,4,5-三氟苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(2,2-二甲基-6-(2,3,4-三氟苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(4-(2-甲氧基乙氧基)苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(3-(2-甲氧基乙氧基)苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(2-(2-甲氧基乙氧基)苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(4-(甲氧基甲氧基)苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(3-(甲氧基甲氧基)苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(2-(甲氧基甲氧基)苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(2-甲氧基吡啶-4-基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(2,2-二甲基-6-(2-甲基吡啶-4-基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(2-氟吡啶-4-基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(2,2-二甲基-6-(2-(三氟甲基)吡啶-4-基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(4-甲氧基苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(3-甲氧基苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(3-乙氧基苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(2-氯-4-甲氧基苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(4-氯-3-甲氧基苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(2-氯-5-甲氧基苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(3-氟-4-甲氧基苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(3-乙基苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(3-(叔丁基)苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(3-异丙基苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(3-(二氟甲基)苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(3-(二甲基氨基)苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(3-异丙氧基苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(2,3-二甲氧基苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(2,4-二甲氧基苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(2,5-二甲氧基苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(2,6-二甲氧基苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(3,4-二甲氧基苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(3,5-二甲氧基苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(3-氯-4-甲氧基苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(3-氯-4-乙氧基苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(3-氯-4-丙氧基苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(3-氟-4-异丙氧基苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(4-丁氧基-3-氯苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(4-乙氧基-3-氟苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(3-氟-4-丙氧基苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(3,5-二甲基-4-丙氧基苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(4-丁氧基-3,5-二甲基苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(2-氟-4-甲氧基苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(3-氯-4-异丙氧基苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(2-乙酰基噻吩-3-基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(7-(4-氟苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(7-(4-氯苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(2,2-二甲基-7-(4-(三氟甲基)苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(2,2-二甲基-7-(4-(三氟甲氧基)苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(7-(3-氟苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(7-(3-氯苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(2,2-二甲基-7-(3-(三氟甲基)苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(2,2-二甲基-7-(3-(三氟甲氧基)苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(7-(2-氟苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(7-(2-氯苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(2,2-二甲基-7-(2-(三氟甲基)苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(2,2-二甲基-7-(2-(三氟甲氧基)苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(2,2-二甲基-7-(2-(对甲苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(7-(4-(二氟甲氧基)苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(7-(4-(2-甲氧基乙氧基)苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(7-(3-(2-甲氧基乙氧基)苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(7-(2-(2-甲氧基乙氧基)苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(7-(4-(甲氧基甲氧基)苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(7-(3-(甲氧基甲氧基)苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(7-(2-(甲氧基甲氧基)苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(7’-(4-氟苯基)-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-基)氨基甲酸酯;
(S)-奎宁环-3-基(7’-(4-氯苯基)-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-基)氨基甲酸酯;
(S)-奎宁环-3-基(7’-(4-(三氟甲基)苯基)-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-基)氨基甲酸酯;
(S)-奎宁环-3-基(7’-(4-(三氟甲氧基)苯基)-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-基)氨基甲酸酯;
(S)-奎宁环-3-基(7’-(3-氟苯基)-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-基)氨基甲酸酯;
(S)-奎宁环-3-基(7’-(3-氯苯基)-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-基)氨基甲酸酯;
(S)-奎宁环-3-基(7’-(3-(三氟甲基)苯基)-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-基)氨基甲酸酯;
(S)-奎宁环-3-基(7’-(3-(三氟甲氧基)苯基)-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-基)氨基甲酸酯;
(S)-奎宁环-3-基(7’-(2-氟苯基)-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-基)氨基甲酸酯;
(S)-奎宁环-3-基(7’-(2-氯苯基)-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-基)氨基甲酸酯;
(S)-奎宁环-3-基(7’-(2-(三氟甲基)苯基)-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-基)氨基甲酸酯;
(S)-奎宁环-3-基(7’-(2-(三氟甲氧基)苯基)-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-基)氨基甲酸酯;
(S)-奎宁环-3-基(7’-(对甲苯基)-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-基)氨基甲酸酯;
(S)-奎宁环-3-基(7’-(4-(二氟甲氧基)苯基)-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-基)氨基甲酸酯;
(S)-奎宁环-3-基(7’-(4-(甲氧基甲氧基)苯基)-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-基)氨基甲酸酯;
(S)-奎宁环-3-基(6’-(4-氟苯基)-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-基)氨基甲酸酯;
(S)-奎宁环-3-基(6’-(4-氯苯基)-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-基)氨基甲酸酯;
(S)-奎宁环-3-基(6’-(4-(三氟甲基)苯基)-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-基)氨基甲酸酯;
(S)-奎宁环-3-基(6’-(4-(三氟甲氧基)苯基)-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-基)氨基甲酸酯;
(S)-奎宁环-3-基(6’-(3-氟苯基)-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-基)氨基甲酸酯;
(S)-奎宁环-3-基(6’-(3-氯苯基)-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-基)氨基甲酸酯;
(S)-奎宁环-3-基(6’-(3-(三氟甲基)苯基)-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-基)氨基甲酸酯;
(S)-奎宁环-3-基(6’-(3-(三氟甲氧基)苯基)-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-基)氨基甲酸酯;
(S)-奎宁环-3-基(6’-(4-(2-甲氧基乙氧基)苯基)-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-基)氨基甲酸酯;
(S)-奎宁环-3-基(6’-(3-(2-甲氧基乙氧基)苯基)-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-基)氨基甲酸酯;
(S)-奎宁环-3-基(6’-(2-(2-甲氧基乙氧基)苯基)-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-基)氨基甲酸酯;
(S)-奎宁环-3-基(6’-(4-(甲氧基甲氧基)苯基)-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-基)氨基甲酸酯;
(S)-奎宁环-3-基(6’-(3-(甲氧基甲氧基)苯基)-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-基)氨基甲酸酯;
(S)-奎宁环-3-基(6’-(2-(甲氧基甲氧基)苯基)-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-基)氨基甲酸酯;
(S)-奎宁环-3-基(6’-(2-氯-4-甲氧基苯基)-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-基)氨基甲酸酯;
(S)-奎宁环-3-基(6’-(4-氯-3-甲氧基苯基)-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-基)氨基甲酸酯;
(S)-奎宁环-3-基(6’-(3-氟-4-甲氧基苯基)-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-基)氨基甲酸酯;
(S)-奎宁环-3-基(6’-(3-乙基苯基)-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-基)氨基甲酸酯;
(S)-奎宁环-3-基(6’-(3-(叔丁基)苯基)-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-基)氨基甲酸酯;
(S)-奎宁环-3-基(6’-(3-异丙基苯基)-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-基)氨基甲酸酯;
(S)-奎宁环-3-基(6’-(3-(二氟甲基)苯基)-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-基)氨基甲酸酯;
(S)-奎宁环-3-基(6’-(3-(二甲基氨基)苯基)-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-基)氨基甲酸酯;
(S)-奎宁环-3-基(6’-(3-异丙氧基苯基)-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-基)氨基甲酸酯;
(S)-奎宁环-3-基(6’-(2,3-二甲氧基苯基)-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-基)氨基甲酸酯;
(S)-奎宁环-3-基(6’-(2,4-二甲氧基苯基)-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-基)氨基甲酸酯;
(S)-奎宁环-3-基(6’-(2,5-二甲氧基苯基)-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-基)氨基甲酸酯;
(S)-奎宁环-3-基(6’-(2,6-二甲氧基苯基)-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-基)氨基甲酸酯;
(S)-奎宁环-3-基(6’-(3,4-二甲氧基苯基)-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-基)氨基甲酸酯;
(S)-奎宁环-3-基(6’-(3,5-二甲氧基苯基)-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-基)氨基甲酸酯;
(S)-奎宁环-3-基(6’-(4-甲氧基苯基)-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-基)氨基甲酸酯;
(S)-奎宁环-3-基(6’-(3-甲氧基苯基)-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-基)氨基甲酸酯;
(S)-奎宁环-3-基(6’-(4-乙氧基苯基)-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-基)氨基甲酸酯;
(S)-奎宁环-3-基(6’-(3-乙氧基苯基)-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-基)氨基甲酸酯;
(S)-奎宁环-3-基(6’-(4-异丙氧基苯基)-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-基)氨基甲酸酯;
(S)-奎宁环-3-基(6’-(4-丙氧基苯基)-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-基)氨基甲酸酯;
(S)-奎宁环-3-基(6’-(4-乙基苯基)-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-基)氨基甲酸酯;
(S)-奎宁环-3-基(6’-(4-丙基苯基)-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-基)氨基甲酸酯;
(S)-奎宁环-3-基(6’-(4-异丙基苯基)-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-基)氨基甲酸酯;
(S)-奎宁环-3-基(6’-(4-异丁基苯基)-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-基)氨基甲酸酯;
(S)-奎宁环-3-基(6’-(4-(叔丁基)苯基)-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-基)氨基甲酸酯;
(S)-奎宁环-3-基(6’-(4-环丙基苯基)-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-基)氨基甲酸酯;
(S)-奎宁环-3-基(7-氟-6-(3-氟-4-甲氧基苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(3,5-二甲基-4-丙氧基苯基)-(7-氟-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(7-氟-2,2-二甲基-6-(4-丙基苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(7-氟-6-(4-异丁基苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(2-(叔丁氧基)吡啶-4-基)-(7-氟-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(7-氟-6-(4-异丙氧基苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(3-氟-4-甲氧基苯基)-7-甲氧基-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(3,5-二甲基-4-丙氧基苯基)-7-甲氧基-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(7-甲氧基-2,2-二甲基-6-(4-丙基苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(4-异丁基苯基)-7-甲氧基-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(2-(叔丁氧基)吡啶-4-基)-7-甲氧基-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯;以及
(S)-奎宁环-3-基(6-(4-异丙氧基苯基)-7-甲氧基-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯。
式1的化合物或其药学上可接受的盐可以是顺式或反式几何异构体(geometricalisomer)的形式。除非另有说明,式1的化合物或其药学上可接受的盐包括顺式几何异构体和反式几何异构体。式1的化合物或其药学上可接受的盐也可以具有含有不对称原子的取代基,因此呈外消旋混合物(RS)形式或光学异构体形式,例如(R)异构体或(S)异构体。除非另有说明,式1的化合物或其药学上可接受的盐包括外消旋混合物(RS)和各光学异构体例如(R)异构体或(S)异构体。此外,式1的化合物或其药学上可接受的盐可以具有两个或多个手性中心,因此为一种或多种非对映异构体的形式或其混合物的形式。除非另有说明,式1的化合物或其药学上可接受的盐包含各非对映异构体及其混合物。
本发明的式1的化合物可以是药学上可接受的盐形式。该盐可以是常规的酸加成盐(acid addition salt)形式,其包括例如衍生自如盐酸、硫酸、硝酸、磷酸、高氯酸或氢溴酸的无机酸的盐;以及衍生自例如甲酸、乙酸、丙酸、草酸、琥珀酸、苯甲酸、柠檬酸、马来酸、丙二酸、苹果酸、酒石酸、葡萄糖酸、乳酸、龙胆酸(gentisic acid)、富马酸、乳糖酸、水杨酸、邻苯二甲酸、扑酸(embonic acid)、天冬氨酸、谷氨酸、或乙酰水杨酸的有机酸的盐。并且,该盐还包括例如衍生自氨基酸如甘氨酸、丙氨酸、缬氨酸、异亮氨酸、丝氨酸、半胱氨酸、胱氨酸、天冬氨酸、谷氨酰胺、赖氨酸、精氨酸、酪氨酸或脯氨酸的盐。此外,该盐包括例如衍生自磺酸如甲磺酸、乙磺酸、苯磺酸或甲苯磺酸的盐。
根据本发明的式1的化合物或其药学上可接受的盐可以根据各种方法制备。
例如,根据本发明的式1a的化合物或其药学上可接受的盐可以通过包括以下的方法制备:使式2的化合物或其盐与氯甲酸乙酯反应得到式3的化合物;将式3的化合物与式4的化合物偶联,得到式5的化合物;使式5的化合物与被X1、X2、X3或X4取代的A-W-硼酸反应,得到式1a的化合物;并且任选地将式1a的化合物转化为其药学上可接受的盐,如以下反应方案1所示。
<反应方案1>
在反应方案1中,X、Y、Q、Z、W、A环、X1、X2、X3和X4与上文限定的相同。
式2的化合物是市售的或已知的化合物,可以根据文献合成。式2的化合物或其盐与氯甲酸乙酯之间的反应可以在有机碱例如三乙胺、N,N-二异丙基乙胺等或无机碱例如碳酸钾等的存在下进行。基于1当量的式2的化合物可以以1当量至1.5当量范围内的量使用碱或基于1当量式2的化合物的盐(例如盐酸盐)可以以3当量至5当量范围内的量使用碱。该反应可以在溶剂如二氯甲烷或四氢呋喃中进行,优选在0℃至室温下进行。
式3的化合物和式4的化合物(即,奎宁环醇)之间的偶联可以通过包括除去乙醇的缩合反应来进行。该反应可以优选在碱例如氢化钠的存在下进行。此外,可以在120℃至140℃下,在例如甲苯的非极性有机溶剂中进行反应。
式5的化合物与被X1、X2、X3和X4取代的A-W-硼酸之间的反应可以根据铃木反应(Suzuki reaction)进行。所述铃木反应可以使用钯催化剂,例如四(三苯基膦)钯(tetrakis(triphenylphosphine)palladium)(0)(Pd(PPh3)4)、乙酸钯(II)(Pd(OAc)2)、[1,1’-双(二苯基膦基)二茂铁]二氯钯(II)(Pd(dppf)Cl2)等进行。此外,所述铃木反应可以在无机碱如碳酸铯(Cs2CO3)、碳酸钠(Na2CO3)、碳酸钾(K2CO3)、磷酸钾(K3PO4)等的存在下进行。所述铃木反应可以在例如甲苯的非极性有机溶剂或例如1,4-二氧六环、四氢呋喃、乙腈、1,2-二甲氧基乙烷或N,N-二甲基甲酰胺的极性有机溶剂中,在50℃至150℃,优选80℃至120℃下进行。包括反应时间在内的其他反应条件可以根据已知的铃木反应方法确定。
式1a的化合物向其药学上可接受的盐的转化可以按照常规方法进行。例如,式1a的化合物的药学上可接受的盐可以通过将式1a的化合物溶解在水混溶性溶剂(water-miscible solvent)如甲醇、乙醇、丙酮或1,4-二氧六环中,然后加入游离酸(free acid)或游离碱(free base)用于其结晶来制备。
此外,根据本发明的式1a的化合物或其药学上可接受的盐可以通过包括以下的方法制备:使式4的化合物与双(4-硝基苯基)碳酸酯反应得到式7的化合物;使式7的化合物与式2的化合物反应得到式5的化合物;使式5的化合物与被X1、X2、X3或X4取代的A-W-硼酸反应,得到式1a的化合物;并且任选地将式1a的化合物转化为其药学上可接受的盐,如以下反应方案2所示。
<反应方案2>
在反应方案2中,X、Y、Q、Z、W、A环、X1、X2、X3和X4与上文限定的相同。
式4的化合物(即奎宁环醇)与双(4-硝基苯基)碳酸酯之间的反应可以在极性溶剂如N,N-二甲基甲酰胺中优选在0℃至25℃下进行。也可以通过使式4的化合物与氯甲酸-4-硝基苯酯(4-nitrophenyl chloroformate)在碱例如三乙胺的存在下,在溶剂例如二氯甲烷、乙腈等中反应来制备式7的化合物。
式7的化合物和式2的化合物之间的反应可以在0℃至25℃下,在溶剂例如N,N-二甲基甲酰胺、四氢呋喃或乙腈中,在碱例如N,N-二异丙基乙胺或三乙胺的存在下进行。
式5的化合物与被X1、X2、X3或X4取代的A-W-硼酸之间的反应可以根据如上所述的铃木反应进行。此外,式1a的化合物向其药学上可接受的盐的转化可以按照上述常规方法进行。
根据本发明的具有1,2,3,4-四氢萘部分的化合物,即式1的化合物或其药学上可接受的盐,具有优异的针对葡萄糖神经酰胺合酶(GCS)的抑制活性,因此可以有效地用于预防或治疗与GCS相关的各种疾病。
因此,本发明在其范围内包括一种用于抑制葡萄糖神经酰胺合酶(GCS)的药物组合物,该药物组合物包含治疗有效量的式1的化合物或其药学上可接受的盐作为活性成分。在一个实施方案中,本发明提供了一种用于预防或治疗与GCS相关的疾病,例如戈谢病、法布里病、泰-萨克斯病、帕金森病等的药物组合物,该药物组合物包含治疗有效量的式1的化合物或其药学上可接受的盐作为活性成分。
本发明的药物组合物可以包含药学上可接受的载体,例如稀释剂、崩解剂、甜味剂、润滑剂或调味剂。药物组合物可以配制成口服剂型,例如片剂、胶囊剂、散剂、颗粒剂、混悬剂(suspension)、乳剂(emulsion)或糖浆剂;或肠胃外剂型(parenteral dosage form),例如外用溶液剂、外用混悬剂、外用乳剂、凝胶剂(例如软膏)、吸入剂、雾化剂、注射剂。剂型(dosage form)可以是各种形式,例如单次给药或多次给药的剂型。
本发明的药物组合物可以包含例如稀释剂(例如乳糖、玉米淀粉等);润滑剂(例如硬脂酸镁);乳化剂(emulsifying agent);悬浮剂(suspending agent);稳定剂(stabilizer);和/或等渗剂(isotonic agent)。如果需要,该组合物进一步包含甜味剂和/或调味剂。
本发明的组合物可以口服或肠胃外给药,包括吸入的、静脉内的、腹膜内的、皮下的、直肠的和局部的给药途径。因此,本发明的组合物可以配制成各种剂型,例如片剂、胶囊剂、水溶液或混悬剂。在用于口服给药的片剂的情况下,通常使用载体例如乳糖、玉米淀粉和例如硬脂酸镁的润滑剂。在用于口服给药的胶囊剂的情况下,乳糖和/或干玉米淀粉可以用作稀释剂。当口服给药需要水混悬剂时,活性成分可以与乳化剂和/或悬浮剂组合。如果需要,可以使用某些甜味剂和/或调味剂。对于肌肉内的、腹膜内的、皮下的和静脉内的给药,通常制备活性成分的无菌溶液,并适当调节和缓冲(buffered)溶液的pH。对于静脉内的给药,应控制溶质的总浓度以使制剂等渗(isotonic)。本发明的组合物可以是含有药学上可接受的载体的水溶液形式,例如pH值为7.4的盐水。溶液可以通过局部团注(bolusinjection)引入患者的肌肉内血流中。
式1的化合物或其药学上可接受的盐可以以每天约0.0001mg/kg至约100mg/kg的治疗有效量施用于受试患者。当然,剂量可以根据患者的年龄、体重、敏感性、症状或化合物的活性而改变。
本发明在其范围内包括在哺乳动物中抑制葡萄糖神经酰胺合酶(GCS)的方法,该方法包括向有需要的哺乳动物施用治疗有效量的式1的化合物或其药学上可接受的盐。在一个实施方案中,本发明提供了一种用于治疗与GCS相关的疾病,例如戈谢病、法布里病、泰-萨克斯病、帕金森病等的方法,该方法包括向有需要的哺乳动物施用治疗有效量的式1的化合物或其药学上可接受的盐。
本发明还提供了式1的化合物或其药学上可接受的盐在制备用于抑制哺乳动物中的葡萄糖神经酰胺合酶(GCS)的药物中的用途。在一个实施方案中,本发明提供了式1的化合物或其药学上可接受的盐在制备用于预防或治疗与GCS相关的疾病例如戈谢病、法布里病、泰-萨克斯病、帕金森病等的药物中的用途。
提供以下实施例和实验例仅用于说明目的,并不旨在限制本发明的范围。
在以下实施例中,盐水是指饱和氯化钠水溶液。除非另有说明,否则所有温度均以摄氏度(℃)为单位。除非另有说明,否则所有反应均在室温下进行。
以下制备例(Preparation)和实施例中制备的化合物的分析如下进行:核磁共振(NMR)光谱分析使用Bruker 400MHz光谱仪进行,其化学位移以ppm为单位进行分析。在硅胶(Merck,70-230目)上进行柱层析。每种起始材料是根据文献合成或商业购买的已知化合物。在250nm硅胶板上通过薄层色谱(TLC)分析所有反应和色谱馏分(chromatographicfraction),并用紫外线或碘(I2)染色进行可视化。
制备例1.(S)-奎宁环-3-基(6-溴-1,2,3,4-四氢萘-1-基)氨基甲酸酯
步骤1.乙基(6-溴-1,2,3,4-四氢萘-1-基)氨基甲酸酯
将6-溴-1,2,3,4-四氢萘-1-胺(20g,82.6毫摩尔)溶解在二氯甲烷(250mL)中,然后向其中缓慢加入三乙胺(12.7ml,90.9毫摩尔)和氯甲酸乙酯(8.7ml,90.9毫摩尔)。将反应混合物在室温下搅拌4小时。向反应混合物中加入水,然后用二氯甲烷萃取。用无水硫酸镁干燥有机层,然后减压过滤并浓缩。所得残余物通过柱色谱法(正己烷/乙酸乙酯=1/1,v/v)纯化以得到标题化合物,为白色固体。(20.7g,收率:83%)
1H-NMR(400MHz,CDCl3)δ7.31~7.21(m,3H),4.85(s,1H),4.18(m,2H),2.76(m,2H),2.06(m,1H),1.83(m,3H),1.28(t,3H)
步骤2.(S)-奎宁环-3-基(6-溴-1,2,3,4-四氢萘-1-基)氨基甲酸酯
将(S)-(+)-3-奎宁环醇(25.6g,201.2毫摩尔)溶解在甲苯(200ml)中,然后在0℃下向其中加入氢化钠(1.6g,67.1毫摩尔)。将反应混合物搅拌15分钟,然后向其中加入步骤1中制得的乙基(6-溴-1,2,3,4-四氢萘-1-基)氨基甲酸酯(20g,67.1毫摩尔)。将反应混合物在140℃下搅拌回流21小时,然后冷却至室温。向反应混合物中加入盐水(brine),然后用乙酸乙酯萃取。用盐水洗涤有机层两次,用无水硫酸镁干燥,然后减压浓缩。所得残余物通过柱色谱法(乙酸乙酯/(甲醇/氨水=1/1)=9/1,v/v)纯化以得到标题化合物,为白色固体。(17g,收率:66%)
1H-NMR(400MHz,CDCl3)δ7.31~7.19(m,3H),5.08(m,1H),4.85(m,1H),4.77(br,1H),3.24(m,1H),2.84(m,2H),2.74(m,4H),2.10~2.05(m,3H),1.83(m,4H),1.69(m,1H),1.58(m,1H),1.38(m,1H)
制备例2.(S)-奎宁环-3-基(7-溴-1,2,3,4-四氢萘-1-基)氨基甲酸酯
使用7-溴-1,2,3,4-四氢萘-1-胺作为原料,按照与制备例1中相同的步骤制备标题化合物。
1H-NMR(400MHz,CDCl3)δ7.39(d,1H),7.28(d,1H),7.02(d,1H),4.76(s,2H),3.26(q,1H),2.87~2.71(m,7H),2.11~1.88(m,4H),1.85~1.72(m,3H),1.70~1.61(bs,1H),1.56~1.46(m,1H)
制备例3.(S)-奎宁环-3-基(6-溴-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯
步骤1.6-溴-2,2-二甲基-1,2,3,4-四氢萘-1(2H)-酮
将6-溴-1,2,3,4-四氢萘-1-酮(20g,88.9毫摩尔)溶解在四氢呋喃(70ml)中,然后在0℃下向其中加入60%氢化钠(17.8g,444.3毫摩尔)。将反应混合物搅拌15分钟,然后在相同温度下向其中缓慢加入碘甲烷(22.1ml,355.4毫摩尔)。将反应混合物在室温下搅拌过夜。向反应混合物中加入水,然后用乙酸乙酯萃取。用无水硫酸镁干燥有机层,然后减压过滤并浓缩。所得残余物通过柱色谱法(正己烷/乙酸乙酯=10/1,v/v)纯化以得到标题化合物,为白色固体。(20g,收率:90%)
1H-NMR(400MHz,CDCl3)δ8.03(d,1H),7.74(d,1H),7.21(t,1H),3.00(m,2H),2.01(m,2H),1.22(s,6H)
步骤2.6-溴-2,2-二甲基-1,2,3,4-四氢萘-1-胺盐酸盐
将步骤1中制得的6-溴-2,2-二甲基-1,2,3,4-四氢萘-1(2H)-酮(20g,79.0毫摩尔)溶解在甲醇(300ml)中,然后向其中加入乙酸铵(121.8g,1580.1毫摩尔)和氰基硼氢化钠(24.8g,395.0毫摩尔)。将反应混合物在室温下搅拌4小时,然后在80℃下搅拌回流12小时。将反应混合物冷却至室温,用1N氢氧化钠溶液碱化至pH>12,然后用二氯甲烷萃取。用无水硫酸镁干燥有机层,然后减压过滤并浓缩。向所得残余物中加入乙酸乙酯,然后向其中加入盐酸的1,4-二氧六环溶液(4M)。在室温下搅拌混合物1小时。将所得固体减压过滤,用乙酸乙酯洗涤,然后干燥以得到标题化合物,为白色固体。(12g,收率:52%)
1H-NMR(400MHz,CD3OD)δ7.68(d,1H),7.41(d,1H),7.25(t,1H),4.13(s,1H),2.96(m,1H),2.75(m,1H),1.88(m,1H),1.75(m,1H),1.20(s,3H),1.03(s,3H)
步骤3.(S)-奎宁环-3-基(6-溴-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯
将(S)-(+)-3-奎宁环醇(6.3g,49.5毫摩尔)和双(4-硝基苯基)碳酸酯(15.1g,49.5毫摩尔)的N,N-二甲基甲酰胺(80mL)溶液在室温下搅拌8小时。向溶液中加入步骤2中制得的6-溴-2,2-二甲基-1,2,3,4-四氢萘-1-胺盐酸盐(20g,41.3毫摩尔)和二异丙基乙胺(21.6mL,123.9毫摩尔),然后在室温下搅拌过夜。用二异丙醚(100ml×2)萃取反应混合物。用氨水将水层碱化至pH 12,然后用乙酸乙酯萃取。用水洗涤有机层,用无水硫酸镁干燥,然后减压过滤并浓缩。所得残余物通过柱色谱法(乙酸乙酯/(甲醇/氨水=1/1)=9/1,v/v)纯化以得到标题化合物,为白色固体。(6g,收率:36%)
1H-NMR(400MHz,CDCl3)δ7.25(m,2H),7.12(m,1H),5.09(m,1H),4.95(m,1H),4.53(m,1H),3.20(m,1H),2.84~2.65(m,7H),1.95(m,1H),1.81(m,2H),1.66(br,1H),1.53(br,1H),1.38(br,1H),0.99(m,3H),0.88(m,3H)
制备例4.(S)-奎宁环-3-基(7-溴-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯
步骤1.7-溴-2,2-二甲基-1,2,3,4-四氢萘-1(2H)-酮
使用7-溴-3,4-二氢萘-1(2H)-酮作为原料,按照与制备例3的步骤1中相同的步骤制备标题化合物。
1H-NMR(400MHz,CDCl3)δ8.16(s,1H),7.57(d,1H),7.12(d,1H),2.94(m,2H),1.99(m,2H),1.27(s,6H)
步骤2.(7-溴-2,2-二甲基-1,2,3,4-四氢萘-1-胺盐酸盐
使用步骤1中制得的7-溴-2,2-二甲基-1,2,3,4-四氢萘-1(2H)-酮,按照与制备例3的步骤2中相同的步骤,制备标题化合物。
1H-NMR(400MHz,MeOD)δ7.60(s,1H),7.51(d,1H),7.20(d,1H),4.09(s,1H),3.88(m,2H),1.87(m,1H),1.70(m,1H),1.16(s,3H),1.05(s,3H)
步骤3.乙基(7-溴-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯
使用步骤2中制得的7-溴-2,2-二甲基-1,2,3,4-四氢萘-1-胺盐酸盐,按照与制备例1的步骤1中相同的步骤,制备标题化合物。产物无需进一步纯化即可用于随后的反应中。
步骤4.(S)-奎宁环-3-基(7-溴-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯
使用步骤3中制得的乙基(7-溴-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯,按照与制备例1的步骤2中相同的步骤来制备标题化合物。
1H-NMR(400MHz,CDCl3)δ7.40(m,1H),7.25(m,1H),6.95(d,1H),5.09(m,1H),4.78(m,1H),4.59(m,1H),3.22(m,1H),2.86~2.68(m,7H),1.98(m,1H),1.82(m,2H),1.66(m,1H),1.55(m,1H),1.38(m,1H),1.00(m,3H),0.88(m,3H)
制备例5.(S)-奎宁环-3-基(6’-溴-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-基)氨基甲酸酯
步骤1.(2-氯乙基)二甲基碘化锍
在室温下将2-氯乙基甲基硫醚(10g,90.4毫摩尔)在碘甲烷(50ml)中的溶液搅拌2天。将所得固体减压过滤,用丙酮洗涤,然后干燥以得到标题化合物。(16g,收率:70%)产物无需进一步纯化即可用于随后的反应中。
步骤2.6’-溴-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-酮
将6-溴-3,4-氢化萘-1(2H)-酮(1.03g,4.58毫摩尔)溶解在叔丁醇(10mL)中,然后向其中缓慢加入碘化钠(0.131g,0.872毫摩尔)和60%的氢化钠(0.349g,8.72毫摩尔)。在室温下搅拌反应混合物20分钟。在1小时内将步骤1中制得的(2-氯乙基)二甲基碘化锍(1.10g,4.36毫摩尔)缓慢加入到反应混合物中,然后在室温下搅拌过夜。通过向反应混合物中加入水(15ml)来淬灭(quenched)反应,然后用乙酸乙酯萃取反应混合物。用无水硫酸镁干燥有机层,然后减压过滤并浓缩。所得残余物通过柱色谱法(正己烷/乙酸乙酯=10/1,v/v)纯化以得到标题化合物,为白色固体。(789mg,收率:78%)
1H-NMR(400MHz,CDCl3)δ7.99(d,1H),7.73(d,1H),7.19(t,1H),3.08(m,2H),1.99(m,2H),1.40(d,2H),0.86(d,2H)
步骤3.6’-溴-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-胺盐酸盐
使用步骤2中制得的6’-溴-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-酮,按照与制备例3的步骤2中相同的步骤来制备标题化合物。
1H-NMR(400MHz,MeOD)δ7.67(d,1H),7.37(d,1H),7.23(t,1H),3.68(s,1H),3.09(m,1H),2.82(m,1H),2.39(m,1H),1.26(m,1H),0.93(m,1H),0.79(m,1H),0.69(m,1H),0.55(m,1H)
步骤4.乙基(6’-溴-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-基)氨基甲酸酯
使用步骤3中制得的6’-溴-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-胺盐酸盐,按照与制备例1的步骤1中相同的步骤来制备标题化合物。产物无需进一步纯化即可用于随后的反应中。
1H-NMR(400MHz,CDCl3)δ7.48(d,1H),7.30(m,1H),7.06(t,1H),4.98(br,1H),4.27(d,1H),4.15(m,2H),2.95(m,1H),2.74(m,1H),2.03(m,1H),1.31(m,1H),1.27(m,3H),0.85(m,1H),0.50(m,1H),0.45(s,2H)
步骤5.(S)-奎宁环-3-基(6’-溴-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-基)氨基甲酸酯
使用步骤4中制得的乙基(6’-溴-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-基)氨基甲酸酯,按照与制备例1的步骤2中相同的步骤来制备标题化合物。
1H-NMR(400MHz,CDCl3)δ7.47(d,2H),7.27(m,1H),7.04(m,1H),5.30(m,1H),4.78~4.76(m,2H),4.23(d,1H),3.23(m,1H),2.86~2.67(m,7H),2.42(br,1H),1.98(m,1H),1.83(m,1H),1.67(m,1H),1.55(m,1H),1.37(m,1H),0.85(m,1H),0.47~0.44(m,2H)制备例6.(S)-奎宁环-3-基(7’-溴-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-基)氨基甲酸酯
使用7-溴-3,4-氢化萘-1(2H)-酮作为原料,按照与制备例5中相同的步骤来制备标题化合物。
1H-NMR(400MHz,CDCl3)δ7.41(s,1H),7.30(m,1H),6.99(d,1H),5.42(br,1H),4.77(m,2H),4.26(m,1H),3.22(m,1H),2.85~2.67(m,7H),2.10(br,1H),1.98(m,1H),1.83(br,1H),1.67(br,1H),1.55(br,1H),1.39(br,1H),0.85(m,1H),0.51(m,1H),0.49(m,2H)
制备例7.(S)-奎宁环-3-基(6-溴-7-氟-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯
使用6-溴-7-氟-3,4-氢化萘-1(2H)-酮作为原料,按照与制备例3中相同的步骤来制备标题化合物。
1H-NMR(400MHz,CDCl3)δ7.29(m,2H),7.04(m,1H),4.78(m,2H),4.56(d,1H),3.25(m,1H),2.93~2.74(m,7H),2.09(br,1H),1.82(br,1H),1.71(br,3H),1.59(br,1H),1.42(br,1H),1.03(d,3H),0.91(d,3H)
制备例8.(S)-奎宁环-3-基(6-溴-7-甲氧基-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯
使用6-溴-7-甲氧基-3,4-氢化萘-1(2H)-酮作为原料,按照与制备例3中相同的步骤来制备标题化合物。
1H-NMR(400MHz,CDCl3)δ7.27(m,2H),6.79(m,1H),4.77(m,2H),4.55(d,1H),3.84(d,3H),3.25(m,1H),2.93~2.74(m,7H),2.09(br,1H),1.89(br,1H),1.71(br,3H),1.56(br,1H),1.41(br,1H),1.03(d,3H),0.95(d,3H)
实施例1.(S)-奎宁环-3-基(6-(4-氟苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯
向在制备例1中制得的(S)-奎宁环-3-基-(6-溴-1,2,3,4-四氢萘-1-基)氨基甲酸酯(30mg,0.079毫摩尔)、4-氟苯硼酸(16.6mg,0.12毫摩尔)、磷酸钾(50.4mg,0.23毫摩尔)和四(三苯基膦)钯(0)(9.1mg,10摩尔%)的混合物中缓慢加入1,4-二氧六环(1ml)和水(0.5ml)。将反应混合物在120℃下搅拌回流过夜,然后冷却至室温。向反应混合物中加入水,然后用乙酸乙酯萃取反应混合物。用无水硫酸镁干燥有机层,然后减压过滤并浓缩。通过硅胶柱色谱法(乙酸乙酯/(甲醇/氨水=1/1)=9/1,v/v)纯化所得的呈黄色油状形式的残余物以得到标题化合物,为白色固体。(20mg,收率:65%)
1H-NMR(400MHz,CDCl3)δ7.53(m,2H),7.39(m,2H),7.26(m,1H),7.13(m,2H),5.02(m,2H),4.80(m,1H),3.27(m,1H),2.87~2.77(m,7H),2.08(m,2H),1.89(m,4H),1.71(br,1H),1.60(br,1H),1.40(br,1H)
实施例2至实施例54
使用制备例1中制得的(S)-奎宁环-3-基(6-溴-1,2,3,4-四氢萘-1-基)氨基甲酸酯,和相应的取代硼酸(substituted-boronic acid),按照与实施例1中相同的步骤来分别制备实施例2至实施例54的标题化合物。
实施例2.(S)-奎宁环-3-基(6-(4-氯苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.51(m,2H),7.42(m,3H),7.29(m,2H),5.00(m,2H),4.81(br,1H),3.30(m,1H),2.87~2.77(m,7H),2.06(m,2H),1.89(m,4H),1.71(br,1H),1.60(br,1H),1.41(br,1H)
实施例3.(S)-奎宁环-3-基(6-(4-(三氟甲基)苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.69(s,3H),7.45(m,2H),7.35(m,1H),7.28(d,1H),4.99(m,2H),4.80(br,1H),3.29(m,1H),2.88~2.77(m,7H),2.14(m,2H),1.91(m,4H),1.71(br,1H),1.61(br,1H),1.41(br,1H)
实施例4.(S)-奎宁环-3-基(6-(4-(三氟甲氧基)苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.57(d,1H),7.42(m,4H),7.28(m,2H),5.00(m,2H),4.80(br,1H),3.28(m,1H),2.86~2.77(m,7H),2.08(m,2H),1.90(m,4H),1.71(br,1H),1.60(br,1H),1.40(br,1H)
实施例5.(S)-奎宁环-3-基(6-(3-氟苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.46~7.36(m,4H),7.30~7.28(m,2H),7.04(t,1H),5.00(m,2H),4.80(m,1H),3.28(m,1H),2.88~2.77(m,7H),2.13(m,2H),1.89(m,4H),1.71(br,1H),1.60(br,1H),1.40(br,1H)
实施例6.(S)-奎宁环-3-基(6-(3-氯苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.56(s,1H),7.44(m,1H),7.37(m,2H),7.23(m,2H),5.00(m,2H),4.80(br,1H),3.28(m,1H),2.88~2.77(m,7H),2.09(m,2H),1.90~1.82(m,4H),1.71(br,1H),1.60(m,1H),1.41(m,1H)
实施例7.(S)-奎宁环-3-基(6-(3-(三氟甲基)苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.81(s,1H),7.76(d,1H),7.62~7.54(m,2H),7.44(m,2H),7.34(s,1H),5.06~5.03(m,2H),4.81(br,1H),3.28(m,1H),2.88~2.74(m,7H),2.12(m,2H),1.90(m,3H),1.83(br,1H),1.71(br,1H),1.60(br,1H),1.41(br,1H)
实施例8.(S)-奎宁环-3-基(6-(3-(三氟甲氧基)苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.50~7.41(m,5H),7.31(s,1H),7.22(m,1H),5.06~5.04(m,2H),4.80(br,1H),3.27(m,1H),2.87~2.77(m,7H),2.08(m,2H),1.90(m,3H),1.82(br,1H),1.70(br,1H),1.60(br,1H),1.40(br,1H)
实施例9.(S)-奎宁环-3-基(6-(2-氟苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.44(m,3H),7.34(m,2H),7.23(m,1H),7.18(m,1H),5.03(m,1H),4.97(br,1H),4.80(br,1H),3.28(m,1H),2.86~2.77(m,7H),2.06(m,2H),1.90(m,4H),1.70(br,1H),1.60(br,1H),1.40(br,1H)
实施例10.(S)-奎宁环-3-基(6-(2-氯苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯1H-NMR(400MHz,CDCl3)δ7.71(m,1H),7.66(m,1H),7.44(m,4H),7.18(s,1H),5.08(m,1H),4.98(br,1H),4.81(br,1H),3.28(m,1H),2.90~2.78(m,7H),2.13(m,1H),1.90(m,5H),1.70(br,1H),1.60(br,1H),1.40(br,1H)
实施例11.(S)-奎宁环-3-基(6-(2-(三氟甲基)苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.74(m,1H),7.56(m,1H),7.55(1H),7.47(br,1H),7.32(m,1H),7.16(br,1H),7.07(s,1H),5.07(m,1H),4.96(m,1H),4.80(m,1H),3.29(m,1H),2.88~2.81(m,7H),2.09(m,2H),1.90(m,4H),1.71(br,1H),1.61(br,1H),1.41(br,1H)
实施例12.(S)-奎宁环-3-基(6-(2-(三氟甲氧基)苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.41~7.37(m,4H),7.31(m,2H),7.20(1H南部),5.08(m,1H),4.97(br,1H),4.81(m,1H),3.30(m,1H),2.86~2.78(m,7H),2.14(m,2H),1.90(m,4H),1.70(br,1H),1.60(br,1H),1.40(br,1H)
实施例13.(S)-奎宁环-3-基(6-(4-(二氟甲氧基)苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.55(d,2H),7.40(m,2H),7.29(s,1H),7.18(d,2H),6.74~6.37(t,1H),5.18(m,1H),4.95(m,1H),4.79(m,1H),3.27(m,1H),2.86~2.72(m,7H),2.08(m,2H),1.88(m,3H),1.82(br,1H),1.69(br,1H),1.59(br,1H),1.40(br,1H)
实施例14.(S)-奎宁环-3-基(6-(对甲苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.49(d,2H),7.42(d,2H),7.32(s,1H),7.27(m,3H),4.99(m,2H),4.79(br,1H),3.30(m,1H),2.87~2.78(m,7H),2.41(s,3H),2.08(m,2H),1.89(m,3H),1.82(br,1H),1.70(br,1H),1.59(br,1H),1.41(br,1H)
实施例15.(S)-奎宁环-3-基(6-(3,4-二氟苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.43(m,1H),7.37(m,2H),7.26(m,2H),7.21(m,1H),4.98(m,1H),4.96(m,1H),4.80(br,1H),3.30(m,1H),2.87~2.78(m,7H),2.09(m,2H),1.89(m,3H),1.81(m,2H),1.71(br,1H),1.61(br,1H),1.41(br,1H)
实施例16.(S)-奎宁环-3-基(6-(2,5-二氟苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.45(m,1H),7.37(m,1H),7.12(m,2H),7.00(m,1H),5.02(m,2H),4.81(m,1H),3.31(m,1H),2.87~2.78(m,7H),2.06(m,2H),1.89(m,4H),1.71(br,1H),1.60(br,1H),1.41(br,1H)
实施例17.(S)-奎宁环-3-基(6-(3,5-二氟苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.45(m,1H),7.39(m,1H),7.29(m,1H),7.10(d,2H),6.79(m,1H),5.00(m,1H),4.96(m,1H),4.81(br,1H),3.30(m,1H),2.87~2.77(m,7H),2.13(m,2H),1.89(m,4H),1.71(br,1H),1.61(br,1H),1.41(br,1H)
实施例18.(S)-奎宁环-3-基(6-(2,4-二氟苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.43(m,2H),7.32(m,1H),7.24(s,1H),6.94(m,2H),5.00(m,1H),4.96(br,1H),4.79(br,1H),3.30(m,1H),2.86~2.77(m,7H),2.14(m,2H),1.89~1.83(m,4H),1.70(br,1H),1.60(br,1H),1.41(br,1H)
实施例19.(S)-奎宁环-3-基(6-(2,3-二氟苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.45(t,1H),7.37(br,1H),7.28(m,1H),7.15(m,3H),5.01(m,1H),4.97(m,1H),4.81(br,1H),3.30(m,1H),2.86~2.75(br,7H),2.13(m,2H),1.90(m,2H),1.82(m,2H),1.71(br,1H),1.59(br,1H),1.40(br,1H)
实施例20.(S)-奎宁环-3-基(6-(2,3,4-三氟苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.45(t,1H),7.32(m,1H),7.24(s,1H),7.14(m,1H),7.05(m,1H),5.01(m,2H),4.80(br,1H),3.30(m,1H),2.87~2.78(m,7H),2.14(m,2H),1.90(m,2H),1.80(m,2H),1.71(br,1H),1.60(br,1H),1.41(br,1H)
实施例21.(S)-奎宁环-3-基(6-(2,4,5-三氟苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.46(m,1H),7.31(m,1H),7.25(m,2H),7.02(t,1H),5.00(m,2H),4.80(br,1H),3.28(m,1H),2.86~2.73(m,7H),2.14(m,2H),1.89(m,2H),1.82(m,2H),1.71(br,1H),1.60(br,1H),1.41(br,1H)
实施例22.(S)-奎宁环-3-基(6-(3,4-二氯苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.66(m,1H),7.51~7.49(m,2H),7.41(m,3H),4.99(m,2H),4.80(br,1H),3.30(m,1H),2.87~2.78(m,7H),2.13(m,2H),1.90(m,2H),1.82(m,2H),1.71(br,1H),1.61(br,1H),1.42(br,1H)
实施例23.(S)-奎宁环-3-基(6-(2,5-二氯苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.42(m,2H),7.32(s,1H),7.26(m,2H),7.15(s,1H),5.05(m,1H),4.97(m,1H),4.81(br,1H),3.28(m,1H),2.88~2.77(m,7H),2.13(m,2H),1.90~1.87(m,4H),1.70(br,1H),1.60(br,1H),1.41(br,1H)
实施例24.(S)-奎宁环-3-基(6-(3,5-二氯苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.57(m,1H),7.49(m,1H),7.44(s,2H),7.36(m,1H),7.34(m,1H),5.00(m,2H),4.81(br,1H),3.28(m,1H),2.87~2.78(m,7H),2.13(m,2H),1.90(m,2H),1.84(m,2H),1.71(br,1H),1.61(br,1H),1.41(br,1H)
实施例25.(S)-奎宁环-3-基(6-(4-(2-甲氧基乙氧基)苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.51(d,2H),7.40(m,2H),7.28(m,1H),7.01(d,2H),5.02(m,1H),4.95~4.81(m,2H),4.19(d,2H),3.81(d,2H),3.79(s,3H),3.30(m,1H),2.90~2.80(m,7H),2.06(m,4H),1.99(m,2H),1.73(br,1H),1.63(br,1H),1.44(br,1H)
实施例26.(S)-奎宁环-3-基(6-(4-(甲氧基甲氧基)苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.51(m,2H),7.40(m,2H),7.28(m,1H),7.12(d,2H),5.23(s,2H),5.07(m,1H),4.94~4.80(m,2H),3.52(s,3H),3.29(m,1H),2.86~2.78(m,7H),2.06(m,2H),1.88(m,4H),1.70(br,1H),1.60(br,1H),1.40(br,1H)
实施例27.(S)-奎宁环-3-基(6-(3-(2-甲氧基乙氧基)苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.42(m,2H),7.37(m,2H),7.18(m,2H),6.94(d,1H),5.02(m,1H),4.95~4.82(m,2H),4.21(d,2H),3.80(d,2H),3.80(s,3H),3.31(m,1H),2.91~2.81(m,7H),2.31(br,2H),2.12(m,2H),1.89(m,2H),1.73(br,1H),1.62(br,1H),1.44(br,1H)
实施例28.(S)-奎宁环-3-基(6-(3-(甲氧基甲氧基)苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.41(d,2H),7.36(m,2H),7.25(m,2H),7.05(d,1H),5.24(s,2H),5.12(m,1H),4.95~4.80(m,2H),3.52(s,3H),3.28(m,1H),2.87~2.75(m,7H),2.50(br,1H),2.06(m,2H),1.88(m,3H),1.71(br,1H),1.60(br,1H),1.41(br,1H)
实施例29.(S)-奎宁环-3-基(6-(2-(2-甲氧基乙氧基)苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.43~7.30(m,5H),7.04~6.99(m,2H),5.10(m,1H),4.95~4.80(m,2H),4.13(d,2H),3.71(d,2H),3.41(s,3H),3.28(m,1H),2.88~2.79(m,7H),2.39(br,1H),2.06(m,2H),1.88(m,3H),1.71(br,1H),1.60(br,1H),1.42(br,1H)
实施例30.(S)-奎宁环-3-基(6-(2-(甲氧基甲氧基)苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.38(d,2H),7.29(m,2H),7.24(m,2H),7.11(t,1H),5.15(s,2H),5.10(m,1H),4.96~4.79(m,2H),3.45(s,3H),3.28(m,1H),2.88~2.77(m,7H),2.46(br,1H),2.06(m,2H),1.89(m,3H),1.71(br,1H),1.60(br,1H),1.42(br,1H)
实施例31.(S)-奎宁环-3-基(6-(4-乙基苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.52(m,2H),7.43(m,2H),7.28(d,3H),5.14(m,1H),4.98~4.81(m,2H),3.30(m,1H),2.87(m,7H),2.70(q,2H),2.10(m,2H),1.89(m,4H),1.71(br,1H),1.61(br,1H),1.42(br,1H),1.29(t,3H)
实施例32.(S)-奎宁环-3-基(6-(4-丙基苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.51(d,1H),7.43(m,2H),7.27(m,3H),5.09(m,1H),4.96~4.80(m,2H),3.30(m,1H),2.87~2.76(m,7H),2.64(t,2H),2.10(m,2H),1.89(m,3H),1.74(m,3H),1.61(br,1H),1.42(br,1H),0.99(t,3H)
实施例33.(S)-奎宁环-3-基(6-(4-丁基苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.51(d,2H),7.42(d,2H),7.27(m,3H),5.11(m,1H),4.96~4.81(m,2H),3.32(m,1H),2.87~2.78(m,7H),2.66(t,2H),2.10(m,2H),1.89(m,3H),1.72(br,1H),1.67(m,3H),1.43(m,3H),0.98(t,3H)
实施例34.(S)-奎宁环-3-基(6-(4-异丙基苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.52(d,2H),7.42(m,2H),7.32(m,3H),5.05(m,1H),4.96~4.81(m,2H),3.30(m,1H),2.97(m,1H),2.87~2.79(m,7H),2.26(br,1H),2.07(m,2H),1.89(m,3H),1.72(br,1H),1.61(br,1H),1.42(br,1H),1.25(d,6H)
实施例35.(S)-奎宁环-3-基(6-(4-异丁基苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.50(d,1H),7.43(m,3H),7.33(s,1H),7.23(d,2H),5.10(m,1H),4.95~4.81(m,2H),3.30(m,1H),2.87~2.78(m,7H),2.52(d,2H),2.08(m,2H),1.89(m,4H),1.70(br,1H),1.60(br,1H),1.40(br,1H),0.96(d,6H)
实施例36.(S)-奎宁环-3-基(6-(4-(叔丁基)苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.53(m,1H),7.51(m,3H),7.46(m,2H),7.33(s,1H),5.05(m,1H),4.96~4.81(m,2H),3.30(m,1H),2.88~2.78(m,7H),2.31(br,1H),2.06(m,2H),1.88(m,3H),1.72(br,1H),1.61(br,1H),1.38(br,1H),1.28(s,9H)
实施例37.(S)-奎宁环-3-基(6-(4-环丙基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.48~7.41(m,4H),7.31(m,1H),7.15(m,2H),5.14(m,1H),4.94~4.80(m,2H),3.28(m,1H),2.86~2.78(m,7H),2.08(m,2H),1.88(m,4H),1.71(br,1H),1.61(br,1H),1.41(br,1H),1.01(m,2H),0.75(m,2H)
实施例38.(S)-奎宁环-3-基(6-(3-乙基苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.43(m,4H),7.33(m,2H),7.21(d,1H),5.10(m,1H),4.96~4.80(m,2H),3.30(m,1H),2.87~2.75(m,7H),2.74(q,2H),2.09(m,2H),1.89(m,4H),1.71(br,1H),1.0(br,1H),1.42(br,1H),1.30(t,3H)
实施例39.(S)-奎宁环-3-基(6-(3-(叔丁基)苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.58(s,1H),7.44(s,2H),7.42(m,3H),7.32(s,1H),5.03(m,1H),4.97~4.81(m,2H),3.30(m,1H),2.89~2.80(m,7H),2.14(m,2H),1.90(m,4H),1.73(br,1H),1.60(br,1H),1.40(br,1H),1.39(s,9H)
实施例40.(S)-奎宁环-3-基(6-(3-异丙基苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.44~7.33(m,6H),7.24(m,1H),5.11(m,1H),4.96~4.80(m,2H),3.30(m,1H),3.02(m,1H),2.88~2.75(m,7H),2.55(br,1H),2.14(m,2H),1.89(m,3H),1.71(br,1H),1.60(br,1H),1.41(br,1H),1.28(d,6H)
实施例41.(S)-奎宁环-3-基(6-(2-乙基苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.40(m,1H),7.32(m,3H),7.23(m,1H),7.18(m,1H),7.05(s,1H),5.15(m,1H),4.97~4.81(m,2H),3.28(m,1H),2.88~2.77(m,7H),2.62(q,2H),2.46(br,1H),2.06(m,2H),1.89(m,3H),1.71(br,1H),1.60(br,1H),1.41(br,1H),1.13(t,3H)
实施例42.(S)-奎宁环-3-基(6-(2,2-二氟苯并[d][1,3]二氧杂环戊烯-5-基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.45(t,1H),7.36(m,1H),7.25(m,3H),7.12(d,1H),5.07(m,1H),4.95~4.80(m,2H),3.29(m,1H),2.87~2.78(m,7H),2.43(br,1H),2.13(m,2H),1.89(m,3H),1.71(br,1H),1.60(br,1H),1.41(br,1H)
实施例43.(S)-奎宁环-3-基(6-(2,3-二氢苯并[b][1,4]二噁英-6-基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.38(m,2H),7.28(m,1H),7.08(m,2H),6.93(d,1H),5.03(m,1H),4.91~4.80(m,2H),4.31(s,4H),3.28(m,1H),2.22(br,1H),2.06(m,2H),1.87(m,3H),1.71(br,1H),1.61(br,1H),1.42(br,1H)
实施例44.(S)-奎宁环-3-基(6-(2,3-二氢苯并呋喃-6-基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.42~7.27(m,5H),6.85(d,1H),5.05(m,1H),4.94~4.80(m,2H),4.63(t,2H),3.28(m,3H),2.86~2.78(m,7H),2.24(br,1H),2.06(m,2H),1.88(m,3H),1.71(br,1H),1.61(br,1H),1.41(br,1H)
实施例45.(S)-奎宁环-3-基(6-(4-吗啉代苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.53(d,2H),7.40(m,2H),7.30(m,1H),6.98(d,2H),5.07(m,1H),4.95~4.79(m,2H),3.90(m,4H),3.31(m,1H),3.23(m,4H),2.86~2.77(m,7H),2.13(m,2H),1.88(m,4H),1.70(br,1H),1.59(br,1H),1.39(br,1H)
实施例46.(S)-奎宁环-3-基(6-(4-甲氧基苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.53(d,2H),7.40(m,3H),7.28(m,1H),6.98(d,1H),5.04(m,1H),4.95~4.81(m,1H),3.86(s,3H),3.29(m,1H),2.86~2.79(m,7H),2.30(br,1H),2.09(m,2H),1.88(m,3H),1.72(br,1H),1.61(br,1H),1.41(br,1H)
实施例47.(S)-奎宁环-3-基(6-(3-甲氧基苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.43(m,2H),7.36(m,2H),7.17(d,1H),7.10(s,1H),6.91(d,1H),5.07(m,1H),4.96~4.81(m,2H),3.88(s,3H),3.31(m,1H),2.87~2.78(m,7H),2.38(br,1H),2.10(m,2H),1.89(m,3H),1.71(br,1H),1.60(br,1H),1.41(br,1H)
实施例48.(S)-奎宁环-3-基(6-(2-甲氧基苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.39(m,2H),7.31~7.28(m,3H),7.01(m,2H),5.06(m,1H),4.96~4.81(m,2H),3.83(s,3H),3.29(m,1H),2.86~2.79(m,7H),2.30(br,1H),2.07(m,2H),1.88(m,3H),1.72(br,1H),1.62(br,1H),1.41(br,1H)
实施例49.(S)-奎宁环-3-基(6-(3-氟吡啶-4-基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ8.53(s,1H),8.45(s,1H),7.48(m,2H),7.38(m,2H),5.13(m,1H),4.97~4.79(m,2H),3.26(m,1H),2.86~2.76(m,7H),2.05(m,2H),1.81(m,4H),1.70(br,1H),1.59(br,1H),1.40(br,1H)
实施例50.(S)-奎宁环-3-基(6-(2-甲基吡啶-4-基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ8.54(m,1H),7.68(m,1H),7.47(m,2H),7.37(m,2H),4.99(m,2H),4.80(m,1H),3.29(m,1H),2.88~2.79(m,7H),2.63(s,3H),2.09(m,2H),1.89(m,4H),1.72(br,1H),1.61(br,1H),1.41(br,1H)
实施例51.(S)-奎宁环-3-基(6-(2-甲氧基吡啶-4-基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ8.21(s,1H),7.44(,2H),7.35(s,1H),7.08(s,1H),6.93(m,1H),5.04(m,1H),4.96~4.79(m,2H),3.99(s,3H),3.27(m,1H),2.86~2.76(m,7H),2.06(m,2H),1.89(m,4H),1.70(br,1H),1.58(br,1H),1.40(br,1H)
实施例52.(S)-奎宁环-3-基(6-(1H-吡咯并[2,3-b]吡啶-5-基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ9.64(br,1H),8.11(s,1H),7.45(m,2H),7.31(m,1H),7.12(m,2H),6.56(s,1H),5.21(m,1H),4.97~4.81(m,2H),3.29(m,1H),3.87~2.79(m,7H),2.06(m,2H),1.90(m,4H),1.71(br,1H),1.62(br,1H),1.42(br,1H)
实施例53.(S)-奎宁环-3-基(6-(嘧啶-5-基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯1H-NMR(400MHz,CDCl3)δ9.20(s,1H),8.92(s,2H),7.67(m,1H),7.49(m,1H),7.40(m,1H),5.09(m,1H),4.98~4.80(m,2H),3.28(m,1H),2.87~2.77(m,7H),2.06(m,2H),1.91(m,4H),1.70(br,1H),1.59(br,1H),1.40(br,1H)
实施例54.(S)-奎宁环-3-基(6-(1H-吡咯并[2,3-b]吡啶-4-基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ9.84(br,1H),8.37(s,1H),7.60(m,1H),7.54(s,2H),7.40(s,1H),7.18(m,1H),6.71(s,1H),5.10(m,1H),5.01~4.83(m,2H),3.32(m,1H),2.90~2.84(m,7H),2.14(m,2H),1.93(m,4H),1.73(br,1H),1.62(br,1H),1.43(br,1H)
实施例55至实施例85
使用制备例2中制得的(S)-奎宁环-3-基(7-溴-1,2,3,4-四氢萘-1-基)氨基甲酸酯,和相应的取代硼酸,按照与实施例1中相同的步骤制备实施例55至实施例85的标题化合物。
实施例55.(S)-奎宁环-3-基(7-(4-氟苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯1H-NMR(400MHz,CDCl3)δ7.52(d,2H),7.37(d,1H),7.28(m,1H),7.17(d,1H),7.11(m,2H),4.98(m,2H),4.78(m,1H),3.25(m,1H),2.83~2.70(m,7H),2.04(m,2H),1.89(m,3H),1.78(br,1H),1.68(br,1H),1.57(br,1H),1.37(br,1H)
实施例56.(S)-奎宁环-3-基(7-(4-氯苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯1H-NMR(400MHz,CDCl3)δ7.50(m,3H),7.39(m,3H),7.17(d,1H),4.99(m,2H),4.78(m,1H),3.25(m,1H),2.83~2.70(m,7H),2.05(m,2H),1.88(m,3H),1.79(br,1H),1.68(br,1H),1.59(br,1H),1.37(br,1H)
实施例57.(S)-奎宁环-3-基(7-(对甲苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯1H-NMR(400MHz,CDCl3)δ7.44(m,3H),7.23(m,2H),7.15(m,2H),5.10(m,1H),4.93(m,1H),4.76(m,1H),2.27(m,1H),2.86~2.72(m,7H),2.38(s,3H),2.11(m,3H),1.99~1.86(m,3H),1.66(br,1H),1.56(br,1H),1.37(br,1H)
实施例58.(S)-奎宁环-3-基(7-(3-(氟苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯1H-NMR(400MHz,CDCl3)δ7.56(d,1H),7.41(m,2H),7.35(m,2H),7.18(m,1H),7.04(m,1H),5.13(m,1H),4.97(m,1H),4.60(m,1H),3.28(m,1H),2.85~2.75(m,7H),2.24(m,1H),2.08(m,1H),1.89(m,3H),1.81(br,1H),1.69(br,1H),1.58(br,1H),1.39(br,1H)
实施例59.(S)-奎宁环-3-基(7-(3-(氯苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯1H-NMR(400MHz,CDCl3)δ7.54(s,2H),7.40~7.28(m,4H),7.20(m,1H),5.13(m,1H),4.97(m,1H),4.78(m,1H),3.28(m,1H),2.85~2.75(m,7H),2.35(br,1H),2.08(m,1H),1.89(m,3H),1.81(br,1H),1.69(br,1H),1.59(br,1H),1.40(br,1H)
实施例60.(S)-奎宁环-3-基(7-(3-(三氟甲基)苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.78(m,1H),7.73(m,1H),7.55(m,3H),7.42(m,1H),7.20(d,1H),5.00(m,2H),4.78(m,1H),3.26(m,1H),2.84~2.71(m,7H),2.11(m,4H),1.96(m,1H),1.79(br,1H),1.69(br,1H),1.58(br,1H),1.39(br,1H)
实施例61.(S)-奎宁环-3-基(7-(2-(氟苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯1H-NMR(400MHz,CDCl3)δ7.51(m,1H),7.41(m,2H),7.31(m,1H),7.22(m,3H),5.20(m,1H),4.97(m,1H),4.76(m,1H),3.26(m,1H),2.84~2.69(m,7H),2.31(br,1H),2.08(m,1H),1.88(m,3H),1.80(br,1H),1.68(br,1H),1.57(br,1H),1.37(br,1H)
实施例62.(S)-奎宁环-3-基(7-(2-氯苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯1H-NMR(400MHz,CDCl3)δ7.44(m,2H),7.30(m,4H),7.16(d,1H),5.17(m,1H),4.93(m,1H),4.73(m,1H),3.20(m,1H),2.84~2.67(m,7H),2.09(m,3H),1.87(m,2H),1.77(br,1H),1.65(br,1H),1.54(br,1H),1.35(br,1H)
实施例63.(S)-奎宁环-3-基(7-(2-(三氟甲基)苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.73(m,1H),7.56(m,1H),7.45(m,1H),7.30(m,2H),7.13(m,2H),5.12(m,1H),4.92(m,1H),4.71(m,1H),3.20(m,1H),2.82~2.68(m,7H),2.09(m,3H),1.87(m,2H),1.77(br,1H),1.64(br,1H),1.53(br,1H),1.33(br,1H)
实施例64.(S)-奎宁环-3-基(7-(3,4-二氟苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.50(m,1H),7.34(m,2H),7.26~7.16(m,3H),5.11(m,1H),4.94(m,1H),4.76(m,1H),3.26(m,1H),2.82~2.69(m,7H),2.02(m,3H),1.87(m,2H),1.78(br,1H),1.68(br,1H),1.56(br,1H),1.36(br,1H)
实施例65.(S)-奎宁环-3-基(7-(2,4-二氟苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.45(m,1H),7.36(m,2H),7.16(d,1H),6.92(m,2H),5.13(m,1H),4.94(m,1H),4.75(m,1H),3.22(m,1H),2.83~2.68(m,7H),2.11(m,3H),1.87(m,2H),1.77(br,1H),1.66(br,1H),1.55(br,1H),1.35(br,1H)
实施例66.(S)-奎宁环-3-基(7-(2,4,5-三氟苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.44(m,1H),7.30~7.17(m,3H),7.01(m,1H),5.12(m,1H),4.93(m,1H),4.75(m,1H),3.22(m,1H),2.83~2.68(m,7H),2.05(m,3H),1.88(m,2H),1.77(br,1H),1.66(br,1H),1.56(br,1H),1.36(br,1H)
实施例67.(S)-奎宁环-3-基(7-(2,5-二氟苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.50(d,1H),7.35(m,1H),7.18(d,1H),7.11(m,2H),6.98(m,1H),5.18(m,1H),4.95(m,1H),4.78(m,1H),3.25(m,1H),2.85~2.73(m,7H),2.28(br,1H),2.08(m,1H),1.89(m,3H),1.80(br,1H),1.67(m,1H),1.57(br,1H),1.38(br,1H)
实施例68.(S)-奎宁环-3-基(7-(3,5-二氟苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.52(m,1H),7.37(m,1H),7.19(d,1H),7.08(m,2H),6.78(m,1H),5.08(m,1H),4.97(m,1H),4.80(m,1H),3.28(m,1H),2.85~2.76(m,7H),2.09(m,2H),1.93(m,1H),1.89(m,2H),1.81(br,1H),1.69(br,1H),1.60(br,1H),1.40(br,1H)
实施例69.(S)-奎宁环-3-基(7-(2,3,4-三氟苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.43(m,1H),7.28(m,1H),7.18(d,1H),7.10(m,1H),7.03(m,1H),5.27(m,1H),4.94(m,1H),4.76(m,1H),3.23(m,1H),2.82~2.66(m,7H),2.07(m,3H),1.88(m,2H),1.81(br,1H),1.67(br,1H),1.56(br,1H),1.37(br,1H)
实施例70.(S)-奎宁环-3-基(7-(3,4-二氯苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.63(s,1H),7.48(m,2H),7.38(m,2H),7.18(d,1H),5.14(m,1H),4.94(m,1H),4.76(m,1H),3.22(m,1H),2.83~2.68(m,7H),2.06(m,2H),1.87(m,3H),1.78(br,1H),1.67(m,1H),1.56(br,1H),1.37(br,1H)
实施例71.(S)-奎宁环-3-基(7-(2,5-二氯苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.40(m,2H),7.32(m,1H),7.27(m,2H),7.17(m,1H),5.12(m,1H),4.96(m,1H),4.76(m,1H),3.26(m,1H),2.85~2.69(m,7H),2.11(m,3H),1.89(m,2H),1.78(br,1H),1.67(br,1H),1.58(br,1H),1.40(br,1H)
实施例72.(S)-奎宁环-3-基(7-(吡啶-4-基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ8.65(s,2H),7.62(m,1H),7.50(m,3H),7.25(d,1H),5.02(m,2H),4.81(br,1H),3.30(m,1H),2.87~2.72(m,7H),2.13(m,2H),1.90(m,4H),1.71(br,1H),1.61(br,1H),1.41(br,1H)
实施例73.(S)-奎宁环-3-基(7-(吡啶-3-基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ8.82(s,1H),8.59(s,1H),7.87(m,1H),7.58(m,1H),7.44(m,1H),7.42(m,1H),7.24(d,1H),5.07(m,2H),4.80(br,1H),3.27(m,1H),2.87~2.78(m,7H),2.09~1.99(m,5H),1.82(br,1H),1.71(br,1H),1.61(br,1H),1.41(br,1H)
实施例74.(S)-奎宁环-3-基(7-(邻甲苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.34(m,1H),7.26(m,4H),7.17(s,2H),4.99(m,2H),4.77(m,1H),3.29(m,1H),2.85~2.73(m,7H),2.30(s,3H),2.14(m,4H),1.90(br,1H),1.80(br,1H),1.69(br,1H),1.58(br,1H),1.40(br,1H)
实施例75.(S)-奎宁环-3-基(7-(2-甲氧基苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.51(m,1H),7.38(d,1H),7.31(m,2H),7.16(d,1H),7.05~6.99(m,2H),5.01(m,1H),4.97(m,1H),4.77(br,1H),3.83(s,3H),3.25(m,1H),2.84~2.76(m,7H),2.04(m,2H),1.88(m,4H),1.69(br,1H),1.58(br,1H),1.40(br,1H)
实施例76.(S)-奎宁环-3-基(7-(2-乙氧基苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.59(d,1H),7.43(m,1H),7.32(m,2H),7.15(d,1H),7.03~6.97(m,2H),5.00(m,1H),4.97(m,1H),4.76(br,1H),4.07(m,2H),3.26(m,1H),2.85~2.76(m,7H),2.06(m,2H),1.89(m,4H),1.69(br,1H),1.59(br,1H),1.38(t,4H)
实施例77.(S)-奎宁环-3-基(7-(3-甲氧基苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.57(m,1H),7.50~7.48(m,1H),7.42(m,1H),7.18(m,2H),7.14(m,1H),6.88(d,1H),4.99(m,2H),4.79(m,1H),3.83(s,3H),3.28(m,1H),2.85~2.78(m,7H),2.06(m,2H),1.89(m,3H),1.82(br,1H),1.59(br,1H),1.71(br,1H),1.48(br,1H)
实施例78.(S)-奎宁环-3-基(7-(2-异丙氧基苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.60(m,1H),7.41(d,1H),7.31(m,2H),7.13(d,1H),6.99(t,1H),4.99(m,1H),4.93(m,1H),4.77(br,1H),4.54(m,1H),3.28(m,1H),2.84~2.75(m,7H),2.13(m,2H),2.06(m,3H),1.89(m,1H),1.82(br,1H),1.70(br,1H),1.38(br,1H),1.31(d,6H)
实施例79.(S)-奎宁环-3-基(7-(4-(2-甲氧基乙氧基)苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.67(m,1H),7.50(m,3H),7.40(m,1H),7.17(m,1H),7.01(m,1H),5.02(m,1H),4.97~4.78(m,2H),4.18(s,2H),3.79(s,2H),3.48(s,3H),3.29(m,1H),2.84~2.76(m,7H),2.05(m,3H),1.88(m,3H),1.70(br,1H),1.59(br,1H),1.38(br,1H)
实施例80.(S)-奎宁环-3-基(7-(4-甲氧基苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.52(m,3H),7.41(m,1H),7.17(m,1H),6.99(m,2H),5.04(m,1H),4.97(m,1H),4.79(m,1H),3.86(s,3H),3.30(m,1H),2.88~2.74(m,7H),2.13(m,3H),1.92(m,3H),1.70(br,1H),1.60(br,1H),1.40(br,1H)
实施例81.(S)-奎宁环-3-基(7-(4-乙氧基苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.50(m,3H),7.40(d,1H),7.16(m,1H),6.97(m,2H),5.04(m,1H),4.97(m,1H),4.80(m,1H),4.10(m,2H),3.30(m,1H),2.88~2.74(m,7H),2.06(m,2H),1.98(m,4H),1.70(br,1H),1.60(br,1H),1.40(br,1H),1.39(t,3H)
实施例82.(S)-奎宁环-3-基(7-(4-丙氧基苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.53(m,3H),7.41(d,1H),7.17(m,1H),6.98(m,2H),5.01(m,1H),4.97(m,1H),4.79(m,1H),3.97(m,2H),3.28(m,1H),2.87~2.76(m,7H),2.06(m,2H),1.84(m,6H),1.69(br,1H),1.61(br,1H),1.40(br,1H),1.08(t,3H)
实施例83.(S)-奎宁环-3-基(7-(4-异丙氧基苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.52(m,3H),7.39(d,1H),7.16(d,1H),6.97(m,2H),5.04(m,1H),4.97(m,1H),4.79(m,1H),4.59(m,1H),3.27(m,1H),2.84~2.71(m,7H),2.05(m,2H),1.93~1.82(m,4H),1.70(br,1H),1.60(br,1H),1.38(br,1H),1.17(d,6H)
实施例84.(S)-奎宁环-3-基(7-(苯并[d]二氧杂环戊烯-5-基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.50(m,1H),7.35(m,1H),7.16(d,1H),7.05(m,2H),6.89(m,1H),6.01(s,2H),5.02(m,1H),4.96(m,1H),4.78(m,1H),3.31(m,1H),2.87~2.72(m,7H),2.06(m,2H),1.88(m,4H),1.70(br,1H),1.60(br,1H),1.28(br,1H)
实施例85.(S)-奎宁环-3-基(7-(间甲苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯1H-NMR(400MHz,CDCl3)δ7.57~7.38(m,5H),7.18(m,2H),5.01(m,2H),4.78(m,1H),3.29(m,1H),2.86~2.76(m,7H),2.43(s,3H),2.08(m,2H),1.89(m,4H),1.62(br,1H),1.59(br,1H),1.38(br,1H)
实施例86至实施例150
使用制备例3中制得的(S)-奎宁环-3-基(6-溴-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯,和相应的取代硼酸,按照与实施例1中相同的步骤分别制备实施例86至实施例150的标题化合物。
实施例86.(S)-奎宁环-3-基(6-(4-氟苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.53(m,3H),7.36(m,2H),7.13(t,2H),4.91(m,2H),4.65(m,1H),3.37(m,1H),3.05~2.85(m,7H),2.29(m,1H),1.96(m,1H),1.83(m,1H),1.72(m,3H),1.36(m,1H),1.17(m,3H),1.00(s,3H)
实施例87.(S)-奎宁环-3-基(6-(4-氯苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.50(m,2H),7.41(m,2H),7.31(m,3H),4.90(m,2H),4.67(m,1H),3.44(m,1H),3.13~3.88(m,7H),2.20(m,1H),2.00(m,1H),1.87(m,1H),1.77(m,1H),1.66(m,3H),1.08(m,3H),1.00(s,3H)
实施例88.(S)-奎宁环-3-基(2,2-二甲基-6-(4-(三氟甲基)苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.69(s,4H),7.48(m,1H),7.38(m,2H),4.94~4.87(m,2H),4.68(m,1H),3.40(m,1H),3.11~2.90(m,7H),2.26(m,1H),1.85(m,1H),1.73(m,1H),1.58(m,3H),1.40(m,1H),1.08(m,3H),0.99(m,3H)
实施例89.(S)-奎宁环-3-基(2,2-二甲基-6-(4-(三氟甲氧基)苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.68(m,1H),7.58(m,2H),7.50(m,1H),7.39(m,1H),7.30(m,2H),4.86(m,2H),4.68(m,1H),3.32(m,1H),3.00~2.84(m,7H),2.31(br,1H),2.15(m,1H),1.91(m,1H),1.73(br,1H),1.66(m,2H),1.50(br,1H),1.08(m,3H),0.99(m,3H)
实施例90.(S)-奎宁环-3-基(6-(3-氟苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.68(m,2H),7.57(m,1H),7.49(m,1H),7.42(m,3H),7.05(m,1H),4.86(m,2H),4.68(m,1H),3.37(m,1H),3.00~2.88(m,7H),2.16(m,2H),1.95(br,1H),1.77(br,1H),1.64(m,2H),1.52(br,1H),1.08(m,3H),0.99(m,3H)
实施例91.(S)-奎宁环-3-基(6-(3-氯苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.55(s,1H),7.45(m,1H),7.31(m,5H),4.85(m,2H),4.68(m,1H),3.31(m,1H),2.96~2.83(m,7H),2.33(m,1H),2.26(m,1H),1.92(br,1H),1.73(m,2H),1.68(br,1H),1.51(br,1H),1.08(m,3H),0.98(m,3H)
实施例92.(S)-奎宁环-3-基(2,2-二甲基-6-(3-(三氟甲基)苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.82(s,1H),7.71(m,1H),7.60(m,1H),7.48~7.35(m,4H),4.84(m,2H),4.68(m,1H),3.37(m,1H),2.99~2.83(m,7H),2.20(m,2H),2.04(br,1H),1.71(m,3H),1.52(br,1H),1.08(m,3H),0.99(m,3H)
实施例93.(S)-奎宁环-3-基(2,2-二甲基-6-(3-(三氟甲氧基)苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.71(m,2H),7.65(m,2H),7.43(m,2H),7.20(m,1H),4.85(m,2H),4.68(m,1H),3.40(m,1H),3.06~2.61(m,7H),2.22(m,1H),2.10(s,1H),1.96(m,1H),1.82(br,1H),1.73(m,2H),1.58(br,1H),1.08(m,3H),0.99(m,3H)
实施例94.(S)-奎宁环-3-基(6-(2-氟苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.69(m,1H),7.40(m,1H),7.35(m,3H),7.21(m,1H),7.15(m,1H),4.89(m,2H),4.68(m,1H),3.38(m,1H),3.05~2.71(m,7H),2.22(br,1H),2.10(s,1H),1.96(m,1H),1.80(br,1H),1.71(m,2H),1.55(br,1H),1.08(m,3H),0.99(m,3H)
实施例95.(S)-奎宁环-3-基(6-(2-氯苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.48(d,1H),7.32(m,5H),7.19(s,1H),4.87(m,2H),4.67(m,1H),3.37(m,1H),2.99~2.86(m,7H),2.38(m,2H),2.34(m,1H),1.93(m,1H),1.76(m,2H),1.52(br,1H),1.08(m,3H),0.99(m,3H)
实施例96.(S)-奎宁环-3-基(2,2-二甲基-6-(2-(三氟甲基)苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.74(m,1H),7.55(m,1H),7.48(m,1H),7.33(m,2H),7.15(m,1H),7.07(s,1H),4.92(m,2H),4.68(m,1H),3.40(m,1H),3.08~2.62(m,7H),2.26(m,1H),2.10(s,1H),1.99(m,1H),1.82(m,1H),1.73(m,2H),1.58(br,1H),1.08(m,3H),0.99(m,3H)
实施例97.(S)-奎宁环-3-基(2,2-二甲基-6-(2-(三氟甲氧基)苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.71(m,1H),7.57(m,1H),7.49(m,1H),7.42(m,1H),7.37(m,2H),7.21(s,1H),4.89(m,2H),4.68(m,1H),3.33(m,1H),2.99~2.86(m,7H),2.31(m,1H),2.18(m,1H),1.99(m,1H),1.75(m,3H),1.52(m,1H),1.08(m,3H),0.99(m,3H)
实施例98.(S)-奎宁环-3-基(2,2-二甲基-6-(对甲苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.69(m,1H),7.49(m,3H),7.35(s,1H),7.24(m,2H),5.39(m,2H),4.67(m,1H),3.38(m,1H),3.00~2.87(m,7H),2.41(s,3H),2.04(m,3H),1.96(br,1H),1.73(br,2H),1.50(br,1H),1.08(m,3H),0.97(m,3H)
实施例99.(S)-奎宁环-3-基(6-(4-(二氟甲氧基)苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.57(m,2H),7.39(m,2H),7.29(m,1H),7.20(d,2H),6.75~6.38(t,1H),4.88(m,2H),4.66(m,1H),3.37(m,1H),2.98(m,7H),2.24(br,1H),1.95(br,1H),1.76(br,1H),1.72(m,3H),1.50(m,1H),1.07(m,3H),1.00(m,3H)
实施例100.(S)-奎宁环-3-基(6-(3,4-二氟苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.71(m,1H),7.50(m,1H),7.39(m,3H),7.20(m,1H),4.85(m,2H),4.67(m,1H),3.36(m,1H),3.00~2.84(m,7H),2.33(br,1H),2.17(m,1H),1.90(m,1H),1.77(m,2H),1.70(br,1H),1.51(br,1H),1.08(m,3H),0.99(m,3H)
实施例101.(S)-奎宁环-3-基(6-(2,4-二氟苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.71(m,1H),7.50(m,1H),7.38(m,2H),6.94(m,2H),4.85(m,2H),4.68(m,1H),3.37(m,1H),3.02~2.78(m,7H),2.48(br,1H),2.18(m,1H),2.10(s,1H),1.92(br,1H),1.77(m,2H),1.52(br,1H),1.08(m,3H),0.99(m,3H)
实施例102.(S)-奎宁环-3-基(6-(2,3-二氟苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.70(m,1H),7.66(m,1H),7.49(m,1H),7.35(d,1H),7.15(m,2H),4.88(m,2H),4.68(m,1H),3.33(m,1H),3.01~2.81(m,7H),2.59(br,1H),2.25(br,1H),1.82(br,1H),1.76(m,3H),1.50(br,1H),1.08(m,3H),0.99(m,3H)
实施例103.(S)-奎宁环-3-基(6-(2,5-二氟苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.69~7.49(m,1H),7.35(m,2H),7.13(m,2H),7.01(m,1H),4.90(m,2H),4.68(m,1H),3.29(m,1H),3.04~2.81(m,7H),2.22(m,1H),2.15(m,1H),1.99(m,1H),1.81(br,1H),1.72(m,2H),1.53(br,1H),1.08(m,3H),0.99(m,3H)
实施例104.(S)-奎宁环-3-基(6-(3,5-二氟苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.68~7.49(m,1H),7.39(m,2H),7.09(m,2H),6.79(m,1H),4.94(m,2H),4.67(m,1H),3.43(m,1H),3.02~2.88(m,7H),2.28(m,1H),2.16(m,1H),1.99(br,1H),1.86(br,1H),1.72(m,2H),1.50(br,1H),1.08(m,3H),0.99(m,3H)
实施例105.(S)-奎宁环-3-基(6-(2,5-二氯苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.71(m,2H),7.57(m,1H),7.50(m,2H),7.25(m,1H),4.89(m,2H),4.66(m,1H),3.33(m,1H),3.02~2.86(m,7H),2.37(br,2H),2.10(br,1H),1.92(br,1H),1.77(m,2H),1.50(br,1H),1.08(m,3H),0.99(m,3H)
实施例106.(S)-奎宁环-3-基(6-(3,4-二氯苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.71(m,2H),7.55(m,1H),7.50(m,2H),7.38(m,1H),4.86(m,2H),4.68(m,1H),3.39(m,1H),3.04~2.88(m,7H),2.26(m,2H),2.04(br,1H),1.99(br,1H),1.78(m,2H),1.53(br,1H),1.08(m,3H),0.99(m,3H)
实施例107.(S)-奎宁环-3-基(6-(3,5-二氯苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.71(m,1H),7.56(m,1H),7.50(m,2H),7.34(m,2H),4.85(m,2H),4.68(m,1H),3.31(m,1H),2.98~2.86(m,7H),2.14(m,2H),1.94(br,1H),1.73(m,2H),1.65(m,1H),1.51(m,1H),1.08(m,3H),0.99(m,3H)
实施例108.(S)-奎宁环-3-基(2,2-二甲基-6-(2,4,5-三氟苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.69(m,1H),7.55(m,1H),7.38(m,1H),7.26(m,1H),7.02(m,1H),4.86(m,2H),4.67(m,1H),3.30(m,1H),2.95~2.87(m,7H),2.51(br,2H),2.08(br,1H),1.73(br,1H),1.64(m,2H),1.49(br,1H),1.06(m,3H),0.98(m,3H)
实施例109.(S)-奎宁环-3-基(2,2-二甲基-6-(2,3,4-三氟苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.68(m,1H),7.54~7.48(m,1H),7.32(m,1H),7.24(m,1H),7.12(m,1H),4.91(m,2H),4.67(m,1H),3.44(m,1H),3.07(m,7H),2.27(br,2H),2.10(br,1H),1.99(br,1H),1.73(m,2H),1.63(br,1H),1.08(m,3H),0.98(m,3H)
实施例110.(S)-奎宁环-3-基(6-(4-(2-甲氧基乙氧基)苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.29~7.24(m,2H),7.18(d,2H),7.11(m,1H),6.98(d,2H),4.85(m,1H),4.80(br,1H),4.66(m,1H),4.17(m,2H),3.79(m,2H),3.48(s,3H),3.25(m,1H),2.88~2.76(m,5H),2.59(m,2H),2.10(br,1H),1.85(br,1H),1.70(br,1H),1.59(m,3H),1.40(br,1H),1.05(d,3H),0.96(d,3H)
实施例111.(S)-奎宁环-3-基(6-(3-(2-甲氧基乙氧基)苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.33~7.23(m,3H),7.11(m,1H),6.91(d,1H),6.85(m,2H),4.85(m,1H),4.80(br,1H),4.66(m,1H),4.15(m,2H),3.78(m,2H),3.47(s,3H),3.25(m,1H),2.88~2.76(m,5H),2.59(m,2H),2.10(br,1H),1.85(br,1H),1.70(br,1H),1.59(m,3H),1.40(br,1H),1.05(d,3H),0.96(d,3H)
实施例112.(S)-奎宁环-3-基(6-(2-(2-甲氧基乙氧基)苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.32~7.21(m,3H),7.10(m,1H),7.07(m,2H),6.96(d,1H),4.88(m,1H),4.79(br,1H),4.66(m,1H),4.12~3.99(m,2H),3.53(m,2H),3.25(m,1H),3.22(m,3H),2.88~2.76(m,5H),2.39(m,2H),2.10(br,1H),1.85(br,1H),1.70(br,1H),1.59(m,3H),1.40(br,1H),1.05(d,3H),0.96(d,3H)
实施例113.(S)-奎宁环-3-基(6-(4-(甲氧基甲氧基)苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.31(m,2H),7.19(d,2H),7.09(m,3H),5.23(s,2H),4.88(m,1H),4.79(br,1H),4.66(m,1H),3.31(s,3H),3.25(m,1H),3.22(m,3H),2.88~2.76(m,5H),2.39(m,2H),2.10(br,1H),1.85(br,1H),1.70(br,1H),1.59(m,3H),1.40(br,1H),1.05(d,3H),0.96(d,3H)
实施例114.(S)-奎宁环-3-基(6-(3-(甲氧基甲氧基)苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.33~7.23(m,3H),7.11(m,1H),6.91(d,1H),6.85(m,2H),5.20(s,2H),4.88(m,1H),4.79(br,1H),4.66(m,1H),3.30(s,3H),3.25(m,1H),3.22(m,3H),2.88~2.76(m,5H),2.39(m,2H),2.10(br,1H),1.85(br,1H),1.70(br,1H),1.59(m,3H),1.40(br,1H),1.05(d,3H),0.96(d,3H)
实施例115.(S)-奎宁环-3-基(6-(2-(甲氧基甲氧基)苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.32(m,1H),7.31~7.13(m,3H),7.08(m,3H),5.05(s,2H),4.88(m,1H),4.79(br,1H),4.66(m,1H),3.34~3.31(m,3H),3.29(m,1H),3.22(m,3H),2.88~2.76(m,5H),2.39(m,2H),2.10(br,1H),1.85(br,1H),1.70(br,1H),1.59(m,3H),1.40(br,1H),1.05(d,3H),0.96(d,3H)
实施例116.(S)-奎宁环-3-基(6-(2-甲氧基吡啶-4-基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ8.20(d,1H),7.37(m,1H),7.27(m,1H),7.06(m,1H),6.79(m,1H),6.66(s,1H),4.87(m,1H),4.77(m,1H),4.65(m,1H),3.98(s,3H),3.25(m,1H),2.88~2.76(m,5H),2.58(m,2H),2.10(br,1H),1.85(br,1H),1.70(br,1H),1.59(m,3H),1.40(br,1H),1.04(m,3H),0.96(m,3H)
实施例117.(S)-奎宁环-3-基(2,2-二甲基-6-(2-甲基吡啶-4-基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ8.54(d,1H),7.36(m,1H),7.27(s,2H),7.04(s,1H),7.02(d,1H),4.87(m,1H),4.77(m,1H),4.65(m,1H),3.25(m,1H),2.88~2.76(m,5H),2.57(s,3H),2.56(m,2H),2.10(br,1H),1.85(br,1H),1.70(br,1H),1.59(m,3H),1.40(br,1H),1.05(m,3H),0.97(m,3H)
实施例118.(S)-奎宁环-3-基(6-(2-氟吡啶-4-基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ8.26(d,1H),7.38(m,1H),7.27(m,2H),7.08(m,1H),7.07(m,1H),6.84(s,1H),4.87(m,1H),4.77(m,1H),4.65(m,1H),3.25(m,1H),2.88~2.76(m,5H),2.56(m,2H),2.10(br,1H),1.85(br,1H),1.70(br,1H),1.59(m,3H),1.40(br,1H),1.05(m,3H),0.96(m,3H)
实施例119.(S)-奎宁环-3-基(2,2-二甲基-6-(2-(三氟甲基)吡啶-4-基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ8.78(d,1H),7.62(s,1H),7.44(m,2H),7.31(m,1H),7.09(m,1H),4.87(m,1H),4.77(m,1H),4.65(m,1H),3.25(m,1H),2.88~2.76(m,5H),2.56(m,2H),2.10(br,1H),1.85(br,1H),1.70(br,1H),1.59(m,3H),1.40(br,1H),1.07(m,3H),0.96(m,3H)
实施例120.(S)-奎宁环-3-基(6-(4-甲氧基苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.32(m,2H),7.20(m,2H),7.11(m,1H),6.95(d,2H),4.87(m,2H),4.65(m,1H),3.86(s,3H),3.25(m,1H),2.88~2.76(m,5H),2.56(m,2H),2.10(br,1H),1.85(br,1H),1.70(br,1H),1.59(m,3H),1.40(br,1H),1.05(m,3H),0.96(m,3H)
实施例121.(S)-奎宁环-3-基(6-(3-甲氧基苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.34(m,2H),7.27(m,2H),7.13(m,1H),6.86(m,2H),6.81(s,1H),4.87(m,2H),4.65(m,1H),3.84(s,3H),3.25(m,1H),2.88~2.76(m,5H),2.56(m,2H),2.10(br,1H),1.85(br,1H),1.70(br,1H),1.59(m,3H),1.40(br,1H),1.05(m,3H),0.97(m,3H)
实施例122.(S)-奎宁环-3-基(6-(3-乙氧基苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.34~7.12(m,3H),7.09(m,1H),6.87(d,1H),6.84(d,1H),6.81(s,1H),4.87(m,2H),4.65(m,1H),4.01(m,2H),3.25(m,1H),2.88~2.76(m,5H),2.56(m,2H),2.10(br,1H),1.85(br,1H),1.70(br,1H),1.59(m,3H),1.40(br,1H),1.45(t,3H),1.05(m,3H),0.97(m,3H)
实施例123.(S)-奎宁环-3-基(6-(2-氯-4-甲氧基苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.34(m,1H),7.25(m,1H),7.08(m,1H),7.01(m,2H),6.87(d,1H),4.91(m,1H),4.87(m,1H),4.65(m,1H),3.87(s,3H),3.25(m,1H),2.88~2.76(m,5H),2.56(m,2H),2.10(br,1H),1.85(br,1H),1.70(br,1H),1.59(m,3H),1.40(br,1H),1.03(m,3H),0.97(m,3H)
实施例124.(S)-奎宁环-3-基(6-(4-氯-3-甲氧基苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.38(d,1H),7.28(m,1H),7.25(m,1H),7.10(m,1H),6.79(m,2H),4.91(m,1H),4.85(m,1H),4.66(m,1H),3.86(s,3H),3.25(m,1H),2.88~2.76(m,5H),2.56(m,2H),2.10(br,1H),1.85(br,1H),1.70(br,1H),1.59(m,3H),1.40(br,1H),1.03(m,3H),0.97(m,3H)
实施例125.(S)-奎宁环-3-基(6-(2-氯-5-甲氧基苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.37(m,2H),7.26(m,1H),7.03(m,1H),6.86(m,1H),6.74(m,1H),4.91(m,1H),4.85(m,1H),4.66(m,1H),3.81(s,3H),3.25(m,1H),2.88~2.76(m,5H),2.56(m,2H),2.10(br,1H),1.85(br,1H),1.70(br,1H),1.59(m,3H),1.40(br,1H),1.03(m,3H),0.97(m,3H)
实施例126.(S)-奎宁环-3-基(6-(3-氟-4-甲氧基苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.34~7.22(m,2H),7.04(m,1H),7.00(m,3H),4.91(m,1H),4.85(m,1H),4.66(m,1H),3.94(s,3H),3.25(m,1H),2.88~2.76(m,5H),2.56(m,2H),2.10(br,1H),1.85(br,1H),1.70(br,1H),1.59(m,3H),1.40(br,1H),1.03(m,3H),0.97(m,3H)
实施例127.(S)-奎宁环-3-基(6-(3-乙基苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.34(m,1H),7.26(m,2H),7.18(d,1H),7.10(m,3H),4.87(m,1H),4.77(m,1H),4.65(m,1H),3.25(m,1H),2.88~2.76(m,5H),2.67(m,2H),2.58(m,2H),2.10(br,1H),1.85(br,1H),1.70(br,1H),1.59(m,2H),1.40(br,1H),1.28(t,3H),1.04(m,3H),0.96(m,3H)
实施例128.(S)-奎宁环-3-基(6-(3-(叔丁基)苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.39~7.27(m,5H),7.14(m,1H),7.10(d,1H),4.87(m,1H),4.77(m,1H),4.65(m,1H),3.25(m,1H),2.88~2.76(m,5H),2.58(m,2H),2.10(br,1H),1.85(br,1H),1.70(br,1H),1.59(m,2H),1.40(br,1H),1.35(s,9H),1.06(m,3H),0.99(m,3H)
实施例129.(S)-奎宁环-3-基(6-(3-异丙基苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.35(m,2H),7.26(m,2H),7.20(m,1H),7.11(s,1H),7.08(m,1H),4.87(m,1H),4.77(m,1H),4.65(m,1H),3.25(m,1H),2.95(m,1H),2.88~2.76(m,5H),2.58(m,2H),2.10(br,1H),1.85(br,1H),1.70(br,1H),1.59(m,2H),1.40(br,1H),1.28(d,6H),1.06(m,3H),0.99(m,3H)
实施例130.(S)-奎宁环-3-基(6-(3-(二氟甲基)苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.51(m,2H),7.42(m,2H),7.30(m,1H),7.25(m,1H),7.10(m,2H),6.84~6.55(t,1H),4.85(m,1H),4.77(m,1H),4.67(m,1H),3.25(m,1H),2.88~2.76(m,5H),2.58(m,2H),2.10(br,1H),1.85(br,1H),1.70(br,1H),1.59(m,2H),1.40(br,1H),1.06(m,3H),0.99(m,3H)
实施例131.(S)-奎宁环-3-基(6-(3-(二甲基氨基)苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.30(m,4H),7.15(m,1H),6.73(m 1H),6.63(m,2H),4.87(m,1H),4.77(m,1H),4.67(m,1H),3.25(m,1H),2.98(s,6H),2.88~2.76(m,5H),2.58(m,2H),2.10(br,1H),1.85(br,1H),1.70(br,1H),1.59(m,2H),1.40(br,1H),1.06(m,3H),0.99(m,3H)
实施例132.(S)-奎宁环-3-基(6-(3-异丙氧基苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.30(m,4H),7.12(m,1H),6.87(m 1H),6.79(m,2H),4.87(m,1H),4.77(m,1H),4.67(m,1H),4.57(m,1H),3.25(m,1H),2.88~2.76(m,5H),2.58(m,2H),2.10(br,1H),1.85(br,1H),1.70(br,1H),1.59(m,2H),1.40(br,1H),1.36(d,6H),1.06(m,3H),0.99(m,3H)
实施例133.(S)-奎宁环-3-基(6-(2,3-二甲氧基苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.30(m,1H),7.25(m,1H),7.11(m,2H),6.95(d,1H),6.74(m,1H),4.87(m,1H),4.77(m,1H),4.67(m,1H),3.92(s,3H),3.50(m,3H),3.25(m,1H),2.88~2.76(m,5H),2.58(m,2H),2.10(br,1H),1.85(br,1H),1.70(br,1H),1.59(m,2H),1.40(br,1H),1.06(m,3H),0.99(m,3H)
实施例134.(S)-奎宁环-3-基(6-(2,4-二甲氧基苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.29(m,1H),7.25(m,1H),7.07(m,1H),7.01(m,1H),6.55(m,2H),4.87(m,1H),4.77(m,1H),4.67(m,1H),3.86(s,3H),3.73(m,3H),3.25(m,1H),2.88~2.76(m,5H),2.58(m,2H),2.10(br,1H),1.85(br,1H),1.70(br,1H),1.59(m,2H),1.40(br,1H),1.06(m,3H),0.99(m,3H)
实施例135.(S)-奎宁环-3-基(6-(2,5-二甲氧基苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.27(m,1H),7.25(m,1H),7.08(m,1H),6.89(s,2H),6.70(d,1H),4.87(m,1H),4.77(m,1H),4.67(m,1H),3.79(s,3H),3.69(m,3H),3.25(m,1H),2.88~2.76(m,5H),2.58(m,2H),2.10(br,1H),1.85(br,1H),1.70(br,1H),1.59(m,2H),1.40(br,1H),1.06(m,3H),0.99(m,3H)
实施例136.(S)-奎宁环-3-基(6-(2,6-二甲氧基苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.31(m,3H),7.03(m,1H),6.65(d,2H),4.87(m,1H),4.77(m,1H),4.67(m,1H),3.72(s,6H),3.25(m,1H),2.88~2.76(m,5H),2.58(m,2H),2.10(br,1H),1.85(br,1H),1.70(br,1H),1.59(m,2H),1.40(br,1H),1.03(m,3H),0.95(m,3H)
实施例137.(S)-奎宁环-3-基(6-(3,4-二甲氧基苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.31(m,2H),7.11(m,1H),6.91(d,1H),6.79(m,2H),4.87(m,1H),4.77(m,1H),4.67(m,1H),3.93(s,3H),3.89(s,3H),3.25(m,1H),2.88~2.76(m,5H),2.58(m,2H),2.10(br,1H),1.85(br,1H),1.70(br,1H),1.59(m,2H),1.40(br,1H),1.03(m,3H),0.95(m,3H)
实施例138.(S)-奎宁环-3-基(6-(3,5-二甲氧基苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.34(m,2H),7.11(m,1H),6.46(s,1H),6.41(s,2H),4.87(m,1H),4.77(m,1H),4.67(m,1H),3.82(s,6H),3.25(m,1H),2.88~2.76(m,5H),2.58(m,2H),2.10(br,1H),1.85(br,1H),1.70(br,1H),1.59(m,2H),1.40(br,1H),1.03(m,3H),0.95(m,3H)
实施例139.(S)-奎宁环-3-基(6-(3-氯-4-甲氧基苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.33~7.20(m,3H),7.14(d,1H),7.08(m,1H),6.97(d,1H),4.89(m,1H),4.77(m,1H),4.67(m,1H),3.94(s,3H),3.25(m,1H),2.88~2.76(m,5H),2.57(m,2H),2.10(br,1H),1.85(br,1H),1.70(br,1H),1.61(br,3H),1.42(br,1H),1.03(m,3H),0.95(m,3H)
实施例140.(S)-奎宁环-3-基(6-(3-氯-4-乙氧基苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.33~7.20(m,3H),7.11(d,2H),6.95(d,1H),4.87(m,1H),4.77(m,1H),4.65(m,1H),4.13(m,2H),3.25(m,1H),2.88~2.76(m,5H),2.58(m,2H),2.10(br,1H),1.93(br,1H),1.85(br,1H),1.70(br,1H),1.61(br,3H),1.48(t,3H),1.42(br,1H),1.03(m,3H),0.95(m,3H)
实施例141.(S)-奎宁环-3-基(6-(3-氯-4-丙氧基苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.31~7.21(m,3H),7.08(m,2H),6.95(d,1H),4.87(m,1H),4.77(m,1H),4.65(m,1H),4.02(m,2H),3.25(m,1H),2.88~2.76(m,5H),2.58(m,2H),2.10(br,1H),1.93(br,1H),1.87(m,2H),1.85(br,1H),1.70(br,1H),1.61(br,3H),1.42(br,1H),1.10(t,3H),1.03(m,3H),0.95(m,3H)
实施例142.(S)-奎宁环-3-基(6-(3-氟-4-异丙氧基苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.33~7.22(m,2H),7.08(m,1H),7.00(m,2H),6.97(m,1H),4.87(m,1H),4.77(m,1H),4.65(m,1H),4.57(m,1H),3.25(m,1H),2.88~2.76(m,5H),2.58(m,2H),2.10(br,1H),1.85(br,1H),1.70(br,1H),1.61(br,3H),1.40(d,6H),1.03(m,3H),0.94(m,3H)
实施例143.(S)-奎宁环-3-基(6-(4-丁氧基-3-氯苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.31~7.22(m,3H),7.08(m,2H),6.97(d,1H),4.87(m,1H),4.77(m,1H),4.65(m,1H),4.06(m,2H),3.25(m,1H),2.88~2.76(m,5H),2.58(m,2H),2.10(br,1H),1.85(m,3H),1.70(br,1H),1.59(m,5H),1.40(br,1H),1.05(m,3H),1.03(t,3H),0.95(m,3H)
实施例144.(S)-奎宁环-3-基(6-(4-乙氧基-3-氟苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.33~7.22(m,2H),7.08(m,1H),6.99(m,3H),4.87(m,1H),4.77(m,1H),4.65(m,1H),4.17(m,2H),3.25(m,1H),2.88~2.76(m,5H),2.58(m,2H),2.10(br,1H),1.85(br,1H),1.70(br,1H),1.59(m,3H),1.48(t,3H),1.40(br,1H),1.04(m,3H),0.96(m,3H)
实施例145.(S)-奎宁环-3-基(6-(3-氟-4-丙氧基苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.33~7.22(m,2H),7.08(m,1H),6.99(m,3H),4.87(m,1H),4.77(m,1H),4.65(m,1H),4.05(m,2H),3.25(m,1H),2.88~2.76(m,5H),2.58(m,2H),2.10(br,1H),1.88(m,2H),1.85(br,1H),1.70(br,1H),1.59(m,3H),1.40(br,1H),1.08(t,3H),1.04(m,3H),0.96(m,3H)
实施例146.(S)-奎宁环-3-基(6-(3,5-二甲基-4-丙氧基苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.28~7.20(m,2H),7.07(m,1H),6.89(s,2H),4.86(m,1H),4.78(m,1H),4.65(m,1H),3.78(m,2H),3.25(m,1H),2.88~2.76(m,5H),2.58(m,2H),2.31(s,6H),2.10(br,1H),1.88(m,2H),1.85(br,1H),1.70(br,1H),1.59(m,3H),1.40(br,1H),1.12(t,3H),1.04(m,3H),0.96(m,3H)
实施例147.(S)-奎宁环-3-基(6-(4-丁氧基-3,5-二甲基苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.28~7.20(m,2H),7.08(m,1H),6.89(s,2H),4.86(m,1H),4.78(m,1H),4.65(m,1H),3.80(m,2H),3.25(m,1H),2.88~2.76(m,5H),2.58(m,2H),2.31(s,6H),2.10(br,1H),1.85(m,3H),1.70(br,1H),1.59(m,5H),1.40(br,1H),1.05(m,3H),1.01(t,3H),0.95(m,3H)
实施例148.(S)-奎宁环-3-基(6-(2-氟-4-甲氧基苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.35(m,1H),7.25(m,1H),7.08(m,2H),6.77(d,1H),6.68(d,1H),4.86(m,1H),4.80(m,1H),4.68(m,1H),3.84(s,3H),3.25(m,1H),2.88~2.76(m,5H),2.55(br,2H),2.10(br,1H),1.85(br,1H),1.70(br,1H),1.59(m,3H),1.40(br,1H),1.05(m,3H),0.95(m,3H)
实施例149.(S)-奎宁环-3-基(6-(3-氯-4-异丙氧基苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.32~7.21(m,3H),7.07(m,2H),6.97(d,1H),4.89(m,1H),4.80(m,1H),4.68(m,1H),4.59(m,1H),3.25(m,1H),2.88~2.76(m,5H),2.55(m,2H),2.10(br,1H),1.85(br,1H),1.70(br,1H),1.59(m,3H),1.40(d,7H),1.03(m,3H),0.96(m,3H)
实施例150.(S)-奎宁环-3-基(6-(2-乙酰基噻吩-3-基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.62(d,1H),7.37(m,1H),7.26(m,1H),7.09(m,1H),6.93(m,1H),4.80(m,1H),4.70(m,1H),4.67(m,1H),3.25(m,1H),2.88~2.76(m,5H),2.44(m,2H),2.10(br,1H),1.95(m,3H),1.85(br,1H),1.70(br,1H),1.61(br,1H),1.42(br,1H),1.01(m,3H),0.89(m,3H)
实施例151至实施例170
使用制备例4中制得的(S)-奎宁环-3-基(7-溴-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯,和相应的取代硼酸,按照与实施例1中相同的步骤,分别制备实施例151至实施例170的标题化合物。
实施例151.(S)-奎宁环-3-基(7-(4-氟苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.53(m,2H),7.46(m,1H),7.38(m,1H),7.18(m,1H),7.11(m,2H),4.83(m,2H),4.68(m,1H),3.30(m,1H),2.99~2.81(m,7H),2.14(m,1H),1.99(m,1H),1.89(m,1H),1.74(m,2H),1.64(m,1H),1.37(m,1H),1.12(m,3H),1.08(s,3H)
实施例152.(S)-奎宁环-3-基(7-(4-氯苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.56(m,1H),7.48(m,3H),7.42(m,2H),7.20(d,1H),4.84(m,2H),4.66(m,1H),3.32(m,1H),2.98~2.85(m,7H),2.12(m,2H),1.86(m,1H),1.72(m,2H),1.64(m,1H),1.51(m,1H),1.08(m,3H),0.99(s,3H)
实施例153.(S)-奎宁环-3-基(2,2-二甲基-7-(4-(三氟甲基)苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.66(m,4H),7.51~7.42(m,2H),7.23(m,1H),4.85~4.81(m,2H),4.68(m,1H),3.29(m,1H),2.88~2.75(m,7H),2.26(m,1H),2.09(m,1H),1.84(m,1H),1.73(m,2H),1.61(m,1H),1.43(m,1H),1.08(m,3H),0.99(s,3H)
实施例154.(S)-奎宁环-3-基(2,2-二甲基-7-(4-(三氟甲氧基)苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.71(m,1H),7.55(m,2H),7.48(m,2H),7.39(m,1H),7.19(m,1H),4.84(m,2H),4.68(m,1H),3.30(m,1H),2.85(m,7H),2.23~2.14(m,2H),1.85(m,1H),1.72(m,2H),1.63(m,1H),1.44(m,1H),1.08(m,3H),0.99(s,3H)
实施例155.(S)-奎宁环-3-基(7-(3-氟苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.71(m,1H),7.56(m,1H),7.45(m,2H),7.39(m,1H),7.26(m,1H),7.03(m,1H),4.87(m,2H),4.69(m,1H),3.31(m,1H),2.87~2.73(m,7H),2.09(m,2H),1.84(m,1H),1.72(m,2H),1.61(br,1H),1.43(br,1H),1.09(m,3H),0.99(m,3H)
实施例156.(S)-奎宁环-3-基(7-(3-氯苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.53~7.31(m,6H),7.20(m,1H),4.83(m,2H),4.68(m,1H),3.33(m,1H),2.88~2.81(m,7H),2.09(m,2H),1.86(br,1H),1.72(m,2H),1.62(br,1H),1.46(br,1H),1.09(m,3H),0.99(m,3H)
实施例157.(S)-奎宁环-3-基(2,2-二甲基-7-(3-(三氟甲基)苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.80(m,2H),7.56(m,2H),7.51(m,1H),7.43(m,1H),7.22(m,1H),4.87(m,2H),4.69(m,1H),3.30(m,1H),2.88~2.77(m,7H),2.13(m,2H),1.86(m,1H),1.73(m,2H),1.62(br,1H),1.42(br,1H),1.09(m,3H),0.99(m,3H)
实施例158.(S)-奎宁环-3-基(2,2-二甲基-7-(3-(三氟甲氧基)苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.48(m,3H),7.40(m,2H),7.21(m,2H),4.86(m,2H),4.71(m,1H),3.32(m,1H),2.92~2.86(m,7H),2.17(br,1H),2.10(m,2H),1.90(m,1H),1.70(br,1H),1.66(br,1H),1.47(br,1H),1.09(m,3H),0.99(m,3H)
实施例159.(S)-奎宁环-3-基(7-(2-氟苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.71(m,1H),7.47(m,3H),7.21(m,2H),7.16(m,1H),4.86(m,2H),4.69(m,1H),3.30(m,1H),2.89~2.81(m,7H),2.13(m,2H),1.86(br,1H),1.72(m,2H),1.62(br,1H),1.45(br,1H),1.09(m,3H),1.00(m,3H)
实施例160.(S)-奎宁环-3-基(7-(2-氯苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.71(m,1H),7.55(m,2H),7.31(m,3H),7.17(m,1H),4.85(m,2H),4.69(m,1H),3.30(m,1H),2.87~2.77(m,7H),2.19(m,2H),1.86(m,1H),1.72(m,2H),1.60(br,1H),1.41(br,1H),1.09(m,3H),1.00(m,3H)
实施例161.(S)-奎宁环-3-基(2,2-二甲基-7-(2-(三氟甲基)苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.74(m,1H),7.56(m,1H),7.48(m,1H),7.33(m,1H),7.26(m,1H),7.15(s,2H),4.82(m,2H),4.67(m,1H),3.29(m,1H),2.87~2.72(m,7H),2,20(m,2H),1.86(br,1H),1.72(m,2H),1.59(br,1H),1.43(br,1H),1.08(m,3H),0.99(m,3H)
实施例162.(S)-奎宁环-3-基(2,2-二甲基-7-(2-(三氟甲氧基)苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.69(m,2H),7.48(m,4H),7.18(m,1H),4.81(m,2H),4.68(m,1H),3.30(m,1H),2.87~2.77(m,7H),2.10(m,2H),1.86(br,1H),1.73(m,2H),1.61(br,1H),1.45(br,1H),1.08(m,3H),0.99(m,3H)
实施例163.(S)-奎宁环-3-基(2,2-二甲基-7-(2-(对甲苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.93(m,1H),7.45(m,2H),7.21(m,4H),4.84(m,2H),4.68(m,1H),3.12(m,1H),2.98~2.84(m,7H),2.40(s,3H),2.16(m,1H),2.13(m,1H),1.93(br,1H),1.72(m,2H),1.63(br,1H),1.47(br,1H),1.07(m,3H),0.98(m,3H)
实施例164.(S)-奎宁环-3-基(7-(4-(二氟甲氧基)苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.71(m,2H),7.55(m,1H),7.37(m,1H),7.20(s,3H),6.74~6.38(t,1H),4.84(m,2H),4.69(m,1H),3.21(m,1H),2.91~2.81(m,7H),2.22(m,2H),1.89(br,1H),1.72(m,2H),1.64(br,1H),1.47(br,1H),1.08(m,3H),0.99(m,3H)
实施例165.(S)-奎宁环-3-基(7-(4-(2-甲氧基乙氧基)苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.50(m,3H),7.40(m,1H),7.17(m,1H),7.09(m,1H),7.01(m,1H),4.90~4.80(m,2H),4.67(m,1H),4.18(s,2H),3.79(s,2H),3.48(s,3H),3.25(m,1H),2.91~2.76(m,7H),2.10(m,2H),1.88(br,1H),1.71(br,2H),1.60(br,1H),1.40(br,1H),1.08(m,3H),0.98(m,3H)
实施例166.(S)-奎宁环-3-基(7-(3-(2-甲氧基乙氧基)苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.46(m,1H),7.41(m,1H),7.34(m,1H),7.18(m,3H),6.90(d,1H),4.90~4.80(m,2H),4.67(m,1H),4.18(s,2H),3.79(m,2H),3.48(m,3H),3.27(m,1H),2.86~2.72(m,7H),2.10(m,2H),1.88(br,1H),1.73(br,2H),1.60(br,1H),1.40(br,1H),1.07(m,3H),0.98(m,3H)
实施例167.(S)-奎宁环-3-基(7-(2-(2-甲氧基乙氧基)苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.48(d,1H),7.41(d,1H),7.28(m,2H),7.12(m,1H),7.04(m,2H),4.98(d,1H),4.76(br,1H),4.67(d,1H),4.12(m,2H),3.70(m,2H),3.37(s,3H),3.26(m,1H),2.85~2.76(m,7H),2.10(m,2H),1.88(br,1H),1.73(br,2H),1.60(br,1H),1.40(br,1H),1.07(m,3H),0.98(m,3H)
实施例168.(S)-奎宁环-3-基(7-(4-(甲氧基甲氧基)苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.48(m,3H),7.37(d,1H),7.16(d,1H),7.09(m,2H),5.22(s,2H),4.80(m,2H),4.67(d,1H),3.51(s,3H),3.27(m,1H),2.87~2.72(m,7H),2.22(m,2H),1.89(br,1H),1.72(m,2H),1.64(br,1H),1.47(br,1H),1.08(m,3H),0.99(m,3H)
实施例169.(S)-奎宁环-3-基(7-(3-(甲氧基甲氧基)苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.49(m,1H),7.39(d,1H),7.33(m,1H),7.23~7.16(m,3H),7.02(d,1H),5.23(s,2H),4.81(m,2H),4.67(d,1H),3.51(s,3H),3.27(m,1H),2.87~2.72(m,7H),2.22(m,2H),1.89(br,1H),1.72(m,2H),1.64(br,1H),1.47(br,1H),1.08(m,3H),0.99(m,3H)
实施例170.(S)-奎宁环-3-基(7-(2-(甲氧基甲氧基)苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.55(m,1H),7.49(m,1H),7.37(m,1H),7.26(m,2H),7.20(m,1H),7.07(m,1H),5.13(m,2H),4.84(m,2H),4.69(m,1H),3.43(s,3H),3.25(m,1H),2.91~2.74(m,7H),2.22(m,2H),1.89(br,1H),1.72(m,2H),1.64(br,1H),1.47(br,1H),1.08(m,3H),0.99(m,3H)
实施例171至实施例185
使用制备例6中制得的(S)-奎宁环-3-基(7’-溴-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-基)氨基甲酸酯,和相应的取代硼酸,按照与实施例1中相同的步骤,分别制备实施例171至实施例185的标题化合物。
实施例171.(S)-奎宁环-3-基(7’-(4-氟苯基)-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.53(m,3H),7.40(d,1H),7.23(d,1H),7.13(m,2H),5.15(br,1H),4.76(br,1H),4.32(m,1H),3.26(m,1H),2.94~2.72(m,7H),2.13(m,3H),1.79(br,1H),1.67(br,1H),1.58(br,1H),1.38(br,1H),0.92(m,1H),0.58(m,1H),0.49(m,2H)
实施例172.(S)-奎宁环-3-基(7’-(4-氯苯基)-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.49(m,2H),7.41(m,4H),7.24(d,1H),5.17(br,1H),4.76(m,1H),4.33(m,1H),3.26(m,1H),2.91~2.73(m,7H),2.09(m,3H),1.79(br,1H),1.69(br,1H),1.59(br,1H),1.38(br,1H),0.92(m,1H),0.58(m,1H),0.49(m,2H)
实施例173.(S)-奎宁环-3-基(7’-(4-(三氟甲基)苯基)-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.69(s,4H),7.56(d,1H),7.46(d,1H),7.25(m,1H),5.18(br,1H),4.77(m,1H),4.34(m,1H),3.27(m,1H),2.92~2.73(m,7H),2.14(m,3H),1.79(br,1H),1.69(br,1H),1.58(br,1H),1.38(br,1H),0.92(m,1H),0.58(m,1H),0.50(m,2H)
实施例174.(S)-奎宁环-3-基(7’-(4-(三氟甲氧基)苯基)-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.58(m,2H),7.50(m,1H),7.43(d,1H),7.28(m,3H),5.17(br,1H),4.76(m,1H),4.33(m,1H),3.29(m,1H),2.90~2.78(m,7H),2.13(m,3H),1.79(br,1H),1.69(br,1H),1.59(br,1H),1.39(br,1H),0.92(m,1H),0.58(m,1H),0.49(m,2H)
实施例175.(S)-奎宁环-3-基(7’-(3-氟苯基)-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.53(d,1H),7.44~7.35(m,3H),7.24(t,2H),7.04(t,1H),5.20(m,1H),4.77(m,1H),4.34(m,1H),3.27(m,1H),2.94~2.73(m,7H),2.06(m,3H),1.82(br,1H),1.70~1.67(br,1H),1.58(br,1H),1.41(br,1H),0.92(m,1H),0.58(br,1H),0.49(m,2H)
实施例176.(S)-奎宁环-3-基(7’-(3-氯苯基)-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.69(t,1H),7.55~7.41(m,4H),7.36(m,1H),7.23(d,1H),5.16(m,1H),4.77(m,1H),4.35(m,1H),3.26(m,1H),2.90~2.73(m,7H),2.06(m,3H),1.79(br,1H),1.69(br,1H),1.59(br,1H),1.39(br,1H),0.93(m,1H),0.58(m,1H),0.49(m,2H)
实施例177.(S)-奎宁环-3-基(7’-(3-(三氟甲基)苯基)-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.79(m,2H),7.55(m,3H),7.45(m,1H),7.27(m,1H),5.17(m,1H),4.77(m,1H),3.35(m,1H),3.26(m,1H),2.92~2.74(m,7H),2.13(br,1H),2.08(m,2H),1.81(br,1H),1.69(br,1H),1.59(br,1H),1.39(br,1H),0.92(m,1H),0.59(m,1H),0.50(m,2H)
实施例178.(S)-奎宁环-3-基(7’-(3-(三氟甲氧基)苯基)-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.54~7.41(m,5H),7.26(m,1H),7.27(m,1H),5.16(m,1H),4.77(m,1H),4.35(m,1H),3.26(m,1H),2.94~2.74(m,7H),2.18(br,1H),2.07(m,2H),1.80(br,1H),1.70(br,1H),1.59(br,1H),1.39(br,1H),0.93(m,1H),0.58(m,1H),0.50(m,2H)
实施例179.(S)-奎宁环-3-基(7’-(2-氟苯基)-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.49(m,1H),7.41(m,2H),7.32(m,1H),7.24(m,2H),7.15(m,1H),5.18(m,1H),4.76(m,1H),4.35(m,1H),3.27(m,1H),2.91~2.73(m,7H),2.13(m,1H),2.08(d,2H),1.82(br,1H),1.69(br,1H),1.59(br,1H),1.43(br,1H),0.93(m,1H),0.60(m,1H),0.49(m,2H)
实施例180.(S)-奎宁环-3-基(7’-(2-氯苯基)-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.48(d,1H),7.41(d,1H),7.33(m,4H),7.22(m,1H),5.19(m,1H),4.74(m,1H),4.14(m,1H),3.23(m,1H),2.95~2.68(m,7H),2.13(m,3H),1.80(br,1H),1.68(br,1H),1,57(br,1H),1.39(br,1H),0.90(m,1H),0.59(m,1H),0.49(m,2H)
实施例181.(S)-奎宁环-3-基(7’-(2-(三氟甲基)苯基)-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.75(d,1H),7.56(m,1H),7.46(m,1H),7.33(m,2H),7.18(s,2H),5.14(m,1H),4.73(m,1H),4.32(m,1H),3.23(m,1H),2.95~2.69(m,7H),2.09(m,3H),1,81(br,1H),169(br,1H),1.56(br,1H),1.38(br,1H),0.89(m,1H),0.59(m,1H),0.49(m,2H)
实施例182.(S)-奎宁环-3-基(7’-(2-(三氟甲氧基)苯基)-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.43~7.31(m,6H),7.20(m,1H),5.15(m,1H),4.75(m,1H),4.33(m,1H),3.27(m,1H),2.95~2.63(m,7H),2.09(m,3H),1.81(br,1H),1.69(br,1H),1.58(br,1H),1.39(br,1H),0.93(m,1H),0.57(m,1H),0.49(m,2H)
实施例183.(S)-奎宁环-3-基(7’-(对甲苯基)-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.70(m,1H),7.57~7.46(m,4H),7.28~7.21(m,2H),5.15(m,1H),4.77(m,1H),4.34(m,1H),3.26(m,1H),2.90~2.68(m,7H),2.40(s,3H),2.13(m,3H),1.81(br,1H),1.69(br,1H),1.59(br,1H),1.39(br,1H),0.94(m,1H),0.58(m,1H),0.48(m,2H)
实施例184.(S)-奎宁环-3-基(7’-(4-(二氟甲氧基)苯基)-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.56(m,3H),7.42(m,1H),7.22(m,3H),6.74~6.37(t,1H),5.16(m,1H),4.76(m,1H),4.33(m,1H),3.26(m,1H),2.90~2.67(m,7H),2.06(m,3H),1.75(br,1H),1.69(br,1H),1.59(br,1H),1.38(br,1H),0.92(m,1H),0.57(br,1H),0.49(m,2H)
实施例185.(S)-奎宁环-3-基(7’-(4-(甲氧基甲氧基)苯基)-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.50(m,3H),7.40(d,1H),7.19(d,1H),7.11(m,2H),5.22(s,2H),5.13(m,1H),4.74(br,1H),4.33(d,1H),3.51(s,3H),3.25(m,1H),2.88~2.67(m,7H),2.05(br,2H),1.75(br,1H),1.68(br,1H),1.58(br,1H),1.37(br,1H),1.26(br,1H),0.93(m,1H),0.57(br,1H),0.47(m,2H)
实施例186至实施例226
使用制备例5中制得的(S)-奎宁环-3-基(6’-溴-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-基)氨基甲酸酯,和相应的取代硼酸,按照与实施例1中相同的步骤,分别制备实施例186至实施例226的标题化合物。
实施例186.(S)-奎宁环-3-基(6’-(4-氟苯基)-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.36(m,1H),7.32(m,1H),7.23(m,2H),7.13(d,2H),7.08(m,1H),5.13(m,1H),4.78(br,1H),4.31(d,1H),3.25(m,1H),2.85~2.76(m,7H),2.05(br,1H),1.95(br,1H),1.82(br,1H),1.69(br,1H),1.59(br,1H),1.35(br,1H),1.14(br,1H),0.89(m,1H),0.58(m,1H),0.45(m,2H)
实施例187.(S)-奎宁环-3-基(6’-(4-氯苯基)-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.37(d,2H),7.33(m,1H),7.25(m,3H),7.12(m,1H),5.13(m,1H),4.77(br,1H),4.34(d,1H),3.25(m,1H),2.85~2.76(m,7H),2.05(br,1H),1.95(br,1H),1.82(br,1H),1.69(br,1H),1.59(br,1H),1.35(br,1H),1.14(br,1H),0.89(m,1H),0.58(m,1H),0.45(m,2H)
实施例188.(S)-奎宁环-3-基(6’-(4-(三氟甲基)苯基)-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.68(d,2H),7.40(d,2H),7.25(m,2H),7.12(m,1H),5.13(m,1H),4.77(br,1H),4.36(d,1H),3.25(m,1H),2.85~2.76(m,7H),2.05(br,1H),1.95(br,1H),1.82(br,1H),1.69(br,1H),1.59(br,1H),1.35(br,1H),1.14(br,1H),0.89(m,1H),0.58(m,1H),0.45(m,2H)
实施例189.(S)-奎宁环-3-基(6’-(4-(三氟甲氧基)苯基)-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.58(m,1H),7.35(d,2H),7.29~7.25(m,3H),7.12(m,1H),5.15(m,1H),4.77(br,1H),4.36(d,1H),3.25(m,1H),2.85~2.76(m,7H),2.05(br,1H),1.95(br,1H),1.82(br,1H),1.69(br,1H),1.59(br,1H),1.35(br,1H),1.14(br,1H),0.89(m,1H),0.58(m,1H),0.45(m,2H)
实施例190.(S)-奎宁环-3-基(6’-(3-氟苯基)-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.39(m,3H),7.15(m,1H),7.09~7.01(m,3H),5.14(m,1H),4.78(br,1H),4.35(d,1H),3.25(m,1H),2.85~2.74(m,7H),2.05(br,1H),1.95(br,1H),1.82(br,1H),1.69(br,1H),1.59(br,1H),1.35(br,1H),1.14(br,1H),0.89(m,1H),0.56(m,1H),0.42(m,2H)
实施例191.(S)-奎宁环-3-基(6’-(3-氯苯基)-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.38~7.26(m,5H),7.19(m,1H),7.12(m,1H),5.14(m,1H),4.78(br,1H),4.36(d,1H),3.25(m,1H),2.85~2.74(m,7H),2.05(br,1H),1.95(br,1H),1.82(br,1H),1.69(br,1H),1.59(br,1H),1.35(br,1H),1.14(br,1H),0.89(m,1H),0.59(m,1H),0.46(m,2H)
实施例192.(S)-奎宁环-3-基(6’-(3-(三氟甲基)苯基)-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.62(m,1H),7.56(m,2H),7.39(m,1H),7.29(m,2H),7.13(m,1H),5.14(m,1H),4.78(br,1H),4.36(d,1H),3.25(m,1H),2.85~2.74(m,7H),2.05(br,1H),1.95(br,1H),1.82(br,1H),1.69(br,1H),1.60(br,1H),1.35(br,1H),1.14(br,1H),0.89(m,1H),0.59(m,1H),0.48(m,2H)
实施例193.(S)-奎宁环-3-基(6’-(3-(三氟甲氧基)苯基)-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.50~7.26(m,3H),7.25~7.13(m,4H),5.14(m,1H),4.78(br,1H),4.35(d,1H),3.25(m,1H),2.85~2.74(m,7H),2.05(br,1H),1.95(br,1H),1.82(br,1H),1.69(br,1H),1.60(br,1H),1.35(br,1H),1.14(br,1H),0.89(m,1H),0.59(m,1H),0.47(m,2H)
实施例194.(S)-奎宁环-3-基(6’-(4-(2-甲氧基乙氧基)苯基)-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.32~7.25(m,2H),7.22(d,2H),7.15(m,1H),6.98(d,2H),5.12(m,1H),4.76(br,1H),4.37(d,1H),4.18(d,2H),3.79(d,2H),3.48(s,3H),3.25(m,1H),2.85~2.74(m,7H),2.05(br,1H),1.95(br,1H),1.82(br,1H),1.69(br,1H),1.59(br,1H),1.35(br,1H),1.10(br,1H),0.89(m,1H),0.56(m,1H),0.42(m,2H)
实施例195.(S)-奎宁环-3-基(6’-(3-(2-甲氧基乙氧基)苯基)-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.35~7.25(m,3H),7.15(m,1H),6.93(d,1H),6.87(s,2H),5.14(m,1H),4.76(br,1H),4.35(d,1H),4.15(d,2H),3.78(d,2H),3.47(s,3H),3.25(m,1H),2.85~2.74(m,7H),2.05(br,1H),1.94(br,1H),1.80(br,1H),1.70(br,1H),1.59(br,1H),1.38(br,1H),1.14(br,1H),0.89(m,1H),0.58(m,1H),0.45(m,2H)
实施例196.(S)-奎宁环-3-基(6’-(2-(2-甲氧基乙氧基)苯基)-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.35~7.25(m,3H),7.15(m,1H),7.05(m,1H),7.03(m,1H),6.97(d,1H),5.15(m,1H),4.76(br,1H),4.33(m,1H),4.10(m,2H),3.61(m,2H),3.30~3.24(m,3H),3.25(m,1H),2.85~2.74(m,7H),2.05(br,1H),1.94(br,1H),1.80(br,1H),1.70(br,1H),1.59(br,1H),1.38(br,1H),1.14(br,1H),0.89(m,1H),0.58(m,1H),0.45(m,2H)
实施例197.(S)-奎宁环-3-基(6’-(4-(甲氧基甲氧基)苯基)-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.32~7.25(m,2H),7.22(d,2H),7.14(m,1H),7.08(d,2H),5.22(s,2H),5.13(m,1H),4.77(br,1H),4.37(d,1H),3.53(s,3H),3.25(m,1H),2.85~2.67(m,7H),2.05(br,1H),1.95(br,1H),1.82(br,1H),1.69(br,1H),1.59(br,1H),1.35(br,1H),1.10(br,1H),0.89(m,1H),0.56(m,1H),0.42(m,2H)
实施例198.(S)-奎宁环-3-基(6’-(3-(甲氧基甲氧基)苯基)-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.35~7.25(m,3H),7.15(m,1H),6.93(d,1H),6.87(s,2H),5.20(s,2H),5.13(m,1H),4.77(br,1H),4.37(d,1H),3.51(s,3H),3.25(m,1H),2.85~2.67(m,7H),2.05(br,1H),1.95(br,1H),1.82(br,1H),1.69(br,1H),1.59(br,1H),1.35(br,1H),1.10(br,1H),0.89(m,1H),0.56(m,1H),0.42(m,2H)
实施例199.(S)-奎宁环-3-基(6’-(2-(甲氧基甲氧基)苯基)-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.35~7.25(m,3H),7.15(m,1H),7.05(m,1H),7.03(m,1H),5.15(m,1H),5.10~5.07(m,2H),4.77(br,1H),4.36(d,1H),3.32~3.27(m,3H),3.25(m,1H),2.85~2.74(m,7H),2.05(br,1H),1.94(br,1H),1.80(br,1H),1.70(br,1H),1.59(br,1H),1.38(br,1H),1.14(br,1H),0.89(m,1H),0.58(m,1H),0.45(m,2H)
实施例200.(S)-奎宁环-3-基(6’-(2-氯-4-甲氧基苯基)-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.38(m,1H),7.26(m,1H),7.14(m,1H),7.10(m,1H),7.04(m,1H),6.88(d,1H),5.20~5.10(m,1H),4.75(m,1H),4.33(t,1H),3.85(s,3H),3.25(m,1H),2.85~2.73(m,5H),2.46(m,2H),2.05(br,1H),1.95(br,1H),1.82(br,1H),1.69(br,1H),1.59(br,1H),1.35(br,1H),1.10(br,1H),0.88(m,1H),0.56(m,1H),0.42(m,2H)
实施例201.(S)-奎宁环-3-基(6’-(4-氯-3-甲氧基苯基)-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.39(d,2H),7.26(m,1H),7.13(m,1H),6.84(m,2H),5.14(m,1H),4.75(m,1H),4.35(d,1H),3.91(s,3H),3.25(m,1H),2.86~2.63(m,7H),2.00(m,1H),1.95(br,1H),1.75(br,1H),1.69(br,1H),1.59(br,1H),1.35(br,1H),1.10(br,1H),0.90(m,1H),0.58(m,1H),0.45(m,2H)
实施例202.(S)-奎宁环-3-基(6’-(3-氟-4-甲氧基苯基)-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.35(m,1H),7.26(m,1H),7.14(m,1H),7.06(m,1H),7.00(m,2H),5.15(m,1H),4.75(m,1H),4.36(d,1H),3.94(s,3H),3.25(m,1H),2.84~2.65(m,7H),2.06(br,1H),1.95(br,1H),1.82(br,1H),1.69(br,1H),1.59(br,1H),1.35(br,1H),1.10(br,1H),0.89(m,1H),0.56(m,1H),0.42(m,2H)
实施例203.(S)-奎宁环-3-基(6’-(3-乙基苯基)-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.35(m,2H),7.27(m,1H),7.17(m,1H),7.15(m,3H),5.15(m,1H),4.77(br,1H),4.34(d,1H),3.25(m,1H),2.87~2.71(m,7H),2.67(m,2H),2.10(br,1H),1.92(br,1H),1.80(br,1H),1.68(br,1H),1.59(m,1H),1.40(br,1H),1.26(t,3H),1.10(m,1H),0.90(m,1H),0.59(m,1H),0.45(m,2H)
实施例204.(S)-奎宁环-3-基(6’-(3-(叔丁基)苯基)-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.40~7.33(m,4H),7.27(m,1H),7.18(m,1H),7.12(d,1H),5.15(m,1H),4.77(br,1H),4.38(d,1H),3.25(m,1H),2.87~2.66(m,7H),2.10(br,1H),1.92(br,1H),1.80(br,1H),1.68(br,1H),1.59(m,1H),1.40(br,1H),1.37(s,9H),1.10(m,1H),0.90(m,1H),0.59(m,1H),0.45(m,2H)
实施例205.(S)-奎宁环-3-基(6’-(3-异丙基苯基)-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.36(m,2H),7.27(m,2H),7.17(m,2H),7.13(d,1H),5.15(m,1H),4.77(br,1H),4.34(d,1H),3.25(m,1H),2.94(m,1H),2.87~2.71(m,7H),2.67(m,2H),2.10(br,1H),1.92(br,1H),1.80(br,1H),1.68(br,1H),1.59(m,1H),1.40(br,1H),1.28(m,6H),1.10(m,1H),0.90(m,1H),0.59(m,1H),0.45(m,2H)
实施例206.(S)-奎宁环-3-基(6’-(3-(二氟甲基)苯基)-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.51(m,2H),7.43(m,2H),7.38(m,1H),7.27(m,1H),7.14(m,1H),6.84~6.55(t,1H),5.15(m,1H),4.77(br,1H),4.34(d,1H),3.25(m,1H),2.86~2.60(m,7H),2.10(br,1H),1.92(br,1H),1.80(br,1H),1.68(br,1H),1.59(m,1H),1.40(br,1H),1.10(m,1H),0.90(m,1H),0.59(m,1H),0.45(m,2H)
实施例207.(S)-奎宁环-3-基(6’-(3-(二甲基氨基)苯基)-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.39~7.18(m,4H),6.74(d,1H),6.66(s,2H),5.15(m,1H),4.77(br,1H),4.34(d,1H),3.25(m,1H),2.97(s,6H),2.86~2.60(m,7H),2.10(br,1H),1.92(br,1H),1.80(br,1H),1.68(br,1H),1.59(m,1H),1.40(br,1H),1.10(m,1H),0.88(m,1H),0.59(m,1H),0.44(m,2H)
实施例208.(S)-奎宁环-3-基(6’-(3-异丙氧基苯基)-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.35~7.15(m,3H),7.15(m,1H),6.86(m,3H),5.15(m,1H),4.77(br,1H),4.57(m,1H),4.35(d,1H),3.25(m,1H),2.85~2.68(m,7H),2.08(br,1H),1.92(br,1H),1.80(br,1H),1.68(br,1H),1.59(br,1H),1.39(br,1H),1.35(d,6H),1.15(m,1H),0.88(m,1H),0.59(m,1H),0.44(m,2H)
实施例209.(S)-奎宁环-3-基(6’-(2,3-二甲氧基苯基)-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.35(m,1H),7.24(m,1H),7.11(m,2H),6.96(d,1H),6.75(d,1H),5.16(m,1H),4.77(br,1H),4.34(m,1H),3.92(s,3H),3.52(s,3H),3.25(m,1H),2.85~2.74(m,7H),2.08(br,1H),1.92(br,1H),1.80(br,1H),1.68(br,1H),1.59(br,1H),1.39(br,1H),1.15(m,1H),0.87(m,1H),0.56(m,1H),0.43(m,2H)
实施例210.(S)-奎宁环-3-基(6’-(2,4-二甲氧基苯基)-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.31(m,1H),7.24(m,1H),7.11(m,1H),7.09(m,1H),6.56(d,2H),5.16(m,1H),4.76(br,1H),4.34(d,1H),3.86(s,3H),3.75(s,3H),3.25(m,1H),2.85~2.74(m,7H),2.08(br,1H),1.92(br,1H),1.80(br,1H),1.68(br,1H),1.59(br,1H),1.39(br,1H),1.15(m,1H),0.89(m,1H),0.56(m,1H),0.43(m,2H)
实施例211.(S)-奎宁环-3-基(6’-(2,5-二甲氧基苯基)-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.34(m,1H),7.24(m,1H),7.11(m,1H),6.88(m,2H),6.71(m,1H),5.16(m,1H),4.76(br,1H),4.35(d,1H),3.79(s,3H),3.71(d,3H),3.25(m,1H),2.85~2.74(m,7H),2.08(br,1H),1.92(br,1H),1.80(br,1H),1.68(br,1H),1.59(br,1H),1.39(br,1H),1.15(m,1H),0.88(m,1H),0.56(m,1H),0.42(m,2H)
实施例212.(S)-奎宁环-3-基(6’-(2,6-二甲氧基苯基)-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.32(m,2H),7.24(m,1H),7.06(d,1H),6.65(d,2H),5.16(m,1H),4.76(br,1H),4.35(d,1H),3.73(d,6H),3.25(m,1H),2.85~2.74(m,7H),2.08(br,1H),1.92(br,1H),1.80(br,1H),1.68(br,1H),1.58(br,1H),1.39(br,1H),1.15(m,1H),0.89(m,1H),0.56(m,1H),0.40(m,2H)
实施例213.(S)-奎宁环-3-基(6’-(3,4-二甲氧基苯基)-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.33(m,1H),7.24(m,1H),7.18(m,1H),6.92(d,1H),6.85(m,2H),5.14(m,1H),4.77(br,1H),4.35(d,1H),3.93(s,3H),3.89(s,3H),3.25(m,1H),2.85~2.67(m,7H),2.08(br,1H),1.92(br,1H),1.80(br,1H),1.69(br,1H),1.58(br,1H),1.39(br,1H),1.15(m,1H),0.89(m,1H),0.58(m,1H),0.46(m,2H)
实施例214.(S)-奎宁环-3-基(6’-(3,5-二甲氧基苯基)-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.34(m,1H),7.24(m,1H),7.17(m,1H),6.47(s,1H),6.44(d,2H),5.16(m,1H),4.76(br,1H),4.35(d,1H),3.82(s,6H),3.25(m,1H),2.85~2.67(m,7H),2.08(br,1H),1.92(br,1H),1.80(br,1H),1.69(br,1H),1.59(br,1H),1.39(br,1H),1.15(m,1H),0.89(m,1H),0.58(m,1H),0.45(m,2H)
实施例215.(S)-奎宁环-3-基(6’-(4-甲氧基苯基)-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.32(m,1H),7.22(m,3H),7.14(m,1H),6.96(m,2H),5.15(m,1H),4.77(br,1H),4.34(d,1H),3.86(s,3H),3.25(m,1H),2.87~2.71(m,7H),2.10(br,1H),1.92(br,1H),1.80(br,1H),1.68(br,1H),1.59(m,1H),1.40(br,1H),1.10(m,1H),0.90(m,1H),0.59(m,1H),0.44(m,2H)
实施例216.(S)-奎宁环-3-基(6’-(3-甲氧基苯基)-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.34(t,2H),7.24(m,1H),7.17(m,1H),6.88(m,2H),6.84(s,1H),5.15(m,1H),4.77(br,1H),4.34(d,1H),3.86(s,3H),3.25(m,1H),2.87~2.71(m,7H),2.10(br,1H),1.97(br,1H),1.80(br,1H),1.68(br,1H),1.59(m,1H),1.40(br,1H),1.10(m,1H),0.89(m,1H),0.59(m,1H),0.45(m,2H)
实施例217.(S)-奎宁环-3-基(6’-(4-乙氧基苯基)-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.31(m,1H),7.25(m,3H),7.14(m,1H),6.94(d,2H),5.15(m,1H),4.77(br,1H),4.34(d,1H),4.07(m,2H),3.25(m,1H),2.87~2.71(m,7H),2.10(br,1H),1.92(br,1H),1.80(br,1H),1.68(br,1H),1.59(m,1H),1.47(t,3H),1.40(br,1H),1.10(m,1H),0.90(m,1H),0.59(m,1H),0.44(m,2H)
实施例218.(S)-奎宁环-3-基(6’-(3-乙氧基苯基)-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.33(m,2H),7.24(m,1H),7.15(m,1H),6.89(m,2H),6.83(s,1H),5.15(m,1H),4.77(br,1H),4.35(d,1H),4.05(m,2H),3.25(m,1H),2.87~2.71(m,7H),2.10(br,1H),1.98(br,1H),1.80(br,1H),1.68(br,1H),1.59(m,1H),1.45(t,3H),1.40(br,1H),1.10(m,1H),0.89(m,1H),0.59(m,1H),0.45(m,2H)
实施例219.(S)-奎宁环-3-基(6’-(4-异丙氧基苯基)-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.32(m,1H),7.24(m,1H),7.21(d,2H),7.13(m,1H),6.93(d,2H),5.15(m,1H),4.77(br,1H),4.57(m,1H),4.34(d,1H),3.25(m,1H),2.87~2.71(m,7H),2.10(br,1H),1.92(br,1H),1.80(br,1H),1.68(br,1H),1.59(m,1H),1.40(br,1H),1.38(d,6H),1.15(m,1H),0.89(m,1H),0.58(m,1H),0.44(m,2H)
实施例220.(S)-奎宁环-3-基(6’-(4-丙氧基苯基)-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.33(m,1H),7.23(m,3H),7.15(m,1H),6.95(d,2H),5.15(m,1H),4.77(br,1H),4.57(m,1H),4.34(d,1H),3.95(m,2H),3.25(m,1H),2.87~2.71(m,7H),2.10(br,1H),1.92(br,1H),1.85(m,2H),1.80(br,1H),1.68(br,1H),1.59(m,1H),1.40(br,1H),1.38(d,6H),1.15(m,1H),1.06(t,3H),0.88(m,1H),0.58(m,1H),0.44(m,2H)
实施例221.(S)-奎宁环-3-基(6’-(4-乙基苯基)-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.34(m,1H),7.26(m,5H),7.14(m,1H),5.15(m,1H),4.77(br,1H),4.57(m,1H),4.34(d,1H),3.25(m,1H),2.87~2.71(m,7H),2.67(m,2H),2.10(br,1H),1.92(br,1H),1.85(m,2H),1.80(br,1H),1.68(br,1H),1.59(m,1H),1.40(br,1H),1.26(t,3H),1.15(m,1H),1.06(t,3H),0.88(m,1H),0.58(m,1H),0.44(m,2H)
实施例222.(S)-奎宁环-3-基(6’-(4-丙基苯基)-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.34(m,1H),7.26(m,5H),7.14(m,1H),5.15(m,1H),4.77(br,1H),4.57(m,1H),4.34(d,1H),3.25(m,1H),2.87~2.71(m,7H),2.62(m,2H),2.10(br,1H),1.92(br,1H),1.80(br,1H),1.70(m,2H),1.68(br,1H),1.59(m,1H),1.40(br,1H),1.26(t,3H),1.15(m,1H),1.01(t,3H),0.88(m,1H),0.58(m,1H),0.44(m,2H)
实施例223.(S)-奎宁环-3-基(6’-(4-异丙基苯基)-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.34(m,1H),7.26(m,5H),7.14(m,1H),5.15(m,1H),4.77(br,1H),4.57(m,1H),4.34(d,1H),3.25(m,1H),2.96(m,1H),2.87~2.68(m,7H),2.10(br,1H),1.92(br,1H),1.80(br,1H),1.68(br,1H),1.59(m,1H),1.40(br,1H),1.28(d,6H),1.15(m,1H),0.88(m,1H),0.58(m,1H),0.44(m,2H)
实施例224.(S)-奎宁环-3-基(6’-(4-异丁基苯基)-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.34(m,1H),7.27(m,1H),7.15(m,5H),5.15(m,1H),4.77(br,1H),4.57(m,1H),4.34(d,1H),3.25(m,1H),2.87~2.68(m,7H),2.52(d,2H),2.10(br,1H),1.92(m,2H),1.80(br,1H),1.68(br,1H),1.59(m,1H),1.40(br,1H),1.15(m,1H),0.92(d,6H),0.88(m,1H),0.58(m,1H),0.44(m,2H)
实施例225.(S)-奎宁环-3-基(6’-(4-(叔丁基)苯基)-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.44(d,2H),7.34(m,1H),7.23(m,3H),7.15(m,1H),5.15(m,1H),4.77(br,1H),4.57(m,1H),4.34(d,1H),3.25(m,1H),2.87~2.68(m,7H),2.10(br,1H),1.92(br,1H),1.80(br,1H),1.68(br,1H),1.59(m,1H),1.40(br,1H),1.35(s,9H),1.15(m,1H),0.92(d,6H),0.88(m,1H),0.58(m,1H),0.44(m,2H)
实施例226.(S)-奎宁环-3-基(6’-(4-环丙基苯基)-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.34(m,1H),7.27(m,1H),7.19(m,2H),7.10(m,3H),5.15(m,1H),4.77(br,1H),4.36(d,1H),3.25(m,1H),2.85~2.68(m,7H),2.08(br,1H),1.92(br,1H),1.80(br,1H),1.68(br,1H),1.59(br,1H),1.39(br,1H),1.35(d,6H),1.15(m,1H),1.00(m,2H),0.88(m,1H),0.75(m,2H),0.59(m,1H),0.44(m,2H)
实施例227至实施例232
使用制备例7中制得的(S)-奎宁环-3-基(6-溴-7-氟-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯,和相应的取代硼酸,按照与实施例1中相同的步骤,分别制备实施例227至实施例232的标题化合物。
实施例227.(S)-奎宁环-3-基(7-氟-6-(3-氟-4-甲氧基苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.27(m,2H),7.10(d,1H),7.02(m,2H),4.92(m,1H),4.80(m,1H),4.61(d,1H),3.92(s,3H),3.27(m,1H),2.92~2.66(m,7H),2.08(br,1H),1.95(br,1H),1.82(m,2H),1.68(br,1H),1.60(br,1H),1.42(br,1H),1.05(m,3H),0.90(m,3H)
实施例228.(S)-奎宁环-3-基(6-(3,5-二甲基-4-丙氧基苯基)-(7-氟-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.17(s,2H),7.12(d,1H),7.04(m,1H),4.88(m,1H),4.81(m,1H),4.63(d,1H),3.77(m,2H),3.27(m,1H),2.95~2.68(m,7H),2.35(s,6H),2.12(br,1H),1.93(m,1H),1.85(m,2H),1.71(m,3H),1.59(br,1H),1.43(br,1H),1.08(m,6H),0.95(m,3H)
实施例229.(S)-奎宁环-3-基(7-氟-2,2-二甲基-6-(4-丙基苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.45(d,2H),7.24(m,2H),7.15(d,1H),7.06(m,1H),4.92(m,1H),4.81(m,1H),4.64(d,1H),3.27(m,1H),2.94~2.69(m,7H),2.62(m,2H),2.14(br,2H),1.85(br,1H),1.70(m,5H),1.60(br,1H),1.42(br,1H),1.07(m,3H),0.99(m,6H)
实施例230.(S)-奎宁环-3-基(7-氟-6-(4-异丁基苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.42(d,2H),7.21(d,2H),7.16(d,1H),7.05(m,1H),4.91(m,1H),4.79(m,1H),4.66(d,1H),3.30(m,1H),2.95~2.72(m,7H),2.53(d,2H),2.12(br,2H),1.90(m,1H),1.85(br,1H),1.71(m,3H),1.59(br,1H),1.43(br,1H),1.08(m,3H),0.93(m,9H)
实施例231.(S)-奎宁环-3-基(6-(2-(叔丁氧基)吡啶-4-基)-(7-氟-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ8.14(d,1H),7.18(d,1H),7.09(m,1H),7.00(br,1H),6.82(s,1H),4.91(m,1H),4.79(m,1H),4.64(d,1H),3.28(m,1H),2.95~2.69(m,7H),2.11(br,1H),1.94(br,1H),1.84(br,1H),1.72(m,3H),1.60(br,1H),1.42(br,1H),1.07(m,3H),0.94(m,3H)
实施例232.(S)-奎宁环-3-基(7-氟-6-(4-异丙氧基苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.45(d,2H),7.13(d,1H),7.05(m,1H),6.59(d,2H),4.91(m,1H),4.81(m,1H),4.64(m,2H),3.28(m,1H),2.97~2.69(m,7H),2.12(br,1H),1.84(br,1H),1.71(m,3H),1.60(br,1H),1.43(br,1H),1.38(d,6H),1.07(m,3H),0.94(m,3H)
实施例233至实施例238
使用制备例8中制得的(S)-奎宁环-3-基(6-溴-7-甲氧基-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯;和相应的取代硼酸,按照与实施例1中相同的步骤,分别制备实施例233至实施例238的标题化合物。
实施例233.(S)-奎宁环-3-基(6-(3-氟-4-甲氧基苯基)-7-甲氧基-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.31(m,1H),7.22(m,1H),6,99(m,2H),6.83(d,1H),4.90(m,1H),4.82(m,1H),4.61(d,1H),3.92(s,3H),3.77(d,3H),3.25(m,1H),2.95~2.77(m,7H),2.09(br,2H),1.86(br,2H),1.67(br,1H),1.57(br,1H),1.41(br,1H),1.08(m,3H),0.99(m,3H)
实施例234.(S)-奎宁环-3-基(6-(3,5-二甲基-4-丙氧基苯基)-7-甲氧基-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.12(s,2H),7.00(s,1H),6.84(d,1H),4.84(m,1H),4.81(m,1H),4.60(d,1H),3.75(m,3H),3.26(m,1H),2.89~2.76(m,7H),2.31(s,6H),2.08(br,1H),1.85(m,3H),1.68(m,3H),1.56(br,1H),1.40(br,1H),1.10(t,3H),1.05(m,3H),0.99(m,3H)
实施例235.(S)-奎宁环-3-基(7-甲氧基-2,2-二甲基-6-(4-丙基苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.42(d,2H),7.21(d,2H),7.03(s,1H),6.84(d,1H),4.83(m,1H),4.81(m,1H),4.63(d,1H),3.75(d,3H),3.27(m,1H),2.90~2.78(m,7H),2.63(m,2H),2.11(br,2H),1.85(br,1H),1.70(m,5H),1.60(br,1H),1.43(br,1H),1.06(m,3H),0.96(m,6H)
实施例236.(S)-奎宁环-3-基(6-(4-异丁基苯基)-7-甲氧基-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.42(d,2H),7.15(d,2H),7.06(s,1H),6.86(d,1H),4.87(m,1H),4.73(m,1H),4.64(d,1H),3.78(d,3H),3.28(m,1H),2.89~2.79(m,7H),2.51(d,2H),2.12(br,2H),1.90(m,1H),1.82(br,1H),1.68(m,3H),1.56(br,1H),1.42(br,1H),1.06(m,3H),0.99(m,3H),0.95(d,6H)
实施例237.(S)-奎宁环-3-基(6-(2-(叔丁氧基)吡啶-4-基)-7-甲氧基-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ8.12(d,1H),7.07(s,1H),7.01(br,1H),6.88(d,1H),6.81(s,1H),4.82(m,1H),4.73(m,1H),4.62(d,1H),3.77(d,3H),3.27(m,1H),2.86~2.74(m,7H),2.11(br,1H),1.94(br,1H),1.84(br,1H),1.77(m,3H),1.60(s,9H),1.43(br,1H),1.08(m,3H),0.99(m,3H)
实施例238.(S)-奎宁环-3-基(6-(4-异丙氧基苯基)-7-甲氧基-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯
1H-NMR(400MHz,CDCl3)δ7.42(d,2H),7.04(s,1H),6.92(d,2H),683(d,1H),4.86(m,1H),4.80(m,1H),4.70(m,1H),4.60(m,1H),3.79(d,3H),3.26(m,1H),2.88~2.76(m,7H),2.12(br,1H),1.86(br,1H),1.68(m,3H),1.58(br,1H),1.42(br,1H),1.36(d,6H),1.05(m,3H),1.00(m,3H)
实验例1:对GCS的抑制活性的评价
根据已知文献中描述的方法(Hayashi Y et al.,A sensitive andreproducible assay to measure the activity of glucosylceramide synthase andlactosylceramide synthase using HPLC and fluorescent substrates,AnalyticalBiochemistry 345(2005)181-186),对本发明的化合物对GCS的抑制活性进行如下评价。将已知作为GCS抑制剂的Ibiglustat用作对照。
(1)材料
A549细胞(ATCC,CCL-185)
NBD C6-神经酰胺(Thermo Fisher,N1154)
UDP-葡萄糖(Sigma,U4625)
氯化钾(Sigma,P9333)
超级纯TM(UltraPure TM)0.5M EDTA(Invitrogen,15575-038)
BCA蛋白检测试剂盒(Thermo Fisher,23227)
Ibiglustat(上海双福生物科技有限公司(Shanghai Systeam Biochem Co.,ltd),Genz-682452)
HEPES(sigma,H3375)
蛋白酶/磷酸酶抑制剂混合物(protease/phosphatase inhibitor cocktail)(CST,5872s)
DMEM(GIBCO,11995-065)
FBS(GIBCO,16000-044)
抗生素-抗真菌剂(Antibiotic-Antimycotic)(100X)(GIBCO,15240-112)
200mM L-谷氨酰胺(GIBCO,25030081)
PBS(GIBCO,10010-023)
0.25%胰蛋白酶-EDTA(GIBCO,25200-056)
二甲基亚砜(Sigma,34869)
2-丙醇,HPLC级(Burdick&Jackson,AH323-4)
己烷,HPLC级(Burdick&Jackson,AH216-4)
氯仿(Sigma,C2432)
甲醇(Merck,1.06009.1011)
(2)方案(Protocol)
<1>细胞裂解物(cell lysate)的制备
在37℃和5%CO2的培养箱中,将A549细胞(ATCC,CCL-185)在补充有10%胎牛血清(FBS)、1x抗生素-抗真菌剂和1x L-谷氨酰胺的DMEM培养基中培养。将附着在培养皿上的细胞用磷酸盐缓冲液(PBS)洗涤后,用细胞刮刀刮去细胞,然后离心(4000rpm,3分钟,4℃)收集细胞于50ml管中。将细胞团块(cell pellets)悬浮在裂解缓冲液(50mM HEPES,pH 7.3,含有1x蛋白酶/磷酸酶抑制剂混合物)中,通过超声裂解,然后将裂解物(lysate)离心(13000rpm,10分钟,4℃)。获得的上清液用于蛋白质的定量分析。使用牛血清白蛋白作为标准物((standard),使用BCA蛋白检测试剂盒测量蛋白质的量。
<2>GCS酶反应(enzyme reaction)
通过将以下反应材料依次加入96深孔板(deep-well plate)中来引发酶促反应(Enzymatic reaction)。此后,酶促反应在37℃进行90分钟。
酶反应混合物(Enzyme reaction Mix)(共50μl)
<3>脂质提取
通过加入100μl的氯仿/甲醇(2:1,v/v)停止酶促反应。涡旋(vortexing)15秒后,将每种混合物离心(4000rpm,10分钟,18℃)。将下层(50μl)转移到新的96深孔板中,并用减压浓缩器(reduced concentrator)干燥。
<4>HPLC分析
将脂质溶解在100μl的异丙醇/正己烷/H2O(55:44:1,v/v/v)中,然后转移到玻璃小瓶中用于HPLC(Agilent,8004-HP-H/i3u)。将样品(100μl)自动加载到正相色谱柱(Intersil SIL 150A-5,4.6×250mm,GL Sciences,日本)上,然后用异丙醇/正己烷/H2O(55:44:1,v/v/v)以2.0ml/分钟的流速洗脱。分别使用470nm和530nm作为激发波长和发射波长,用荧光检测器(安捷伦(Agilent),1260FLD Spectra)测量其荧光。
<5>数据分析
通过以下等式进行数据分析。
%面积(样品)=面积(GlcCer)/[面积(Cer)+面积(GlcCer)]×100
%GCS活性=[面积(样品)-面积(ibiglustat)]/[面积(DMSO)-面积(ibiglustat)]×100
使用软件GraphPad Prism(Ver 5.01)分析获得的%GCS活性数据以计算IC50值。结果示于下表1和表2中。
表1
实施例 | IC50(nM) | 实施例 | IC50(nM) | 实施例 | IC50(nM) |
1 | 6.78 | 41 | 9.08 | 82 | 30.26 |
2 | 3.04 | 42 | 6.71 | 83 | 39.12 |
3 | 2.3 | 43 | 6.06 | 84 | 75.63 |
4 | 1.417 | 44 | 7.59 | 85 | 74.3 |
5 | 0.989 | 45 | 21.31 | 86 | 2.6 |
6 | 0.697 | 46 | 12.96 | 87 | 6 |
7 | 1.69 | 47 | 2.52 | 88 | 3.5 |
8 | 2.1 | 48 | 3.02 | 89 | 2.2 |
9 | 2.65 | 49 | 35.01 | 90 | 1.01 |
10 | 2.56 | 50 | 33.46 | 91 | 0.81 |
11 | 8.18 | 51 | 9.42 | 92 | 1.04 |
12 | 9.28 | 52 | 31.75 | 93 | 1.76 |
13 | 23.55 | 53 | 86.44 | 94 | 0.97 |
14 | 8.8 | 54 | 61.83 | 95 | 0.85 |
15 | 6.88 | 55 | 34.15 | 96 | 1.79 |
16 | 3.96 | 57 | 23.4 | 97 | 0.86 |
17 | 5.75 | 58 | 10.85 | 98 | 1.7 |
18 | 5.41 | 59 | 18.95 | 99 | 1.65 |
19 | 3.44 | 60 | 106.5 | 100 | 1.78 |
20 | 7.16 | 61 | 8.48 | 101 | 1.59 |
21 | 2.53 | 62 | 7.37 | 102 | 1 |
22 | 8.42 | 63 | 6.7 | 103 | 0.95 |
23 | 1.8 | 64 | 13.03 | 104 | 2.25 |
24 | 9.1 | 65 | 14.2 | 105 | 1.39 |
25 | 15 | 66 | 46.94 | 106 | 4.05 |
26 | 6.61 | 67 | 7.3 | 107 | 5.86 |
27 | 2.49 | 68 | 63.48 | 108 | 2.55 |
28 | 1.33 | 69 | 40.47 | 109 | 2.89 |
29 | 8.52 | 70 | 83.93 | 110 | 0.64 |
30 | 7.93 | 71 | 22.8 | 111 | 2.36 |
31 | 6.58 | 72 | 66.04 | 112 | 3.75 |
32 | 8.31 | 73 | 359 | 113 | 0.94 |
33 | 3.95 | 74 | 14.43 | 114 | 1.8 |
34 | 6.1 | 75 | 22.69 | 115 | 1.17 |
35 | 9.16 | 76 | 18.73 | 116 | 8.62 |
36 | 22.43 | 77 | 74.94 | 117 | 30.27 |
37 | 5.07 | 78 | 30.1 | 118 | 17.02 |
38 | 1.7 | 79 | 12.94 | 119 | 11.16 |
39 | 2.88 | 80 | 15.45 | 120 | 5.65 |
40 | 1.77 | 81 | 63.26 | 121 | 5.51 |
表2
实施例 | IC50(nM) | 实施例 | IC50(nM) | 实施例 | IC50(nM) |
122 | 3.38 | 162 | 10.55 | 202 | 1.16 |
123 | 0.97 | 163 | 15.3 | 203 | 13.53 |
124 | 1.6 | 164 | 9.23 | 204 | 38.39 |
125 | 1.1 | 165 | 18.4 | 205 | 34.2 |
126 | 0.83 | 166 | 56.23 | 206 | 10.17 |
127 | 1.92 | 167 | 19.55 | 207 | 23.21 |
128 | 2.84 | 168 | 17.88 | 208 | 21.2 |
129 | 2.08 | 169 | 40.91 | 209 | 15.24 |
130 | 1.24 | 170 | 9.41 | 210 | 23.65 |
131 | 1.49 | 171 | 5.33 | 211 | 27.57 |
132 | 1.16 | 172 | 4.83 | 212 | 104.2 |
133 | 1.05 | 173 | 1.61 | 213 | 34.20 |
134 | 2.95 | 174 | 4.35 | 214 | 32.56 |
135 | 2.81 | 175 | 14.8 | 215 | 2.35 |
136 | 9.22 | 176 | 14.92 | 216 | 12.20 |
137 | 2.14 | 177 | 23.48 | 217 | 1.01 |
138 | 1.19 | 178 | 22.73 | 218 | 19.79 |
139 | 4.78 | 179 | 10 | 219 | 1.1 |
140 | 1.49 | 180 | 9.54 | 220 | 0.63 |
141 | 1.51 | 181 | 12.7 | 221 | 2.01 |
142 | 1.11 | 182 | 11.92 | 222 | 0.75 |
143 | 1.44 | 183 | 12.92 | 223 | 2.4 |
144 | 1.39 | 184 | 7.52 | 224 | 1.53 |
145 | 0.87 | 185 | 14.78 | 225 | 6.55 |
146 | 1.8 | 186 | 24.4 | 226 | 0.93 |
147 | 1 | 187 | 13.9 | 227 | 0.5 |
148 | 3.21 | 188 | 16.1 | 228 | 1.34 |
149 | 3.5 | 189 | 18.9 | 229 | 0.31 |
150 | 8.7 | 190 | 11.9 | 230 | 0.3 |
151 | 7.27 | 191 | 9.9 | 231 | 0.86 |
152 | 5.72 | 192 | 12.9 | 232 | 0.29 |
153 | 4.43 | 193 | 20.9 | 233 | 0.65 |
154 | 8.4 | 194 | 1.03 | 234 | 1.45 |
155 | 20.97 | 195 | 5.39 | 235 | 0.19 |
156 | 19.56 | 196 | 6.02 | 236 | 0.53 |
157 | 32.24 | 197 | 3.13 | 237 | 1.84 |
158 | 34.23 | 198 | 5.17 | 238 | 0.55 |
159 | 10.87 | 199 | 7.24 | ||
160 | 14.54 | 200 | 8.85 | ||
161 | 26.52 | 201 | 33.46 |
从表1和表2的结果可以看出,本发明的化合物对GCS表现出优异的抑制活性。
实验例2:对GM1产生的抑制活性的评价
GM1是鞘脂代谢的最终产物,在细胞膜上表达,因此易于检测。此外,GM1的量代表神经酰胺转化为葡萄糖神经酰胺。因此,根据已知文献(Dijkhuis et al.,Gangliosidesdo not affect ABC transporter function in human neuroblastoma cells.TheJournal of Lipid Research 47(2006).1187-1195)中描述的方法,如下评价本发明化合物对GM1产生的抑制活性。将已知作为GCS抑制剂的Ibiglustat用作对照。
(1)材料
白血病细胞(Jurkat cells),克隆E6-1(ATCC,TIB-152)
霍乱毒素亚基B(Cholera toxin subunit B,CTB),FITC(Sigma,C1655)
Ibiglustat(上海双福生物科技有限公司,Genz-682452)
DMSO(Sigma,D2650)
固定缓冲液(Fixation buffer)(BD,554655)
RPMI 1640(Gibco,A1049101)
FBS(Gibco,16000-044)
抗生素-抗真菌剂(100X)(Gibco,15240-122)
FACS鞘液(Sheath Fluid)(BD,342003)
白血病细胞在补充有10%FBS和1X抗生素-抗真菌剂的RPMI 1640培养基中培养。通过将10ml FBS加入到490ml FACS鞘液中制备洗涤液(washing solution)。通过用洗涤液稀释CTB-FITC储备溶液(10mg/ml)至最终浓度为2μg/ml来制备CTB-FITC溶液。
(2)方案
用培养基(补充有10%FBS和1X抗生素-抗真菌剂的RPMI 1640培养基)制备细胞混悬剂(1×105个细胞/ml)。将细胞混悬剂(200μl)加入到96孔板的每个孔中(20,000个细胞/孔),然后以每孔0.05至3000nM(3倍(fold),11个点)的最终浓度对混合物(compounds)进行处理。每种混合物(mixture)在CO2培养箱中于37℃培养72小时。以1500rpm离心3分钟以除去培养基后,将细胞重新悬浮在每孔200μl洗涤液中。在以1500rpm离心3分钟以除去洗涤液后,将细胞重新悬浮在200μl的2ug/ml CTB-FITC溶液中。将得到的混悬剂在4℃培养60分钟,同时不暴露于光。以1500rpm离心3分钟以除去CTB-FITC溶液后,用200μl洗涤液洗涤细胞。洗涤过程另外重复两次。将洗涤后的板以1500rpm离心3分钟以除去洗涤液,然后将细胞完全重新悬浮于200μl固定缓冲液中。由通过用GuavaTM easyCyte 5HT(Merck Milipore,0500-4005)量化FITC荧光获得的值确定IC50。
通过以下等式进行数据分析。
%MFI(中位荧光强度)=(药物处理组的荧光值/DMSO处理组的荧光值)×100
%细胞=(孔中的细胞浓度/DMSO处理组中的细胞浓度)×100
使用软件GraphPad Prism(Ver 5.01)分析%MFI和%细胞数据以计算IC50值。结果如下表3和表4所示。
表3
实施例 | IC50(nM) | 实施例 | IC50(nM) | 实施例 | IC50(nM) |
1 | 62.58 | 41 | 291.5 | 83 | 386.5 |
2 | 54.5 | 42 | 209.6 | 84 | 144.3 |
3 | 58.66 | 43 | 615.8 | 85 | 192.3 |
4 | 34.93 | 44 | 480.3 | 86 | 14.18 |
5 | 27.15 | 45 | 152.1 | 87 | 19.52 |
6 | 15.82 | 46 | 216.5 | 88 | 11.27 |
7 | 13.59 | 47 | 432.9 | 89 | 7.791 |
8 | 12.39 | 48 | 362 | 90 | 4.889 |
9 | 41.32 | 49 | 411.5 | 91 | 2.863 |
10 | 37.66 | 50 | 2189 | 92 | 2.718 |
11 | 38.45 | 51 | 426 | 93 | 0.3883 |
12 | 19.59 | 52 | 22.7 | 94 | 3.105 |
13 | 143.4 | 53 | 313.7 | 95 | 0.123 |
14 | 61.75 | 54 | 216.3 | 96 | 3.294 |
15 | 19.69 | 55 | 109.6 | 97 | 1.385 |
16 | 33.96 | 57 | 81.2 | 98 | 2.048 |
17 | 36.97 | 58 | 73.54 | 99 | 2.558 |
18 | 99.21 | 59 | 153.3 | 100 | 2.589 |
19 | 67.39 | 61 | 61.9 | 101 | 2.548 |
20 | 84.36 | 62 | 49.25 | 102 | 1.432 |
21 | 42.13 | 63 | 41.84 | 103 | 0.9972 |
22 | 22.46 | 64 | 131.2 | 104 | 2.272 |
23 | 27.68 | 65 | 95.49 | 105 | 0.2097 |
24 | 23.14 | 66 | 102.5 | 106 | 3.332 |
25 | 45.06 | 67 | 38.3 | 107 | 6.502 |
26 | 30.84 | 68 | 276.3 | 108 | 6.7 |
27 | 30.29 | 69 | 220.1 | 109 | 2.972 |
28 | 5.312 | 70 | 133 | 110 | 0.2896 |
29 | 155.5 | 71 | 95.43 | 111 | 1.838 |
30 | 71.36 | 72 | 115.8 | 112 | 0.8019 |
31 | 2.92 | 73 | 587.1 | 113 | 0.9638 |
32 | 474.9 | 74 | 54.38 | 114 | 1.275 |
33 | 498.6 | 75 | 138.1 | 115 | 0.5598 |
34 | 297.9 | 76 | 156.2 | 116 | 7.76 |
35 | 265 | 77 | 197.1 | 117 | 37.81 |
36 | 338.6 | 78 | 230.1 | 118 | 12.36 |
37 | 286 | 79 | 65.33 | 119 | 1.862 |
38 | 316.3 | 80 | 225.2 | 120 | 1.83 |
39 | 849.4 | 81 | 410 | 121 | 0.0387 |
40 | 218.2 | 82 | 14.36 | 122 | 0.7739 |
表4
实施例 | IC50(nM) | 实施例 | IC50(nM) | 实施例 | IC50(nM) |
123 | 1.43 | 163 | 55.12 | 203 | 35 |
124 | 3.35 | 164 | 26.07 | 204 | 92.90 |
125 | 2.041 | 165 | 24.3 | 205 | 44.3 |
126 | 1.887 | 166 | 392.10 | 206 | 15.2 |
127 | 2 | 167 | 102.70 | 207 | 57.3 |
128 | 1.3 | 168 | 70.73 | 208 | 47.7 |
129 | 1.3 | 169 | 442.50 | 209 | 47 |
130 | 1.3 | 170 | 38.99 | 210 | 44.2 |
131 | 2.3 | 171 | 94.89 | 211 | 147.2 |
132 | 2 | 172 | 67.89 | 212 | 220.6 |
133 | 1 | 173 | 18.93 | 213 | 145.0 |
134 | 6.6 | 174 | 39.32 | 214 | 62.3 |
135 | 8.3 | 175 | 167.2 | 215 | 57.3 |
136 | 21.2 | 176 | 211.2 | 216 | 115.20 |
137 | 8.4 | 177 | 169.6 | 217 | 15.8 |
138 | 3.8 | 178 | 274 | 218 | 63.30 |
139 | 8.8 | 179 | 115.2 | 219 | 16 |
140 | 1.4 | 180 | 99.06 | 220 | 6.7 |
141 | 1.1 | 181 | 91.71 | 221 | 18.8 |
142 | 3.4 | 182 | 40.36 | 222 | 9.3 |
143 | 0.5 | 183 | 145 | 223 | 24.1 |
144 | 1.6 | 184 | 86.95 | 224 | 6.7 |
145 | 0.7 | 185 | 72.95 | 225 | 22.4 |
146 | 0.8 | 186 | 79.81 | 226 | 10.8 |
147 | 0.1 | 187 | 35.45 | 227 | 12.8 |
148 | 4.6 | 188 | 34.07 | 228 | 12.5 |
149 | 3.9 | 189 | 25.12 | 229 | 1.7 |
150 | 17.1 | 190 | 19.9 | 230 | 1.8 |
151 | 33.42 | 191 | 14.45 | 231 | 3.8 |
152 | 25.89 | 192 | 14.02 | 232 | 2.7 |
153 | 5.542 | 193 | 21.58 | 233 | 21.7 |
154 | 17.73 | 194 | 7.922 | 234 | 14.9 |
155 | 108.2 | 195 | 23.32 | 235 | 3.2 |
156 | 132.4 | 196 | 25.21 | 236 | 3.2 |
157 | 119.8 | 197 | 2.801 | 237 | 18.8 |
158 | 248.9 | 198 | 8.684 | 238 | 3.5 |
159 | 49.78 | 199 | 7.634 | ||
160 | 67.68 | 200 | 45.99 | ||
161 | 121.6 | 201 | 111 | ||
162 | 57.37 | 202 | 24.45 |
从表3和表4的结果可以看出,本发明的化合物对GM1的产生表现出优异的抑制活性。
Claims (21)
1.一种式1的化合物或其药学上可接受的盐:
<式1>
其中,
L为-O-,
X是氢;卤素;C1~C6烷基;被1至3个卤素原子取代的C1~C6烷基;具有氮原子、氧原子或硫原子的C1~C6烷基;C1~C6烷氧基;或被1至3个卤素原子取代的C1~C6烷氧基,
Y、Q和Z彼此独立地是-CR4R5-,
R4和R5彼此独立地是氢;卤素;C1~C6烷基;具有氮原子、氧原子或硫原子的C1~C6烷基;C3~C10环烷基;3-元至12-元杂环;或C1~C6烷氧基;或R4和R5与它们所连接的Y、Q或Z的碳原子一起形成C3~C10环烷基,
W是一个键,
A环是苯基、苯并二氧杂环戊烯基、2,3-二氢苯并二噁英基、2,3-二氢苯并呋喃基、吡啶基、吡咯并[2.3-b]吡啶基、嘧啶基或噻吩基,并且
X1、X2、X3和X4彼此独立地是氢;氰基;卤素;C1~C6烷基;被1至3个卤素原子取代的C1~C6烷基;C3~C10环烷基;3-元至12-元杂环;C1~C6烷氧基;C1~C6烷氧基-C1~C6烷氧基;被1至3个卤素原子取代的C1~C6烷氧基;C1~C6烷硫基;吗啉基;氨基;单-或双-C1~C6烷基氨基;C1~C6烷基羰基;羟基;或硝基。
2.根据权利要求1所述的化合物或其药学上可接受的盐,其中X是氢;卤素;或C1~C6烷氧基。
3.根据权利要求1所述的化合物或其药学上可接受的盐,其中R4和R5彼此独立地是氢或C1~C6烷基;或R4和R5与它们所连接的Y、Q或Z的碳原子一起形成C3~C10环烷基。
4.根据权利要求1所述的化合物或其药学上可接受的盐,其中Y是-CH2-。
5.根据权利要求1所述的化合物或其药学上可接受的盐,其中Q是-CH2-。
6.根据权利要求1所述的化合物或其药学上可接受的盐,其中Y是-CH2-;Q是-CH2-;并且Z为-CR4R5-;并且R4和R5彼此独立地是氢或C1~C6烷基;或R4和R5与Z的碳原子一起形成C3~C10环烷基。
7.根据权利要求1所述的化合物或其药学上可接受的盐,其中X1、X2、X3和X4彼此独立地是氢;氰基;卤素;C1~C6烷基;被1至3个卤素原子取代的C1~C6烷基;C3~C10环烷基;C1~C6烷氧基;C1~C6烷氧基-C1~C6烷氧基;被1至3个卤素原子取代的C1~C6烷氧基;吗啉基;单-或双-C1~C6烷基氨基;或C1~C6烷基羰基。
8.根据权利要求1所述的化合物或其药学上可接受的盐,其中
X是氢;卤素;或C1~C6烷氧基,
R4和R5彼此独立地是氢或C1~C6烷基;或R4和R5与它们所连接的Y、Q或Z的碳原子一起形成C3~C10环烷基,并且
X1、X2、X3和X4彼此独立地是氢;氰基;卤素;C1~C6烷基;被1至3个卤素原子取代的C1~C6烷基;C3~C10环烷基;C1~C6烷氧基;C1~C6烷氧基-C1~C6烷氧基;被1至3个卤素原子取代的C1~C6烷氧基;吗啉基;单-或双-C1~C6烷基氨基;或C1~C6烷基羰基。
9.根据权利要求8所述的化合物或其药学上可接受的盐,其中Y是-CH2-。
10.根据权利要求8所述的化合物或其药学上可接受的盐,其中Q是-CH2-。
11.根据权利要求8所述的化合物或其药学上可接受的盐,其中Y是-CH2-;Q是-CH2-;并且Z为-CR4R5-;并且R4和R5彼此独立地是氢或C1~C6烷基;或R4和R5与Z的碳原子一起形成C3~C10环烷基。
12.根据权利要求1所述的化合物或其药学上可接受的盐,其选自以下化合物:
(S)-奎宁环-3-基(6-(4-氟苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(4-氯苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(4-(三氟甲基)苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(4-(三氟甲氧基)苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(3-氟苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(3-氯苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(3-(三氟甲基)苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(3-(三氟甲氧基)苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(2-氟苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(2-氯苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(2-(三氟甲基)苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(2-(三氟甲氧基)苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(4-(二氟甲氧基)苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(对甲苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(3,4-二氟苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(2,5-二氟苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(3,5-二氟苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(2,4-二氟苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(2,3-二氟苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(2,3,4-三氟苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(2,4,5-三氟苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(3,4-二氯苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(2,5-二氯苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(3,5-二氯苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(4-(2-甲氧基乙氧基)苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(4-(甲氧基甲氧基)苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(3-(2-甲氧基乙氧基)苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(3-(甲氧基甲氧基)苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(2-(2-甲氧基乙氧基)苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(2-(甲氧基甲氧基)苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(4-乙基苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(4-丙基苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(4-丁基苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(4-异丙基苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(4-异丁基苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(4-(叔丁基)苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(4-环丙基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(3-乙基苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(3-(叔丁基)苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(3-异丙基苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(2-乙基苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(2,2-二氟苯并[d][1,3]二氧杂环戊烯-5-基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(2,3-二氢苯并[b][1,4]二噁英-6-基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(2,3-二氢苯并呋喃-6-基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(4-吗啉代苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(4-甲氧基苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(3-甲氧基苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(2-甲氧基苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(3-氟吡啶-4-基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(2-甲基吡啶-4-基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(2-甲氧基吡啶-4-基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(1H-吡咯并[2,3-b]吡啶-5-基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(嘧啶-5-基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(1H-吡咯并[2,3-b]吡啶-4-基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(7-(4-氟苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(7-(4-氯苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(7-(对甲苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(7-(3-(氟苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(7-(3-(氯苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(7-(3-(三氟甲基)苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(7-(2-(氟苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(7-(2-氯苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(7-(2-(三氟甲基)苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(7-(3,4-二氟苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(7-(2,4-二氟苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(7-(2,4,5-三氟苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(7-(2,5-二氟苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(7-(3,5-二氟苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(7-(2,3,4-三氟苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(7-(3,4-二氯苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(7-(2,5-二氯苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(7-(吡啶-4-基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(7-(吡啶-3-基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(7-(邻甲苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(7-(2-甲氧基苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(7-(2-乙氧基苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(7-(3-甲氧基苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(7-(2-异丙氧基苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(7-(4-(2-甲氧基乙氧基)苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(7-(4-甲氧基苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(7-(4-乙氧基苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(7-(4-丙氧基苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(7-(4-异丙氧基苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(7-(苯并[d]二氧杂环戊烯-5-基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(7-(间甲苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(4-氟苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(4-氯苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(2,2-二甲基-6-(4-(三氟甲基)苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(2,2-二甲基-6-(4-(三氟甲氧基)苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(3-氟苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(3-氯苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(2,2-二甲基-6-(3-(三氟甲基)苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(2,2-二甲基-6-(3-(三氟甲氧基)苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(2-氟苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(2-氯苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(2,2-二甲基-6-(2-(三氟甲基)苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(2,2-二甲基-6-(2-(三氟甲氧基)苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(2,2-二甲基-6-(对甲苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(4-(二氟甲氧基)苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(3,4-二氟苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(2,4-二氟苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(2,3-二氟苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(2,5-二氟苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(3,5-二氟苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(2,5-二氯苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(3,4-二氯苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(3,5-二氯苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(2,2-二甲基-6-(2,4,5-三氟苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(2,2-二甲基-6-(2,3,4-三氟苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(4-(2-甲氧基乙氧基)苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(3-(2-甲氧基乙氧基)苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(2-(2-甲氧基乙氧基)苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(4-(甲氧基甲氧基)苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(3-(甲氧基甲氧基)苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(2-(甲氧基甲氧基)苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(2-甲氧基吡啶-4-基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(2,2-二甲基-6-(2-甲基吡啶-4-基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(2-氟吡啶-4-基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(2,2-二甲基-6-(2-(三氟甲基)吡啶-4-基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(4-甲氧基苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(3-甲氧基苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(3-乙氧基苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(2-氯-4-甲氧基苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(4-氯-3-甲氧基苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(2-氯-5-甲氧基苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(3-氟-4-甲氧基苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(3-乙基苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(3-(叔丁基)苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(3-异丙基苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(3-(二氟甲基)苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(3-(二甲基氨基)苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(3-异丙氧基苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(2,3-二甲氧基苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(2,4-二甲氧基苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(2,5-二甲氧基苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(2,6-二甲氧基苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(3,4-二甲氧基苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(3,5-二甲氧基苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(3-氯-4-甲氧基苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(3-氯-4-乙氧基苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(3-氯-4-丙氧基苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(3-氟-4-异丙氧基苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(4-丁氧基-3-氯苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(4-乙氧基-3-氟苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(3-氟-4-丙氧基苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(3,5-二甲基-4-丙氧基苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(4-丁氧基-3,5-二甲基苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(2-氟-4-甲氧基苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(3-氯-4-异丙氧基苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(2-乙酰基噻吩-3-基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(7-(4-氟苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(7-(4-氯苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(2,2-二甲基-7-(4-(三氟甲基)苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(2,2-二甲基-7-(4-(三氟甲氧基)苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(7-(3-氟苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(7-(3-氯苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(2,2-二甲基-7-(3-(三氟甲基)苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(2,2-二甲基-7-(3-(三氟甲氧基)苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(7-(2-氟苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(7-(2-氯苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(2,2-二甲基-7-(2-(三氟甲基)苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(2,2-二甲基-7-(2-(三氟甲氧基)苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(2,2-二甲基-7-(2-(对甲苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(7-(4-(二氟甲氧基)苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(7-(4-(2-甲氧基乙氧基)苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(7-(3-(2-甲氧基乙氧基)苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(7-(2-(2-甲氧基乙氧基)苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(7-(4-(甲氧基甲氧基)苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(7-(3-(甲氧基甲氧基)苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(7-(2-(甲氧基甲氧基)苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(7’-(4-氟苯基)-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-基)氨基甲酸酯;
(S)-奎宁环-3-基(7’-(4-氯苯基)-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-基)氨基甲酸酯;
(S)-奎宁环-3-基(7’-(4-(三氟甲基)苯基)-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-基)氨基甲酸酯;
(S)-奎宁环-3-基(7’-(4-(三氟甲氧基)苯基)-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-基)氨基甲酸酯;
(S)-奎宁环-3-基(7’-(3-氟苯基)-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-基)氨基甲酸酯;
(S)-奎宁环-3-基(7’-(3-氯苯基)-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-基)氨基甲酸酯;
(S)-奎宁环-3-基(7’-(3-(三氟甲基)苯基)-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-基)氨基甲酸酯;
(S)-奎宁环-3-基(7’-(3-(三氟甲氧基)苯基)-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-基)氨基甲酸酯;
(S)-奎宁环-3-基(7’-(2-氟苯基)-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-基)氨基甲酸酯;
(S)-奎宁环-3-基(7’-(2-氯苯基)-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-基)氨基甲酸酯;
(S)-奎宁环-3-基(7’-(2-(三氟甲基)苯基)-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-基)氨基甲酸酯;
(S)-奎宁环-3-基(7’-(2-(三氟甲氧基)苯基)-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-基)氨基甲酸酯;
(S)-奎宁环-3-基(7’-(对甲苯基)-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-基)氨基甲酸酯;
(S)-奎宁环-3-基(7’-(4-(二氟甲氧基)苯基)-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-基)氨基甲酸酯;
(S)-奎宁环-3-基(7’-(4-(甲氧基甲氧基)苯基)-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-基)氨基甲酸酯;
(S)-奎宁环-3-基(6’-(4-氟苯基)-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-基)氨基甲酸酯;
(S)-奎宁环-3-基(6’-(4-氯苯基)-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-基)氨基甲酸酯;
(S)-奎宁环-3-基(6’-(4-(三氟甲基)苯基)-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-基)氨基甲酸酯;
(S)-奎宁环-3-基(6’-(4-(三氟甲氧基)苯基)-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-基)氨基甲酸酯;
(S)-奎宁环-3-基(6’-(3-氟苯基)-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-基)氨基甲酸酯;
(S)-奎宁环-3-基(6’-(3-氯苯基)-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-基)氨基甲酸酯;
(S)-奎宁环-3-基(6’-(3-(三氟甲基)苯基)-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-基)氨基甲酸酯;
(S)-奎宁环-3-基(6’-(3-(三氟甲氧基)苯基)-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-基)氨基甲酸酯;
(S)-奎宁环-3-基(6’-(4-(2-甲氧基乙氧基)苯基)-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-基)氨基甲酸酯;
(S)-奎宁环-3-基(6’-(3-(2-甲氧基乙氧基)苯基)-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-基)氨基甲酸酯;
(S)-奎宁环-3-基(6’-(2-(2-甲氧基乙氧基)苯基)-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-基)氨基甲酸酯;
(S)-奎宁环-3-基(6’-(4-(甲氧基甲氧基)苯基)-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-基)氨基甲酸酯;
(S)-奎宁环-3-基(6’-(3-(甲氧基甲氧基)苯基)-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-基)氨基甲酸酯;
(S)-奎宁环-3-基(6’-(2-(甲氧基甲氧基)苯基)-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-基)氨基甲酸酯;
(S)-奎宁环-3-基(6’-(2-氯-4-甲氧基苯基)-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-基)氨基甲酸酯;
(S)-奎宁环-3-基(6’-(4-氯-3-甲氧基苯基)-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-基)氨基甲酸酯;
(S)-奎宁环-3-基(6’-(3-氟-4-甲氧基苯基)-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-基)氨基甲酸酯;
(S)-奎宁环-3-基(6’-(3-乙基苯基)-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-基)氨基甲酸酯;
(S)-奎宁环-3-基(6’-(3-(叔丁基)苯基)-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-基)氨基甲酸酯;
(S)-奎宁环-3-基(6’-(3-异丙基苯基)-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-基)氨基甲酸酯;
(S)-奎宁环-3-基(6’-(3-(二氟甲基)苯基)-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-基)氨基甲酸酯;
(S)-奎宁环-3-基(6’-(3-(二甲基氨基)苯基)-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-基)氨基甲酸酯;
(S)-奎宁环-3-基(6’-(3-异丙氧基苯基)-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-基)氨基甲酸酯;
(S)-奎宁环-3-基(6’-(2,3-二甲氧基苯基)-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-基)氨基甲酸酯;
(S)-奎宁环-3-基(6’-(2,4-二甲氧基苯基)-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-基)氨基甲酸酯;
(S)-奎宁环-3-基(6’-(2,5-二甲氧基苯基)-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-基)氨基甲酸酯;
(S)-奎宁环-3-基(6’-(2,6-二甲氧基苯基)-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-基)氨基甲酸酯;
(S)-奎宁环-3-基(6’-(3,4-二甲氧基苯基)-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-基)氨基甲酸酯;
(S)-奎宁环-3-基(6’-(3,5-二甲氧基苯基)-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-基)氨基甲酸酯;
(S)-奎宁环-3-基(6’-(4-甲氧基苯基)-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-基)氨基甲酸酯;
(S)-奎宁环-3-基(6’-(3-甲氧基苯基)-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-基)氨基甲酸酯;
(S)-奎宁环-3-基(6’-(4-乙氧基苯基)-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-基)氨基甲酸酯;
(S)-奎宁环-3-基(6’-(3-乙氧基苯基)-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-基)氨基甲酸酯;
(S)-奎宁环-3-基(6’-(4-异丙氧基苯基)-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-基)氨基甲酸酯;
(S)-奎宁环-3-基(6’-(4-丙氧基苯基)-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-基)氨基甲酸酯;
(S)-奎宁环-3-基(6’-(4-乙基苯基)-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-基)氨基甲酸酯;
(S)-奎宁环-3-基(6’-(4-丙基苯基)-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-基)氨基甲酸酯;
(S)-奎宁环-3-基(6’-(4-异丙基苯基)-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-基)氨基甲酸酯;
(S)-奎宁环-3-基(6’-(4-异丁基苯基)-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-基)氨基甲酸酯;
(S)-奎宁环-3-基(6’-(4-(叔丁基)苯基)-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-基)氨基甲酸酯;
(S)-奎宁环-3-基(6’-(4-环丙基苯基)-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-基)氨基甲酸酯;
(S)-奎宁环-3-基(7-氟-6-(3-氟-4-甲氧基苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(3,5-二甲基-4-丙氧基苯基)-(7-氟-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(7-氟-2,2-二甲基-6-(4-丙基苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(7-氟-6-(4-异丁基苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(2-(叔丁氧基)吡啶-4-基)-(7-氟-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(7-氟-6-(4-异丙氧基苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(3-氟-4-甲氧基苯基)-7-甲氧基-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(3,5-二甲基-4-丙氧基苯基)-7-甲氧基-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(7-甲氧基-2,2-二甲基-6-(4-丙基苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(4-异丁基苯基)-7-甲氧基-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(2-(叔丁氧基)吡啶-4-基)-7-甲氧基-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯;以及
(S)-奎宁环-3-基(6-(4-异丙氧基苯基)-7-甲氧基-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯。
13.根据权利要求1所述的化合物或其药学上可接受的盐,其选自以下化合物:
(S)-奎宁环-3-基(6-(4-氟苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(3-氯苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(3-乙基苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(3-异丙基苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(3-氟-4-异丙氧基苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(3,5-二甲基-4-丙氧基苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(2-氟-4-甲氧基苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6-(3-氯-4-异丙氧基苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯;
(S)-奎宁环-3-基(6’-(4-丙氧基苯基)-3’,4’-二氢-1’H-螺[环丙烷-1,2’-萘]-1’-基)氨基甲酸酯;
(S)-奎宁环-3-基(7-氟-2,2-二甲基-6-(4-丙基苯基)-1,2,3,4-四氢萘-1-基)氨基甲酸酯;和
(S)-奎宁环-3-基(7-氟-6-(4-异丙氧基苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯。
14.(S)-奎宁环-3-基(6-(3-乙基苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯。
15.(S)-奎宁环-3-基(6-(3-氟-4-异丙氧基苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯。
16.(S)-奎宁环-3-基(6-(2-氟-4-甲氧基苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯。
17.(S)-奎宁环-3-基(6-(3-氯-4-异丙氧基苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯。
18.(S)-奎宁环-3-基(7-氟-6-(4-异丙氧基苯基)-2,2-二甲基-1,2,3,4-四氢萘-1-基)氨基甲酸酯。
19.一种用于抑制葡萄糖神经酰胺合酶的药物组合物,其包含如权利要求1至18中任一项所述的化合物或其药学上可接受的盐作为活性成分。
20.根据权利要求1至18中任一项所述的化合物或其药学上可接受的盐在制备用于预防或治疗戈谢病、法布里病、泰-萨克斯病或帕金森病的药物中的用途。
21.根据权利要求1至18中任一项所述的化合物或其药学上可接受的盐在制备用于抑制葡萄糖神经酰胺合酶的药物中的用途。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20190146684 | 2019-11-15 | ||
KR10-2019-0146684 | 2019-11-15 | ||
PCT/KR2020/015867 WO2021096239A1 (en) | 2019-11-15 | 2020-11-12 | Novel derivatives having 1,2,3,4-tetrahydronaphthalene moiety or pharmaceutically acceptable salt thereof and pharmaceutical compositions comprising the same |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114746422A CN114746422A (zh) | 2022-07-12 |
CN114746422B true CN114746422B (zh) | 2024-03-12 |
Family
ID=75911384
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202080075121.6A Active CN114746422B (zh) | 2019-11-15 | 2020-11-12 | 具有1,2,3,4-四氢萘部分的衍生物或其药学上可接受的盐以及包含它们的药物组合物 |
CN202080075799.4A Active CN114641477B (zh) | 2019-11-15 | 2020-11-12 | 对葡萄糖神经酰胺合酶具有抑制活性的化合物或其药学上可接受的盐和包含其的药物组合物 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202080075799.4A Active CN114641477B (zh) | 2019-11-15 | 2020-11-12 | 对葡萄糖神经酰胺合酶具有抑制活性的化合物或其药学上可接受的盐和包含其的药物组合物 |
Country Status (6)
Country | Link |
---|---|
US (2) | US20220402909A1 (zh) |
EP (1) | EP4041734B1 (zh) |
JP (1) | JP2023503832A (zh) |
KR (2) | KR20210059633A (zh) |
CN (2) | CN114746422B (zh) |
WO (2) | WO2021096239A1 (zh) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ762985A (en) | 2017-09-22 | 2024-03-22 | Jubilant Epipad LLC | Heterocyclic compounds as pad inhibitors |
CN111386265A (zh) | 2017-11-06 | 2020-07-07 | 朱比连特普罗德尔有限责任公司 | 作为pd1/pd-l1活化的抑制剂的嘧啶衍生物 |
EP3704120B1 (en) | 2017-11-24 | 2024-03-06 | Jubilant Episcribe LLC | Heterocyclic compounds as prmt5 inhibitors |
BR112020018610A2 (pt) | 2018-03-13 | 2020-12-29 | Jubilant Prodel LLC | Compostos de fórmula i, fórmula ii, fórmula iii, fórmula iv, fórmula v, fórmula vi, ou seus polimorfos, estereoisômeros, tautômeros, profármacos, solvatos e sais farmaceuticamente aceitáveis dos mesmos e uso dos mesmos; processo de preparação; composição farmacêutica; e método para o tratamento e/ou prevenção de várias doenças, que incluem câncer e doenças infecciosas |
CA3216293A1 (en) * | 2021-05-11 | 2022-11-17 | Dong-Hoon Kim | Novel compounds having inhibitory activity against glucosylceramide synthase or pharmaceutically acceptable salt thereof, processes for preparing the same, and pharmaceutical compositions comprising the sam |
WO2023137307A1 (en) * | 2022-01-14 | 2023-07-20 | Enko Chem, Inc. | Protoporphyrinogen oxidase inhibitors |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1211983A (zh) * | 1996-02-23 | 1999-03-24 | 阿斯特拉公司 | 用于治疗的氨基甲酸的氮杂双环酯 |
CN101220026A (zh) * | 2003-02-21 | 2008-07-16 | 塔加西普特公司 | 3-取代的-2-(芳基烷基)-1-氮杂二环烷烃及其使用方法 |
CN103917094A (zh) * | 2011-03-18 | 2014-07-09 | 建新公司 | 葡萄糖基神经酰胺合酶抑制剂 |
CN105073745A (zh) * | 2012-09-11 | 2015-11-18 | 建新公司 | 葡糖神经酰胺合酶抑制剂 |
WO2017075535A1 (en) * | 2015-10-28 | 2017-05-04 | Oxeia Biopharmaceuticals, Inc. | Methods of treating neurodegenerative conditions |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010091164A1 (en) * | 2009-02-06 | 2010-08-12 | Exelixis, Inc. | Inhibitors of glucosylceramide synthase |
WO2010091104A1 (en) * | 2009-02-06 | 2010-08-12 | Exelixis, Inc. | Glucosylceramide synthase inhibitors |
US8961959B2 (en) * | 2011-10-17 | 2015-02-24 | The Regents Of The University Of Michigan | Glucosylceramide synthase inhibitors and therapeutic methods using the same |
CN110372636B (zh) * | 2013-09-20 | 2023-03-28 | 生物马林药物股份有限公司 | 用于治疗疾病的葡萄糖神经酰胺合成酶抑制剂 |
-
2020
- 2020-11-12 WO PCT/KR2020/015867 patent/WO2021096239A1/en unknown
- 2020-11-12 US US17/755,852 patent/US20220402909A1/en active Pending
- 2020-11-12 CN CN202080075121.6A patent/CN114746422B/zh active Active
- 2020-11-12 KR KR1020200150789A patent/KR20210059633A/ko unknown
- 2020-11-12 CN CN202080075799.4A patent/CN114641477B/zh active Active
- 2020-11-12 JP JP2022527914A patent/JP2023503832A/ja active Pending
- 2020-11-12 EP EP20888439.5A patent/EP4041734B1/en active Active
- 2020-11-12 KR KR1020200150793A patent/KR20210059634A/ko unknown
- 2020-11-12 US US17/755,858 patent/US20230002380A1/en active Pending
- 2020-11-12 WO PCT/KR2020/015871 patent/WO2021096241A1/en active Application Filing
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1211983A (zh) * | 1996-02-23 | 1999-03-24 | 阿斯特拉公司 | 用于治疗的氨基甲酸的氮杂双环酯 |
CN101220026A (zh) * | 2003-02-21 | 2008-07-16 | 塔加西普特公司 | 3-取代的-2-(芳基烷基)-1-氮杂二环烷烃及其使用方法 |
CN103917094A (zh) * | 2011-03-18 | 2014-07-09 | 建新公司 | 葡萄糖基神经酰胺合酶抑制剂 |
CN105073745A (zh) * | 2012-09-11 | 2015-11-18 | 建新公司 | 葡糖神经酰胺合酶抑制剂 |
WO2017075535A1 (en) * | 2015-10-28 | 2017-05-04 | Oxeia Biopharmaceuticals, Inc. | Methods of treating neurodegenerative conditions |
Also Published As
Publication number | Publication date |
---|---|
KR20210059633A (ko) | 2021-05-25 |
CN114746422A (zh) | 2022-07-12 |
WO2021096241A1 (en) | 2021-05-20 |
EP4041734A4 (en) | 2023-08-30 |
US20220402909A1 (en) | 2022-12-22 |
KR20210059634A (ko) | 2021-05-25 |
CN114641477A (zh) | 2022-06-17 |
EP4041734B1 (en) | 2024-04-24 |
CN114641477B (zh) | 2024-03-12 |
EP4041734A1 (en) | 2022-08-17 |
US20230002380A1 (en) | 2023-01-05 |
WO2021096239A1 (en) | 2021-05-20 |
JP2023503832A (ja) | 2023-02-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN114746422B (zh) | 具有1,2,3,4-四氢萘部分的衍生物或其药学上可接受的盐以及包含它们的药物组合物 | |
EP4041733B1 (en) | Derivatives having 2,3-dihydro-1h-indene or 2,3-dihydrobenzofuran moiety or pharmaceutically acceptable salt thereof and pharmaceutical compositions comprising the same | |
EP2593462B1 (en) | Novel fused heterocyclic derivatives useful as c-met tyrosine kinase inhibitors | |
EP3061747B1 (en) | Pyridic ketone derivatives, method of preparing same, and pharmaceutical application thereof | |
EP3677584A1 (en) | Compound having bruton's tyrosine kinase (btk)-inhibition and degradation activity | |
EP3323817B1 (en) | Aniline pyrimidine derivatives and uses thereof | |
JP2022503942A (ja) | イソインドリン化合物、その調製方法、医薬組成物および使用 | |
EP2896620A1 (en) | Alkynyl heteroaromatic ring compound and application thereof | |
CA2987466A1 (en) | Use of pteridinone derivative serving as egfr inhibitor | |
WO2016120808A1 (en) | Heteroarylaminoisoquinolines, methods for their preparation and therapeutic uses thereof | |
CN113557237A (zh) | 吡咯并吡啶衍生物及其预防或治疗蛋白激酶相关疾病的用途 | |
RU2686314C1 (ru) | Гетероциклические имидазольные соединения, способ их получения и их применение | |
EP4140997A1 (en) | Pyridine acetamide derivative serving as cdk inhibitor, and preparation method therefor and use thereof | |
CN117222645A (zh) | 对葡萄糖神经酰胺合成酶具有抑制活性的新颖的化合物或其药学上可接受的盐、其制备方法以及包含其的药物组合物 | |
KR20190140005A (ko) | 디히드로오로테이트 옥시게나제 억제제로서의 삼치환 벤조트리아졸 유도체의 사용 방법 | |
JP7144863B2 (ja) | イソキノリン化合物、その調製の方法、およびベータガラクトシダーゼの活性の変質に伴う状態におけるその治療的使用 | |
JP2018087173A (ja) | 悪性脳腫瘍治療薬 | |
KR20130096639A (ko) | 지방산 아미드 하이드롤라제의 조절제 | |
JP5546463B2 (ja) | キノロン化合物を含む薬剤 | |
JPWO2019142883A1 (ja) | ジヒドロインドリジノン誘導体 | |
US9255096B1 (en) | Substituted 1,2,3,4-tetrahydrobenzo[C][2,7] naphthyridines and derivatives thereof as kinase inhibitors | |
CN106565643A (zh) | D‑3‑磷酸甘油酸脱氢酶别构抑制剂及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |